Role of insulin-like growth factor (IGF) axis in the development of tamoxifen resistance in breast cancer epithelial cells by Hawsawi, Yousef MohammedRabaa
       
 
 
Role of insulin-like growth factor (IGF) axis in the development 
of tamoxifen resistance in breast cancer epithelial cells  
 
 
Yousef Mohammedrabaa Hawsawi  
M.Sc. (Hons) 
 
 
Submitted in accordance with the requirements for the 
Degree of Doctor of Philosophy 
 
 
 
 
 
Leeds School of Dentistry, Faculty of Medicine and Health, Univer-
sity of Leeds and Leeds Institute of Cancer Studies and Pathology. 
St. James`s University Hospital, Leeds 
Leeds-UK © June 2015 
[I] 
 
Declaration  
The candidate confirms that the work submitted is his own and that appropriate credit 
has been given where reference has been made to the work of others.  
Statement 1 
This copy has been supplied on the understanding that it is copyright material and 
that no quotation from the thesis may be published without proper acknowledgement.  
Statement 2 
This thesis is the result of my own investigations, except where otherwise stated. 
Where correction services have been used the extent and nature of the correction is 
clearly marked in a footnote (s). Other sources are acknowledged by footnotes giving 
explicit references. A bibliography is appended.  
Statement 3 
The right of  Yousef Mohammedrabaa Hawsawi to be identified as Author of this 
work has been asserted by him in accordance with the Copyright, Designs and Pa-
tents Act 1988, © (2015). The University of Leeds. Yousef Mohammedrabaa 
Hawsawi. 
The candidate confirms that the work submitted is his own, except where work which 
has formed part of jointly authored publications has been included. The contribution of 
the candidate and the other authors to this work has been explicitly indicated below. 
The candidate confirms that appropriate credit has been given within the thesis where 
reference has been made to the work of others.  
© (2015). The University of Leeds. Yousef Mohammedrabaa Hawsawi. 
 
Yousef Mohammedrabaa Hawsawi 
 Signed:                    (candidate)  
Date      :                23/06/2015 
[II] 
 
Acknowledgements 
First and foremost, before I appreciate different people who helped me get through 
my post-graduate career, I must first thanks the God who generously conferred me 
with the strength and ability to complete this beneficial project. All praise is due to Al-
lah, the Lord of the entire worlds, and Allah’s peace and blessings be upon his final 
prophet Muhammad, his pure family, his noble companions, and all those who follow 
them with righteousness until the Day of Judgment. Indeed, it is Allah who bestows 
success. 
 I have to recognise the millions of women that are bravely fighting against breast 
cancer and living with the disease patiently and optimistically. Thanks also for training 
in molecular science which not only taught me to appreciate the very smallest of mol-
ecules but also the very large responsibility  we as researchers have to deliver hope 
to the women diagnosed with breast cancer, their families and their friends. 
Then, I gratefully would like to convey my deepest gratitude and appreciation to my 
principal supervisor Dr James Beattie for his support all along the highway of my sci-
entific journey. I also owe my sincere thanks to my co-supervisors Prof Valerie Speirs 
and Prof Christopher Twelves. Without the full support and encouragement of my su-
pervisors, I could not have completed my thesis. Indeed, I appreciate their unlimited 
support and their willingness to contribute to my project.  
I also would like to extend my enormous thanks to Mrs Claire Godfrey, Mr Gregory 
Baugh and Mr Adam Steel for their superb administrative and logistic support, Dr 
Reem El-Gendy for her leadership and valuable participation in my project. Many 
thanks also go to Dr Hannah Al-Kharobi for continuous support as we shared lab ex-
perience. Special thanks also go to Dr Maria Jove, Matthew Humphries, Alexander 
Wright, Emily Smart, Mike Shires, Michael Hale, Euan Polson and Adam Davison. 
Indeed, I am very lucky to be surrounded with such incredible, talented colleagues.  
[III] 
 
Very special acknowledgements also go to Prof Jennifer Kirkham, Prof Peter Selby 
and Prof Chris Inglehearn for their generous support of my academic pursuits. I would 
also like to express my appreciation to University of Leeds, Faculty of Medicine and 
Health. Particularly, Leeds School of Dentistry and the Leeds Institute of Cancer 
Studies and Pathology.  
Furthermore, I would like to thanks Prof Robert Baxter who offered me a fabulous 
scientific visit to Kolling Institute of Medical Research in Sydney, Australia. Many 
thanks to all his team, Dr Leo Phillips, Dr Janet Martin,  Dr Mike Lin, Dr Aleksandra 
Ochrik, Dr Liping Chung, Dr Carolyn Scoot, Mrs. Hasanthi De Silva and Mrs. Tiffany 
Scully.    
I would also like to extend my sincere thanks to my homeland the Kingdom of Saudi 
Arabia, which has provided me with all the essential supports to success for a promis-
ing future shining with advanced technology. 
Special thanks also go to the Department of Academic and Training Affairs at King 
Faisal Specialist Hospital & Research Centre General Organization (KFSH&RC-Gen. 
Org.) for their generous financial support, encouragement and granting me a full 
scholarship. With special thanks to the research centre at KFSH&RC-Jed. 
Most of all, I would like to extend my warmest thanks to my family specially my par-
ents, brothers, sisters and my beloved two sons Amjad and Abdulmalik. I mentioned 
them last to emphasise the peculiar nature of their encouragement, tremendous ef-
fort, patience and emotional support throughout my candidature. 
 
 
 
 
[IV] 
 
Dedication 
I am pleased to dedicate my thesis to my beloved parents and fabulous family par-
ticularly my beloved two sons Amjad and Abdulmalik. There is no doubt in my mind 
that without their continuous and sincere advice, and full support, I could not have 
completed this thesis. I also dedicate this thesis to my honourable organization (King 
Faisal Specialist Hospital & Research Centre, General Organization) for their financial 
support and encouragement. I am immensely grateful to the Department of Academic 
and Training Affairs at KFSH&RC (Gen. Org.) for generously granting me a full schol-
arship particularly, Dr Hussein Halabi, Dr Abdulrahman Al-Rajhi, Dr Omar Al-Amari, 
Mr Abdulaziz Al Bahkaly and Mr Gassan Mansouri. Also, I would like to extend my 
deepest appreciation to the Laboratory, the Department of Pathology at KFSH&RC-
Jeddah, in particular, Dr Nabela Al-Baz, Dr Abdulghani Maulawi, Mr Mohammed 
AlJohani and Mr Jaffar Khiariy. Special thanks also goes to the Research Centre at 
KFSH&RC-Jed, Dr Ali Al-Zahrani, Dr Bakr M. Bin sadiq and the the top hospital exec-
utive administrations, Dr Qasim al-Qasabi, (CEO) and Dr Tariq Linjawi, (COO). 
I also dedicate this thesis to the government of the Kingdom of Saudi Arabia. Addi-
tionally, I would also like to offer the people at the Ministry of Higher Education and 
the Cultural Bureau (in the United Kingdom and Ireland) my best wishes for continued 
success in life. With special thanks to His Royal Highness (HRH) Prince Mohammed 
bin Nawaf Al Saud. The Ambassador of the K.S.A to the UK. 
Ultimately, it is my great pleasure to dedicate my thesis to the Custodian of the Two 
Holy Mosques, Late King Abdullah bin Abdul-Aziz Al Saud, and King Salman bin Ab-
dul-Aziz Al Saud. Lastly, I would like to offer my special thanks and gratitude for all 
the people of Saudi Arabia. 
 
  
[V] 
 
Abstract 
The development of tamoxifen resistance (TamR) in oestrogen receptor positive 
(ER+) breast cancer is a major therapeutic challenge.  Mechanisms suggested to ac-
count for this have mainly focussed on the activation of alternative growth factor 
pathways. The insulin-like growth factor (IGF) axis is a prime candidate for investiga-
tion in this area and the use of anti-IGF strategies in the clinical setting of tamoxifen 
resistance is under investigation. However such strategies, usually targeted to block 
the IGF-1 receptor (IGF-1R) have proved disappointing. The IGF axis is a multicom-
ponent molecular system and the activity of IGF is modulated by the presence of six 
soluble high affinity IGF binding proteins (IGFBP 1-6). Given the potential role of the 
IGF axis in the development of tamoxifen resistance it is important to investigate 
whether the IGFBP family may play a role in this process opening up a route for alter-
native anti-IGF based therapies. Using the ER+ MCF-7 cell line we demonstrated that 
five IGF axis genes (IGF-IR, IGF-2R, IGFBP-2, IGFBP-4 and IGFBP-5) were ex-
pressed by both parental wt and tamoxifen resistant (TamR) MCF-7 cells with the re-
maining genes (IGF-1, IGF-2, IGFBP-1, IGFBP-3 and IGFBP-6) either not expressed 
or expressed only at a very low level. IGFBP-5 expression was down-regulated by 
approximately 7-fold while IGFBP-2 was up-regulated by approximately 2-fold in 
TamR versus wt cells. These alterations in IGFBP-2 and IGFBP-5 gene expression 
were mirrored in protein levels measured in a conditioned medium by ELISA, Western 
and Ligand blot. Significantly, a knockdown of IGFBP-2 in TamR cells restored sensi-
tivity to 4-hydroxytamoxifen (4-HT), reduced ERα expression to 45 ± 11.9% and en-
hanced cell migration. Knock down of IGFBP-5 in wt cells had no effect on sensitivity 
to 4-HT but enhanced cell migration. Exogenous  IGFBP-2 had no effect on tamoxifen 
sensitivity which may suggest an intracellular mechanism of action for IGFBP-2. Im-
munohistochemical analysis of breast cancer tissue microarrays (TMAs) indicated 
that expression of IGFBP-2 was significantly  associated with survival advantage in 
tamoxifen resistant patients. 
[VI] 
 
Table of Contents 
Declaration…. ................................................................................................... I 
Acknowledgements ........................................................................................ II 
Dedication ..................................................................................................... IV 
Abstract .......................................................................................................... V 
Table of Contents.......................................................................................... VI 
List of figures ................................................................................................ IX 
List of Tables ................................................................................................ XII 
List of abbreviation ..................................................................................... XIII 
Chapter 1 Introduction ................................................................................ 1 
1.1 General overview ........................................................................... 1 
1.1.1 Anatomy of the breast ............................................................ 3 
1.1.2 Signalling ............................................................................... 5 
1.1.3 BC – definitions, risk factors and treatment ........................... 8 
1.1.4 Molecular biology of breast cancer ...................................... 11 
General considerations ........................................................ 11 
BC – subtyping .................................................................... 15 
1.1.5 BC and tamoxifen resistance ............................................... 19 
1.2 IGF Axis ....................................................................................... 21 
1.2.1 Overview .............................................................................. 21 
1.2.2 IGF-I and IGF-2 ................................................................... 21 
1.2.3 IGF Receptors ..................................................................... 24 
1.2.4 IGFBPs ................................................................................ 27 
1.2.4.1 Insulin-like growth factor binding protein-1 ............ 29 
1.2.4.2 Insulin-like growth factor binding protein-2 ............ 29 
1.2.4.3 Insulin-like growth factor binding protein-3 ............ 30 
1.2.4.4 Insulin-like growth factor binding protein-4 ............ 31 
1.2.4.5 Insulin-like growth factor binding protein-5 ............ 31 
1.2.4.6 Insulin-like growth factor binding protein-6 ............ 32 
1.2.4.7 Insulin-like growth factor binding protein-related 
proteins ........................................................................ 33 
1.2.5 IGF Axis and BC .................................................................. 34 
[VII] 
 
1.2.6 IGFBPs ................................................................................ 38 
1.2.7 IGF axis and tamoxifen resistance ....................................... 42 
1.3 Aim and Objectives of the Study .................................................. 47 
1.3.1 Objectives: ........................................................................... 47 
Chapter 2 Materials and Methods ............................................................. 48 
2.1 Materials ...................................................................................... 48 
2.2 Methods ....................................................................................... 51 
2.2.1 Tissue culture ...................................................................... 51 
2.2.2 Real Time - Polymerase chain reaction ............................... 52 
2.2.3 Western and Ligand blot analysis ........................................ 54 
2.2.4 Enzyme-Linked Immunosorbent Assay ............................... 55 
2.2.5 Cell proliferation assay ........................................................ 56 
2.2.6 IGFBP knockdown ............................................................... 57 
2.2.7 Cell migration ....................................................................... 59 
2.2.8 Immunohistochemistry ......................................................... 60 
2.2.8.1 Breast cancer patients and ethical approval .......... 60 
2.2.8.2 Samples collection and TMAs Preparation ............ 60 
2.2.8.3 Antibody Optimisation ............................................ 62 
2.2.8.4 Immunohistochemistry ........................................... 64 
2.2.8.5 Definition for cut-off point ....................................... 65 
Chapter 3 Results ...................................................................................... 66 
The IGF axis in wt and TamR MCF-7 cells .......................................... 66 
3.1 Introduction .................................................................................. 66 
3.2 RNA Quantification ...................................................................... 66 
3.3 Validation of housekeeping gene. ................................................ 68 
3.4 Raw Ct values for qRT-PCR ........................................................ 69 
3.5 Expression of the IGF Axis in wt v TamR cells ............................ 71 
3.6 Western blot ................................................................................. 73 
3.7 Ligand blot ................................................................................... 76 
3.8 Elisa ............................................................................................. 78 
3.9 Discussion ................................................................................... 80 
Chapter 4 Results ...................................................................................... 85 
Role of the IGF axis in development of tamoxifen resistance .............. 85 
[VIII] 
 
4.1 Introduction .................................................................................. 85 
4.2 Puromycin optimisation ................................................................ 85 
4.3 IGFBP-2 knockdown .................................................................... 86 
4.4 IGFBP-5 knockdown .................................................................... 93 
4.5 Cell proliferation and tamoxifen sensitivity ................................... 98 
4.6 Effects of exogenous IGFBP-2 and IGFBP-5 on wt and TamR .104 
4.7 Oestrogen Receptor (ER) expression ........................................ 114 
4.8 Discussion ................................................................................. 117 
Chapter 5 Results .................................................................................... 122 
Cell migration ..................................................................................... 122 
5.1 Introduction ................................................................................ 122 
5.2 Migration of parental wt and TamR cells .................................... 122 
5.3 Migration of IGFBP-2 KO cells ................................................... 123 
5.4 Migration of IGFBP-5 KO cells ................................................... 123 
5.5 Discussion ................................................................................. 131 
Chapter 6 Clinical significance of IGFBP2 & IGFBP-5 expression in 
tamoxifen-resistant breast cancer ................................................. 134 
6.1 Introduction ................................................................................ 134 
6.2 Antibody optimisation ................................................................. 136 
6.3 Definition of cut-off point for scoring .......................................... 136 
6.4 Scoring algorithm ....................................................................... 140 
6.5 Positive expression of IGFBP-2: TS v TR. ................................. 144 
6.6 Negative expression of IGFBP-2: TS v TR ................................ 146 
6.7 Mining a public data set for IGFBP-2 and IGFBP-5 ................... 147 
6.7.1 IGFBP-2 assessment in ER+ BC patients ......................... 147 
6.7.2 IGFBP-5 assessment in ER+ BC patients ......................... 150 
6.8 Discussion ................................................................................. 151 
Chapter 7 General Discussion ................................................................ 155 
References ...................................................................................... 163 
Appendixes ...................................................................................... 179 
Publications & Awards ......................................................................... 2 
Published Abstracts ............................................................................. 3 
  
[IX] 
 
List of figures 
Figure ‎1-1  Incidence and mortality rates for cancer (by gender) in US.................... 2 
Figure ‎1-2 Schematic representation of IGF-1 signalling pathways. ........................ 7 
Figure ‎1-3 Characteristics of developing tumours. ................................................. 12 
Figure ‎1-4 Representation of different phases of the cell cycle. ............................. 13 
Figure ‎1-5 Histological classification of BC ............................................................ 16 
Figure ‎1-6 Overall survival rate (OSR) for BC by subtype classification ................. 18 
Figure ‎1-7  Structural homology in the insulin/IGF peptide family. ......................... 23 
Figure ‎1-8  Domain structure of the IGF-IR/IR. ...................................................... 25 
Figure ‎1-9 Mechanisms of action for anti-oestrogenic therapeutics. ...................... 26 
Figure ‎1-10 Schematic and generic structure for IGFBP family. ............................ 28 
Figure ‎1-11  Diagrammatic representation of the IGF axis. .................................... 33 
Figure ‎1-12  Aspects of IGF axis involvement in malignancy ................................. 36 
Figure ‎1-13  Schematic representation of anti-IGF therapies used in BC. .............. 44 
Figure ‎2-1 Mechanism of shRNA based gene silencing. ........................................ 58 
Figure ‎2-2 TMAs constructions. ............................................................................. 61 
Figure ‎2-3 FFPE multi- tissue sections. ................................................................. 63 
Figure ‎3-1 (A) A260/280 ratios and mRNA concentrations .................................... 67 
Figure ‎3-2 Validation of housekeeping gene (RPLP0). .......................................... 68 
Figure ‎3-3 Fold changes in selected IGF axis genes in TamR v wt cells. ............... 72 
Figure ‎3-4A Western blot for IGFBP-5. .................................................................. 74 
Figure ‎3-5A Western blot for IGFBP-2 ................................................................... 75 
Figure ‎3-6 Ligand blot analysis .............................................................................. 77 
[X] 
 
Figure ‎3-7 ELISA  .................................................................................................. 79 
Figure ‎4-1 Knockdown of IGFBP-2. ....................................................................... 88 
Figure ‎4-2 IGFBP-2 KO evaluation by qRT-PCR. .................................................. 90 
Figure ‎4-3 Profiling of IGF axis after Knockdown of IGFBP-2. ............................... 91 
Figure ‎4-4  Limited dilution cloning of IGFBP-2 knockdown cells. .......................... 92 
Figure ‎4-5 Knockdown of IGFBP-5 in wt MCF-7 cells. ........................................... 95 
Figure ‎4-6 Profile of IGF axis after knockdown of IGFBP-5. ................................... 96 
Figure ‎4-7 Limited dilution cloning of BP-5 KO cells. ............................................. 97 
Figure ‎4-8A Growth of wt or TamR cells in 1uM 4HT ............................................. 99 
Figure ‎4-9 Growth of TamR BP-2 KO clone F8 in 1uM 4HT. ............................... 102 
Figure ‎4-10 Growth of wt BP-5 KO clone B4 in 1um 4HT. ................................... 103 
Figure ‎4-11 Effect of IGF-1 on growth of wt and TamR MCF-7 cells. ................... 106 
Figure ‎4-12 Effect of IGFBP-2 on growth of wt and TamR MCF-7 cells. .............. 107 
Figure ‎4-13 Effect of IGFBP-5 on growth of wt and TamR MCF-7 cells. .............. 108 
Figure ‎4-14 Effect of IGF-1 ± IGFBP-2 or IGFBP-5 on growth of wt cells. ............ 109 
Figure ‎4-15 Effect of IGF-1 ± IGFBP-2 or IGFBP-5 on growth of TamR cells. ...... 110 
Figure ‎4-16 Exognous IGFBP-2 and Tamoxifen sensitivity of wt MCF-7 cells. ..... 112 
Figure ‎4-17 Exognous IGFBP-5 and Tamoxifen sensitivity. ................................. 113 
Figure ‎4-18 Expression of ERα in IGFBP-2 KO TamR cells................................. 116 
Figure ‎5-1 Migration of wt and TamR MCF-7 cells ............................................... 124 
Figure ‎5-2 Migration of wt and TamR cells plotted RWD vs time. ........................ 125 
Figure ‎5-3 Migration of IGFBP-2 KO clone F8. .................................................... 126 
Figure ‎5-4 Migration of IGFBP-2 KO clone F8 plotted as RWD v time. ................ 127 
[XI] 
 
Figure ‎5-5 Migration of IGFBP-5 KO clone B4. .................................................... 128 
Figure ‎5-6 Migration of IGFBP-5 KO clone B4 plotted as RWD v time. ................ 129 
Figure ‎5-7 Composite data from Figs 5.2, 5.4 and 5.6. ........................................ 130 
Figure ‎6-1 Consort diagram representing the patient samples used in the study. 137 
Figure ‎6-2 ROC curve to determine optimum cut-off point. .................................. 139 
Figure ‎6-3 IGFBP-2 immunohistochemistry in breast TMA cores ......................... 141 
Figure ‎6-4 Kaplan-Meier survival curve for Tam sensitive (TS) cohort. ................ 142 
Figure ‎6-5 Kaplan-Meier survival curve for Tam resistant  (TR) cohort. ............... 143 
Figure ‎6-6 Kaplan-Meier survival curve- positive IGFBP-2 expression:TS v TR. .. 145 
Figure ‎6-7 Kaplan-Meier survival curve-negative IGFBP-2 expression:TS v TR. . 146 
Figure ‎6-8 Consort diagram representing the patient samples used in the study. 148 
Figure ‎6-9 Meta-analysis of IGFBP-2 expression in ER+ cohort. ......................... 149 
Figure ‎6-10  Meta-analysis of IGFBP-5 expression in ER+ cohort ....................... 150 
 
  
[XII] 
 
List of Tables 
Table ‎1-1 Incidence of BC by basic molecular profile ............................................ 15 
Table ‎2-1 Summary of the RT-PCR reaction ......................................................... 53 
Table ‎3-1 Individual Ct values for IGF axis expression in wt and TamR................. 70 
Table ‎4-1 Knockdown of IGFBP-2. ........................................................................ 89 
Table ‎4-2 Raw Ct values for ER isoforms in wt and TamR cells. ......................... 115 
  
[XIII] 
 
List of abbreviation 
4-HT 4-hydroxytamoxifen  
ALs Aromatase inhibitors 
BC Breast cancer 
BSA Bovine serum albumin  
Cdks Cyclin-dependent kinases  
cDNA Complementary DNA 
CSCs Cancer stem cells  
DCS Dextran charcoal stripped  
DFS Disease free survival 
E Oestrogen 
E2 Oestradiol 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix  
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor  
eIF4E Eukaryotic translation initiation factor 4E  
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial-mesenchymal transition 
ER Oestrogen receptor 
FAK Focal adhesion kinase  
[XIV] 
 
FBS Foetal bovine serum  
FFPE Formalin-fixed, paraffin-embedded  
FOX Forkhead transcription factors  
GAGs Glycosoaminoglycans  
GH Growth hormone 
GM Growth medium  
GnRH Gonadotropin-releasing hormone  
GPER G protein-coupled ER  
HBD Heparin binding domain 
HER2 Human Epidermal Growth Factor Receptor 2 
HIF1α Hypoxia-inducible factor 1α  
HRP Horseradish peroxidase  
IGF Insulin-like Growth  Factor  
IGFBPs Insulin-like Growth Factor Binding  Proteins 
IHC Immunosistochemistry  
ILK Integrin linked kinase 
IP3 Inositol triphosphate  
IR Insulin receptor  
IRS Insulin receptor substrate 
kDa Kilodalton 
Mab Monoclonal antibody 
[XV] 
 
MAPK Mitogen activated protein kinase 
MCF-7 Michigan Cancer Foundation-7 (Human BC cell line) 
MECs Mammary epithelial cells  
MMP Matrix metalloproteinase 
mTOR Mammalian target of rapamycin  
NLS Nuclear localisation signal 
NSAIDs Non-steroidal anti-inflammatory drugs 
OS 
P 
Overall survival  
Progesterone 
PR Progesterone receptor  
p53 Protein 53 or tumour suppressor protein 53 
PAPA-1 Pim-1 associated protein 
PAPP-A Pregnancy-associated plasma protein-A (PAPP-A) 
PBS Phosphate buffered saline 
Pen/Strep Penicillin/streptomycin  
PI3K Phosphatidylinositol-3-kinase  
PP2A Protein phosphorylase 2A  
PRF Phenol red free media  
PRL Prolactin  
PTEN Phosphatase and tensin homologue on chromosome 
10 
[XVI] 
 
PTM Post-translational modifications  
qRT-PCR Quantitative real-time PCR  
RGD Arg-Gly-Asp  
ROC Receiver Operating Characteristic  
RT Room temperature  
RWD Relative wound density  
RXR Retinoid X receptor (RXR) 
nRXR Nuclear retinoid X receptor (RXR)-α 
S6K1 Ribosomal S6 kinases 
SERDs Selective oestrogen receptor down-regulators  
SERM Selective oestrogen receptor modulator 
siRNA short inhibitory RNA 
SNPs Single nucleotide polymorphisms  
Tam-R Tamoxifen resistant MCF-7 cells   
Tam-S Tamoxifen-sensitive MCF-7 Cells  
TBS Tris buffered saline    
TGF-βVR Transforming growth factor-beta V receptor  
TMAs Tissue microarrays  
VEGF Vascular endothelial growth factor 
WT Wild type (wt) 
ZEB Zinc-finger enhancer binding (ZEB) 1 
  
[1] 
 
Chapter 1 Introduction 
1.1 General overview 
Over the past decades, millions of women have died from breast cancer (BC) as a 
result of late diagnosis, disease relapse [1] and the development of resistance to en-
docrine and chemotherapeutic treatment regimens [2]. For several reasons the global 
incidence of BC has increased significantly in  recent  years [3]. Although this is partly 
a result of improved screening methodologies, in the developed world lifestyle factors 
(smoking, increased adiposity) have also had a bearing on BC incidence and BC re-
mains the most common non-cutaneous female malignancy [4]. Currently BC is re-
sponsible for 15% of all female death caused by cancer and is the second most com-
mon form of cancer in women after lung cancer Fig 1.1 [5].  A conservative estimate 
suggests that worldwide there are approximately 1.38M cases of BC and around 
458,000 deaths occur annually due to the disease [6]. In the United States, more than 
232,670 estimated new cases of BC were reported in 2012 (Fig 1.1) with over 40,00 
BC related deaths [7]. Currently, about 570,000 people are estimated to live with 
breast malignancy in the UK, and the rate is increasing 
http://publications.cancerresearchuk.org/downloads/Product/CS_REPORT_TOP10IN
CMORT.pdf. 
Despite recent breakthroughs in molecular biology and advances in the early detec-
tion of BC, about 30% of BC patients have recurrent disease [8] with a resulting im-
pact on individual wellbeing and healthcare costs [9]. To tackle BC it is important to 
examine areas such as such as aetiology, risk factors and the molecular biology as-
sociated with the disease. In the next sections we briefly highlight these features and 
precede them with a short discussion of the anatomy of the breast. 
[2] 
 
. 
 
Figure  1-1  Incidence and mortality rates for cancer (by gender) in US (2012). 
Adapted from [7].  
[3] 
 
1.1.1  Anatomy of the breast 
Mammary gland development in humans starts at the fifth week of embryogenesis 
where mammary epithelial cells (MECs) develop from an ectodermal bud [10]. After 
sixteen weeks of gestation, the embryonic glandular structures grow to become epi-
thelial buds with some individual branch points. At thirty two weeks rudimentary lob-
ule-alveolar composition develops surrounded by a compact stromal compartment 
[10]. During the neonate stage, the primitive branched composition contains one 
squamous epithelial layer  and one basal cuboidal layer [11]. Extensive development 
then occurs during puberty under the regulation of ovarian secretion of oestradiol (E) 
and progesterone (P), both of which are essential for normal mammary gland ductal 
elongation and reproductive development. In addition mammary gland development is 
also controlled via pituitary-derived hormones, such as prolactin (PRL) and growth 
hormone (GH) [12]. 
At puberty, the adult female breast is completed as a tear-shaped gland which is 
composed mostly of adipose tissue and is situated between the third and sixth ribs 
[13]. It is enclosed within a thin fibrous envelope which separates it from the skin 
above and the muscle underneath. For clinical purposes, the breast has been divided 
into four quadrants: upper outer (where most cancers occur), upper inner, lower outer 
and lower inner. Anatomically, the mammary gland consists of 15-20 lobes which 
branch out from the nipple [14]. The size of each lobe varies greatly over a 20- to 30-
fold range [13]. All lobes are enclosed by subcutaneous fat and fibrous connective 
tissue. These lobes are branched into small lobules [14], and each lobule is subdivid-
ed into 10 to 100 small branched alveoli. Each alveolus serves as a milk producing 
unit of the breast [15].  
[4] 
 
The mammary gland represents a unique organ where numerous rounds of lactation, 
differentiation, proliferation, and involution take place during reproductive life [16]. 
These complicated dynamic molecular, biochemical and structural alterations are 
regulated via ovarian sex steroid hormones E and P [17]. E is important for mammary 
epithelial cell (MEC) proliferation within the ducts and their elongation through puber-
ty. Although the main source of E in the pre-menopausal woman is the ovary, E is 
also secreted in smaller amounts in other tissues such as subcutaneous adipose tis-
sue. Several lines of evidence suggest a direct effect of E on cell proliferation not on-
ly in the different stages of normal breast growth but also as a mitogenic drive to BC 
cells. [11].  E controls cell proliferation and ductal elongation in the normal mammary 
gland mainly through activation of  nuclear oestrogen receptors (ERs)  [17], although 
the synchronized effects of other secreted growth factors are also involved. Although 
E can play a key role in BC cell growth and transformation the biological characteris-
tics of individual tumours vary greatly and have an important bearing on treatment 
and prognosis of the disease (see Section 1.1.5). 
  
[5] 
 
1.1.2 Signalling  
Binding of IGF-I to receptor leads to recruitment of adaptor proteins belonging to the 
insulin receptor substrate (IRS) family to auto-phosphorylated regions within the cyto-
solic domain of the receptor with subsequent activation of downstream signalling mol-
ecules including the protein kinase B (PKB), which also known as Akt, adapter protein 
Shc/Grb2, Ras/Raf-1, Mitogen-activated protein kinases (MAPK)/Erk and phospho-
inositide 3-kinase (PI3K) resulting in the regulation of various cellular functions includ-
ing mitogenesis, apoptosis, adhesion, migration and differentiation [18]. Since the 
IGFs may play a key role in BC progression, a clear understanding of such signalling 
mechanisms is important for a full understanding of this disease. Activation of PI3K 
and leads to increased inositol triphosphate (IP3) concentrations and stimulation of 
Akt protein kinase [19]. This regulates the activity of anti-apoptotic proteins, such as 
Mouse double minute 2 homolog (MDM2) [20] and the death promoter (BAD) protein 
[21]. Activated Akt also phosphorylates the forkhead transcription factors (FOX) [22], 
triggering the mammalian target of rapamycin (mTOR) to initiate protein synthesis and 
cell division. The targets of mTOR include the ribosomal S6 kinases (S6K1and S6K2) 
together with eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-
BP1), which in concert act to increase translation, proliferation and cell growth. More-
over, phosphorylation of protein phosphorylase 2A (PP2A) via mTOR impedes the 
dephosphorylation of S6K1 and 4EBP1 [23]. The tumour suppressor genes tuberous 
sclerosis TSC1 and TSC2 regulate mTOR.  AMPK phosphorylates TSC2, which in-
creases GTPase activity of the G protein Ras homolog enriched in brain (RHEB) pre-
venting mTOR activation and subsequent activation of protein synthesis [23]. Most of 
these genes (AKT, mTOR, PTEN and MAPK) have been associated directly with the 
development and progression of breast cancer.  Indeed, activation of mTOR in malig-
nant breast cells is linked with resistance to the chemotherapeutic agents tamoxifen 
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and trastuzumab [24].  Signalling by both IGF-I and -2 is negatively regulated by the 
tumour suppressor PTEN and dephosphorylation of Inositol trisphosphate (IP3) by 
PTEN inhibits IGF-1 induced Akt signalling [25].  Loss of PTEN causes an increase in 
IGF-2 signalling through the IGF-IR or IR-A [26, 27]. Therefore PTEN mutation could 
lead to increased IR and IGF-IR signalling resulting in stimulation of tumour growth. 
The involvement of the IGF axis in the signalling pathways discussed above and their 
importance in tumourigenesis has further stimulated research into the molecular de-
tails of IGF axis involvement in BC [28, 29]. An outline of IGF signalling pathways is 
shown in Fig 1.2. 
Epithelial-mesenchymal transition (EMT) is a crucial mechanism involved in metasta-
sis and invasion by cancer cells as it promotes migration and the separation of indi-
vidual cells from the primary cancer and also enables the cells to access the lymphat-
ic system promoting tumour dissemination. In this way tumour cells can easily migrate 
into secondary organs and create micro-metastases. Several extracellular and intra-
cellular signalling pathways have been implicated in the initiation of EMT including the 
involvement of the IGF axis [30]. Cell adhesion to the neighbouring extracellular ma-
trix (ECM) is mediated by cell-surface integrin receptors. Integrins mediate cell at-
tachment, and modulate cell proliferation, apoptosis, migration and spreading. Integrin 
receptors are heterodimeric comprising a combination of one of 18 possible α subu-
nits and 8β subunits. In total 24 different integrin receptors have been described in 
human cells where they act to regulate process such as focal adhesion, cell attach-
ment and migration. For instance, the adaptor protein paxillin binds the β subunit of 
integrin dimers in the focal adhesion complex (FAK) where it recruits other signalling 
proteins to regulate the expression of genes involved in controlling cell structure and 
movement [29, 31]. Integrin receptors also bind ECM components such as fibronectin 
and vitronectin through distinct recognition motifs in the ECM proteins. Along with fo-
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cal adhesions discussed above these interactions of integrins with ECM also regulate 
cell adhesion and motility and have clear relevance in the study of tumour spread. 
Some of the IGFBPs including the IGFBP-5 are found associated with the ECM and 
may play a role in cell adhesion [32].   
  
Figure ‎1-2 Schematic representation of IGF-1 signalling pathways. 
Early events following IGF-1 binding to cognate receptor include recruitment of IRS and 
Shc-Sos-Grb2 adapter proteins to cytosolic domains of IGF-1R and subsequent activa-
tion of PI3-K/AKT and Ras/Raf/MAPK pathways. These in turn regulate downstream the 
activity of mTOR and families of both anti- and pro-apoptotic proteins together with trans 
acting transcription factors such as c-fos and c-jun. Some well characterised tumour 
suppressors (e.g. PTEN) interact with signalling pathways to regulate cell division. 
Adapted from  [100]. 
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1.1.3  BC – definitions, risk factors and treatment 
BC has been defined as a malignant disease characterised by uncontrolled cell prolif-
eration in the mammary gland with frequent subsequent spread to secondary sites 
[33].  Histologically, it is believed that the disease originates from a single cell whose 
division is deregulated essentially due to accumulated genetic and epigenetic altera-
tions resulting in tumour growth and invasion of the surrounding tissues [34]. Clinical-
ly, there are two kinds of breast cancer: non-invasive and invasive. non-invasive tu-
mours generally lack the capability of spreading and occur in well differentiated cells, 
whereas invasive cancers have the ability to spread within the body, and are usually 
characterised by a higher population of undifferentiated cells. Nearly all BC deaths are 
due to metastasising disease, which is resistant to conventional therapies. The meta-
static progression consists of a series of events beginning with invasion of the primary 
tumour into the vascular system, extravasation, and ultimately the development of 
metastatic deposits in secondary target organs [35]. This migration of malignant cells 
is the crucial stage in the metastatic progression and many risk factors contribute in 
the initiation and progression of BC.  
The single leading risk factor for BC is increasing age [36]. The majority of the cases 
(83%) are identified in women aged ≥50 [37], and men aged ≥60 [38]. Whilst BC is 
predominantly a disease of old women it can affect younger women even those less 
than 30 years of age. Genetic mutations (e.g. in ATM, p53, CHEK2, TSC2, PTEN, 
PI3K and AKT-1 genes) are found in 5% to 10% of breast malignancies [39]. Altera-
tions in the BRCA1 and BRCA2 genes are the most common causes of hereditary 
breast malignancies, causing up to 80% of cases [40]. A range of other factors, such 
as low intakes of  fibre and antioxidant vitamins (e.g. vitamin C, vitamin E, selenium 
and beta carotene), hyperglycaemia [41], and excessive  alcohol and smoking [42, 
43], and other issues directly connected with lifestyle and personal behaviour are im-
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portant risk factors.  Use of oral contraceptives, early age of menstruation, late meno-
pause, lack of breast feeding and postmenopausal hormone therapy are also identi-
fied risk factors [44, 45]. In addition, exposure to ionizing radiation, electromagnetic 
fields, artificial oestrogens and use of non-steroidal anti-inflammatory drugs (NSAIDs) 
are also described as  risk factors [46]. Intriguingly, obesity is directly connected to an 
increased risk of cancer and cancer-related mortality and is estimated to be a factor in 
over 20% of cancer deaths in females and 14% in males [47]. In addition the level of 
fasting insulin was positively correlated with BC risk, regardless of obesity. An exten-
sive survey reported increased risk of BC for postmenopausal women with type 2 dia-
betes (T2D) [48] with a reported 20% increased risk of developing BC [49]. Epidemio-
logic investigation reveals a clear link between BC and hyper-insulinemia [50].  Genet-
ic background is also an additional risk factor for BC. In the US, Newman et al. 2006 
pointed out that, the white American women are less likely to be diagnosed with early-
onset BC compared to African American women although when comparing overall 
lifetime risk, white American women have a higher risk of developing BC compared to 
African American women [51]. 
Endocrine therapy is an effective approach to treat some BCs through removal or 
blockade of hormone action and subsequent inhibition of cancer cell growth. E and P 
are the most important steroid hormones involved in mammary gland physiology and 
several disruptors of this particular hormonal axis have been examined and used as to 
remove or ablate the mitogenic drive in breast tumours supplied by steroid hormones. 
These include the classes of agent such as selective estrogen receptor modulators 
(SERMs e.g. tamoxifen), selective estrogen receptor down-regulators (SERDs e.g. 
fulvestrant), gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibi-
tors (e.g. anastrazole), anti-progestins and anti-androgens [52]. In a clinical context, 
endocrine therapy using tamoxifen is regularly given to patients with early-stages of 
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BC. The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and let-
rozole have also emerged as novel important agents for use in adjuvant endocrine 
therapy and work by reducing the level of oestrogen through blocking an  aromatase 
catalysed conversion of testosterone into oestradiol [53]. Fulvestrant has been identi-
fied as an oestrogen receptor down-regulator which is normally used as a third line 
endocrine therapy in postmenopausal women with advanced disease [54]. Interesting-
ly in the context of the current thesis the mechanism of action of fulvestrant has been 
reported to be associated with increased expression of IGFBP-5 in BC cells [55]. Cur-
rently, adjuvant treatment of BC (usually following surgical and/or radio therapeutic 
intervention) largely depends on the molecular profile presented by the tumour cells – 
next section. 
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1.1.4  Molecular biology of breast cancer 
General considerations 
Cancers in general and BC in particular display six main properties important for the 
multistep progress of carcinogenesis. These distinctive and complementary properties 
act together to create an organizing principle for explaining the complexities of 
neoplastic disease. They comprise resisting cell death, evading growth suppressors, 
sustaining proliferative signalling, inducing angiogenesis, enabling replicative 
immortality, and activating invasion and metastasis [56]. Kim and colleagues also 
report that genomic stability and cancer-related inflammation are supplementary 
features associated with tumourigenesis see Fig 1.3. To understand the molecular 
mechanisms involved in BC it is necessary to have some appreciation of the concept 
of the cell cycle which controls replication of DNA and cell division [57]. These events 
can be divided into five dynamic phases starting with the Interphase. Interphase is an 
essential phase which comprises three distinct successive stages.  G1 phase called 
"monitor", and S phase – DNA synthesis followed by G2, where cells continue to grow 
and prepare for mitosis.  Cells subsequently move to a critical phase called mitosis (M) 
phase [58]. In mitosis phase, four different stages take place including; telophase, 
anaphase, metaphase and prophase. Quiescence (G0) is a biochemically distinct 
state which cells can re-enter the cell cycle and go on to DNA replication and mitosis. 
The transitions between these phases are regulated by changes in the activity of 
specific cyclin-dependent kinases (CDKs), with Cdk1/Cdk2 and Cdk2/Cdk4/Cdk6 
controlling the transitions from G2 to mitosis and G1 to S phase, respectively see Fig 
1.4 [58]. 
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Figure ‎1-3 Characteristics of developing tumours.  
Hallmarks include resistance to apoptosis, evasion of growth suppressors, sustained 
proliferative signalling, induction of angiogenesis, enabling replicative immortality, and 
activation of invasion and metastasis.  Adapted from [59]. 
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Figure  1-4 Representation of different phases of the cell cycle.  
G1, S, G2 and M phases are depicted as described in text above. Adapted from  
http://www.bing.com/images/search?q=Cell+Cycle+Diagram&Form=IQFRDR#vie
w=detail&id=7534D1ECC0FD010AB643B5DB8AEC9BB260927FE1&selectedInd
ex=23 
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Breast epithelial cells receive signals from growth factors, steroid hormones, growth  
cytokines and cell matrix components which affect the activity of cyclins and CDK 
inhibitors, and thereby control the G1/S transition [58]. Typically, the D-cyclins, 
comprising cyclin-D1, -D2 and –D3 are up regulated through initial stage of  G1  and 
trigger the transition from cell cycle arrest to S phase under the influence of agents 
such as  epidermal growth factor (EGF), IGF-I and steroid hormones [57, 60]. 
Accordingly EGF and IGF-I play a potentially important role in development of BC. 
However BC is an extremely complex and heterogeneous disorder and disruption to 
the function of key proteins which regulate the processes of cell adhesion and cell 
cycle progression is often seen. [61]. In addition, cells undergo apoptosis as part of a 
normal regulatory process and often in tumour cells these mechanisms are subverted. 
For example, the tumour suppressor protein phosphate and tensin homologue on 
chromosome 10 (PTEN) is an important regulator of apoptosis and often within BC 
and other cancers mutations in this protein result in inhibition of apoptotic processes 
and uncontrolled cell division.  Other important tumour suppressors include p53 and 
BRCA1/2 which are involved in DNA repair. Mutation in these proteins can lead to 
disruption of cell cycle regulation with resulting malignancy and metastasis [39]. 
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BC – subtyping 
BC progression clearly depends on alteration of critical gene expression and a major 
recent breakthrough in BC research is the achievement of complementary DNA 
(cDNA) array analysis to evaluate the effect of a specific tumour signature on 
prognosis and this has opened a new window in molecular classification of breast 
malignancy. The development of microarray technology initially resulted in the 
identification of over 8,000 genes differentially expressed in different subtypes of BC 
[62]. In practical and clinical terms however immunohistochemical analysis has 
identified four different molecular subtypes of BC including normal breast, HER-2-
positive, basal-like and luminal-like. The main subtype luminal has been further 
categorised into luminal A and luminal B [63] see Table 1.1 and Figure 1.5. 
 
Table ‎1-1 Incidence of BC by basic molecular profile 
No Subtypes 
of BC 
ER PR HER2 %  
1 luminal A         +       +       -      44  
2 luminal B         +       +      +      24 
3 HER2         -       -      +      19  
4 Basal-like         -       -      -      11 
5 Normal-like           2  
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Figure  1-5 Histological classification of BC 
A is a schematic showing different breast tumour subtypes. B shows typical histology 
of breast tumours based on differential immunohistochemical staining for ER, PR, and 
HER2. Adapted from [4] 
A 
B 
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Luminal A type BC is the most prevalent subtype followed by luminal B (Table 1.1).  
Both of these subtypes are ER+. Her-2 is expressed in around 40% of BC and is 
divided fairly equally between hormone receptor positive and negative subtypes. 
Basal-like BC tumours comprise a smaller (~10 %) group of tumours and due to their 
molecular profile are also termed triple negative (TN) BCs. 
 BC prognosis is closely related to molecular subtype (see Fig 1.6). Generally ER+ 
subtypes which include luminal A and luminal B usually show a better prognosis with 
around 80%–85% 5-year survival rate. Luminal A neoplasms are associated with a 
significantly better prognosis than luminal B subtype. Prognosis of ER −ve subtypes is 
poorer with a 50%–60% 5-year survival. The better prognosis of ER+ cancers is 
largely due to the anti-oestrogen adjuvant strategies developed in the last few 
decades. Recently Her-2 +ve tumours have been targeted with the specific anti-
receptor antibody trastuzumab (Herceptin). However the development of resistance to 
endocrine therapies (particularly tamoxifen) in ER+ BC and resistance to Herceptin in 
Her-2+ve tumours presents a major therapeutic challenge in the treatment and 
management of these BC subtypes. 
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Figure  1-6 Overall survival rate (OSR) for BC by subtype classification.  
Adapted from  [4] 
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1.1.5 BC and tamoxifen resistance 
The selective ER modulator (SERM) tamoxifen is a front line treatment for endocrine-
responsive BC [64]. Tamoxifen displays mixed ER actions (agonist/antagonist) in a 
tissue specific manner although it acts to block 17β-estradiol activity as a growth pro-
moter in E dependent breast tumours. Tamoxifen binds to ER in BC cells causing a 
conformational change in the receptor which results in an inactive trans acting com-
plex at the promoter regions of E responsive genes. The other main route of endo-
crine therapy via aromatase inhibitors (AIs) depletes E from the tissues resulting in 
inactivated ERs.  Around 50-60 % of ER+ BC patients initially respond to tamoxifen 
although resistance to the drug develops in a large cohort of these patients (70–80%) 
despite the continued expression of ERα [65, 66]. Many mechanisms have been pos-
tulated to account for continued cell division in the face of tamoxifen adjuvant therapy 
including alterations in tamoxifen metabolism [67], altered signal transduction path-
ways [68],  modulation of ER activity [69] and  alterations in binding co-activator and 
co-repressor molecules at the anti-oestrogen-ER complex [70]. 
A large body of evidence also indicates that the activation of alternative growth factor 
pathways may play a role in the development of tamoxifen resistance [71, 72]. The 
IGF axis is a prime candidate for such investigations as this molecular axis plays an 
important part in the development and differentiation of normal breast tissue and there 
is accumulating evidence that the IGF axis interacts with the E axis to regulate many 
aspects of mammary epithelial cell physiology including mitogenesis, apoptosis, 
adhesion, migration and differentiation [73-75].  IGFs have been well characterised as 
amongst the most potent mitogens for breast epithelial cells – reviewed in [76]. 
However so far the results of anti-IGF based strategies in clinical trials has been 
disappointing [66] . This may be due to the fact that the IGF axis is a multi-component 
molecular system consisting of growth factors (IGF-1 and –2), receptors (IGF-1R and 
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IGF-2R and insulin receptor (IR)), soluble growth factor binding proteins (IGFBP1-6) 
and several families of IGFBP proteases. IGFBPs modulate the activity of IGFs by 
various methods and also display growth factor independent activity. Given the 
potential role of IGF axis in the acquisition of tamoxifen resistance in breast cancer 
cell physiology it is important to investigate this molecular family especially with 
respect to expression and function of these genes in normal and cancerous breast 
tissue. As such studies form the basis of the experimental work presented in this 
thesis the second part of the introduction focuses on the structural and functional 
aspects of the components of the IGF axis with an introduction to their role in normal 
mammary gland function and in BC. We conclude the introduction with a short review 
of the limited literature related to the IGF axis and development of tamoxifen 
resistance before outlining the aims and objectives of our experimental work.  
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1.2 IGF Axis 
1.2.1 Overview 
The IGF axis is phylogenetically highly conserved and comprises 10 well-
characterised gene products together with a few related accessory proteins. The axis 
plays a role in normal mammary gland biology and in some circumstances may be 
involved in the aetiology and metastasis of BC. Therefore a thorough understanding of 
the structure and function of the proteins which comprise this axis is essential both in 
the context of normal and abnormal mammary gland function. 
1.2.2 IGF-I and IGF-2 
IGF-I and -2 are small (~7.5kDa) polypeptides which show a structural and functional 
homology to insulin [77].  IGF-1 is mainly secreted by the liver and serum concentra-
tions increase throughout postnatal development. [78]. Although liver is the major 
source of IGF-1 studies have shown that several tissues express IGF-I [79]. Expres-
sion and secretion of IGF-I and IGF-2 occurs in the adipocytes and stromal fibroblasts 
(but not epithelial cells) of the mammary gland and IGFs act as important regulators of 
cell physiology in this tissue [80]. IGF-I is regulated positively by pituitary growth hor-
mone (GH) [81] while the mechanisms of IGF-2 regulation remain unclear [82]. IGF-I 
and IGF-2 share about 40% sequence and structural homology with insulin and both 
IGFs have been highly conserved through vertebrate evolution [83]. In humans the  
IGF-I gene is present as a single copy situated on chromosome 12q23.2 containing 
six exons [84]. Alternative splicing at exons 1, 2, 5 and 6 leads to four potential mRNA 
precursors [85]. IGF-I is synthesized as a larger molecule (propeptide) comprising a 
signal peptide and a carboxyl terminal extension peptide (E peptide). The E peptide 
and signal peptide are removed during processing of the mature IGF-1 [86]. Mature 
IGF-I is a 70 amino acid single peptide chain with three intra-molecular disulfide 
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bonds and differs from insulin by the presence of a carboxyl terminal D domain [87]. 
IGF-2 shares a similar structure and interestingly has been identified as an imprinted 
gene, expressed only from the paternal allele. IGF2 is also involved in development 
and growth although it may play a more important role in foetal than in adult life. In 
humans it is also a single copy gene located on chromosome 11p15.5. Nine alterna-
tive transcripts have been described although these are not represented at the protein 
level.  IGF peptides contain four domains B-C-A-D [88]. The A and B domains of IGF-I 
and -2  show 50% homology to the A and B chains of insulin [89]. Figure 1.7 shows a 
representation of IGF-1, -2 and insulin highlighting the structural homology between 
these polypeptides.  
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Figure ‎1-7  Structural homology in the insulin/IGF peptide family.  
Insulin (T conformation). B. Insulin (R conformation) C. IGF-I. D. IGF-II E. Relaxin. For 
IGF-1  starting from the N-terminus, the B-domain (residues 1-29) is shown in green, 
the C-domain (residues 30-41) is shown in dark blue, A-domain( residues 42-62) is 
shown in blue, and the D-domain (residues 63-70) is shown in light blue. The disul-
phide bridges are shown in yellow. Note that in this Figure part of the C-domain of 
IGF-1 is unresolved. Adapted from http://www.fefchemicals.com/biopharm/scientific-
information/articles/the-insulin-peptide-family/. 
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1.2.3 IGF Receptors 
IGF-IR is a heterotetrameric tyrosine kinase receptor, containing two extracellular α 
subunits (∼135 kDa ) and two membrane-spanning β subunits (95 kDa each) [90]. 
IGF-IR is  synthesized as a precursor which is glycosylated on the extracellular re-
gions, dimerized and proteolytically processed to yield separate α and β chains [91]. 
The IGF-IR also shows a high degree of homology with the insulin receptor (IR) and 
hybrid IGF-IR/insulin receptor species have been reported for both the A and B 
isoforms of the insulin receptor ( IR-A / IR-B) comprising an IGF-IR αβ dimer com-
bined with an αβ dimer of either the IR-A or IR-B isoform. IR isoforms are derived from 
alternative splicing on exon 11 of the IR gene [92]. Although the physiological signifi-
cance of their expression remains unknown such hybrid receptors have been reported 
in BC cells [93]. In term of gene structure, IGF-IR is a large gene comprising 21 exons 
and spanning nearly 100 kb [94]. This gene has been localized to chromosome 
15q26.1 [95]. The 270 kDa IGF-2R gene has no structural homology to either IGF-IR 
or IR and is a single chain transmembrane protein identical to the cation-independent 
mannose-6-phosphate receptor. Killian and Jirtle (1999) revealed that the IGF-2R 
consists of 48 exons and spans nearly 136 kb [96], located at chromosome 6q25-q27 
[97],  In contrast to IGF-2 the IGF-2R gene is maternally imprinted.  Figure 1.8 shows 
the structure of the IGF-IR and IR. The partial structural homology amongst the lig-
ands and receptors in the IGF and insulin molecular family leads to a degree of prom-
iscuity in binding between ligand and receptor and also results in a partial functional 
redundancy between the IGF-I, IGF-2 and insulin ligands [98]. 
 
[25] 
 
 
Figure  1-8  Domain structure of the IGF-IR/IR.  
The schematic diagram represents the heterotetrameric IGF-IR and IR. L1 and L2 repre-
sent the large domains 1/2 with leucine-rich repeats.  CR is the Cys-rich domain and Fn 0, 
1 and 2represent fibronectin type III domains. Ins (insert) domain and Ex11 represent the 
residues encoded by exon11 of the IR.  TM (transmembrane), JM (juxtamembrane), TK 
(tyrosine kinase domain) and CT(C-terminal domains). The left arrows represent the lig-
and binding regions. Adapted from [32]. 
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Figure ‎1-9 Mechanisms of action for anti-oestrogenic therapeutics. 
Oestradiol bound to oestrogen receptors (ER) leads to conformational alteration and 
activation of the receptor through AF1 and AF-2 domains. Tamoxifen interaction with 
ER leads to an altered receptor confirmation such that AF domain function is inhibited.  
Aromatase inhibitors (AI) reduce oestradiol concentrations and reduce the abundance 
of hormone liganded ERs thus decreasing the hormone stimulated mitogenic drive for 
cell division. Adapted from [99]. 
 
  
[27] 
 
1.2.4  IGFBPs  
General  
The six well-characterised IGFBPs (IGFBP1-6) share many structural and functional 
features including the ability to bind IGF-I and IGF-2 with high affinities (KD 0.2 – 0.5 
nM). Indeed the affinity of IGFs for IGFBPs exceeds that for cell surface IGF receptors 
and means that IGFBPs are important regulators of growth factor access to receptors. 
IGFBPs contain three highly conserved structural domains N-terminal, linker and C-
terminal (Fig1.10) and are extensively disulphide bonded proteins. Structural infor-
mation on IGFBPs is limited as no full length protein has yet been crystallised. Alt-
hough IGFBPs bind IGF with high affinity and thereby sequester growth factor from 
cognate receptors they also provide a “reservoir” of IGF in tissues. Furthermore 
IGFBPs are subject to proteolysis which has the effect of releasing bound IGFs in tis-
sue compartments to allow access of growth factors to receptors. IGFBPs also have 
extensive IGF independent effects which must be borne in mind for a full appreciation 
of the spectrum of their biological effects. All these features of the molecular physiolo-
gy of the IGF axis are represented in the mammary gland and IGFBPs in particular 
have been shown to regulate  growth, motility, apoptosis, adhesion and migration of 
both normal an malignant mammary epithelial cells [100] and see below. 
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Figure ‎1-10 Schematic and generic structure for IGFBP family. 
IGFBPs comprise N-terminal (N), linker (L) and C-terminal (C) domains. The primary 
IGF binding site lies in the N-terminal domain although there are also contributions 
from residues in the C-terminal domain. The C-terminal domain also contains binding 
sites for extracellular matrix (ECM) and acid labile subunit (ALS) together with a nu-
clear localisation signal (NLS) for some IGFBPs and structural motifs which may be 
important for some IGF independent actions of IGFBPs (receptor interaction). The L 
domain is the main site for post-translational modification of IGFBPs including phos-
phorylation, glycosylation and proteolysis. Adapted from [100].   
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1.2.4.1 Insulin-like growth factor binding protein-1 
Insulin-like growth factor binding protein-1 (IGFBP-1) is expressed by several tissues 
including decidua, liver, kidney and endometrium. It is present as an extremely abun-
dant 25 kDa protein in amniotic fluid. [101, 102].  It circulates in both phosphorylated 
and non-phosphorylated forms with the former displaying an approximately 5 fold 
higher affinity for IGF-I than the non-phosphorylated form [103]. Although the physio-
logical significance of this remains unknown phospho-IGFBP-1 inhibits IGF-2 activity 
in fibroblasts and cultured vascular smooth muscle cells whereas dephosphorylated 
IGFBP-1 increases the activities of IGF-I in some cell types. IGFBP-1 and -2 have an 
Arg-Gly-Asp (RGD) sequence within their C-terminal domains and IGFBP-1 binds in 
an RGD-dependent manner to α5β1-integrins expressed in CHO cells.  [104].  This 
ability of IGFBP-1 to simultaneously bind the α5β1 fibronectin receptor and present 
IGF-I at wound healing sites is believed to confer enhanced tissue repair properties of 
this IGFBP [105]. 
1.2.4.2 Insulin-like growth factor binding protein-2 
The IGFBP-2 gene is located in region 2q33-q34 and consists of 4 exons containing 
three introns of lengths 27.0, 1.0, and 1.9 kb [106]. IGFBP-2 has a  2-fold lower affinity 
for IGF-I than IGF-2 [107].  IGFBP-2 is found in human, bovine,  porcine and rat milk 
and serum, with particularly high concentrations in cerebrospinal fluid [108]. Interest-
ingly, IGFBP-2 and -5 are located close together in a tail to tail orientation on chromo-
some 2 in humans suggesting that these two IGFBPs arose through an ancestral 
gene duplication event [109]. IGFBP-2 has been shown to mainly inhibit the action of 
IGFs. For example, Hoflich et al (1998) reported inhibition of human embryonic kidney 
fibroblasts proliferation when IGFBP-2 was over expressed [110]. This inhibitory ac-
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tivity of IGFBP-2, as for other IGFBPs is subject to regulation by the action of IGFBP 
proteolytic enzymes [107]. 
1.2.4.3 Insulin-like growth factor binding protein-3 
IGFBP-3 is the most abundant IGFBP in biological fluids binding over 90% of the cir-
culating IGF-I in a 150-kDa ternary complex with an 80kDa acid-labile subunit (ALS). 
IGFBP-3 possesses both growth-inhibitory and -potentiating effects on cells that are 
independent of IGF action. IGFBP-3 binds the transforming growth factor-beta V re-
ceptor (TGF-βVR) on mammary epithelial cells (MECs) providing a potential mecha-
nism for IGF-independent activities of IGFBP-3 [111]. Silha et al have suggested that  
IGFBP-3 may act as a tumour suppressor  by binding  IGF-I and IGF-2 to prevent the 
interaction of growth factor with the IGF-IR  thereby decreasing mitogenic signalling 
through this receptor [112]. As a consequence, the cell cycle is interrupted with sub-
sequent up-regulation of apoptotic signals [113]. IGFBP-3 has also been reported to 
inhibit the actions of IGF in other cell types [114]. 
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1.2.4.4 Insulin-like growth factor binding protein-4 
IGFBP-4 encodes a 258-amino acid polypeptide which has been mapped to chromo-
some 17q12-q21, in the same area as BRCA1 [115]. IGFBP-4 contains 4 exons 
spanning about 15 kb of genomic DNA. In 1990, Shimasaki and co-workers identified 
IGFBP-4 as an inhibitor of IGF-induced bone cell proliferation [116] acting to inhibit 
IGF-1 binding to IGF-1R in muscle and bone [117]. IGFBP-4 activity is regulated by 
pregnancy-associated plasma protein-A (PAPP-A), a placental protease that is also 
secreted by fibroblasts, osteoblasts and granulosa cells [114]. Cleavage of IGFPB-4 
releases IGF-I allowing interaction with cognate cell surface receptors.  
1.2.4.5 Insulin-like growth factor binding protein-5 
IGFBP-5 is a 35-kDa protein located on chromosome 2 in humans closely associated 
with IGFBP-2 [118]. Binding of IGFBP-5 to glycosoaminoglycans (GAGs) decreases 
its affinity to IGF-I by 17-fold whereas simultaneously inhibiting proteolysis of IGFBP-5 
[119].  IGFBP-5 has been shown to stimulate the proliferation of osteoblast cells [120, 
121]. It has also been reported to bind several  other targets including vitronectin 
[122], thrombospondin, osteopontin [123], hydroxyapatite [124], plasminogen activator 
inhibitor-I (PAI-I) [125] and importin β [126] as well as the GAGs heparin, heparin sul-
phate and dermatan sulphate [119].  The production of IGFBP-5 by mammary epithe-
lial cells has been reported to be increased dramatically throughout involution of the 
mammary gland [127] and transgenic mice expressing IGFBP-5 in the mammary 
gland show premature involution of the gland with increased MEC apoptosis [128]. 
Accordingly histological analysis showed reduction in alveolar end buds and de-
creased ductal branching. As well as compromising mammary development, over-
expression of IGFBP-5 increased abundance of pro-apoptotic signalling components, 
increased plasmin generation and decreased expression of pro-survival molecules of 
the Bcl-2 family. IGFBP-5 has also been identified as a pro-apoptotic protein in other 
Figure Domain structure of insulin-like growth factor binding protein 5. 
ALS, acid-labile subunit; ECM, extracellular matrix; IGF, insulin-like growth 
factor 
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tissues [129] and  in the context of BC IGFBP5 shows pleiotropic effects inducing cell 
adhesion, increasing cell survival  but inhibiting  migration of MCF-7 human breast 
cancer cells [130].  Recently, Vijayan et al  confirmed that IGFBP-5 enhances epithe-
lial cell adhesion and also protected epithelial cells from TGFβ1-induced mesenchy-
mal invasion suggesting that IGFBP-5 may act as a tumour suppressor [131].  Inter-
estingly, Ahn et al 2010 reported that IGFBP-5 acts as a modulator of tamoxifen re-
sistance in BC [132] and IGFBP5 expression correlates with increased survival. 
1.2.4.6 Insulin-like growth factor binding protein-6 
IGFBP-6 is a 23 kDa protein which located on chromosome 12q13.13 [133]. IGFBP-6 
is secreted by human keratinocytes and acts as a growth inhibitor in these cells. 
IGFBP-6 also attenuates IGF induced cell migration, proliferation, adhesion and colo-
ny formation [134]. Uniquely amongst the IGFBPs IGFBP-6 has much higher affinity 
for IGF-2 than IGF-I (20-100 folds).  IGFBP-6 is found in high concentrations in cere-
brospinal fluid [135]. 
.  
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1.2.4.7 Insulin-like growth factor binding protein -related proteins  
 Mac 25 is a tumour suppressor with 20-25 % homology to IGFBPs and is now termed 
IGFBP-7 [136]. IGFBP-7 is detectable in human breast, prostate, lung and colon can-
cer cell lines. It was reported that mac25 down-regulation was associated with BC 
progression [137].  Fig 1.11 below shows a cartoon representation of IGF axis com-
ponents. 
 
Figure  1-11  Diagrammatic representation of the IGF axis. 
IGF-1 and -2 bind with high affinity to IGFBP1-6. IGFBP-6 binds IGF-2 with higher af-
finity than IGF-1. Affinities of the other IGFBPs for IGF-1 and -2 are similar. IGFBP-3 
(and -5) is complexed with acid labile subunit (ALS) in biological fluids. IGFBPs sub-
ject to proteolysis to cause the release of growth factors. IGF-1 and -2 interact with 
varying affinities with IGF-1R, IGF-2R, IR-A, IR-B and hybrid IGF-1R/IR. Most IGFBPs 
(shown is IGFBP-5) interact with ECM molecules and there is evidence that specific 
IGFBPs (shown is IGFBP-3) display IGF-independent effects through interaction with 
specific cell surface receptors. Adapted from [138]. 
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1.2.5 IGF Axis and BC 
The IGF axis has long been known to play a role in tumourigenesis. In 1993, Sell et al. 
reported mouse embryonic fibroblasts deficient in IGF-IR could not be transformed by 
the SV40 large T antigen [139]. Subsequently Baserga et al. confirmed that IGF-IR 
expression was required for transformation by Ras activating oncogenes [140] and 
many studies now suggest a role for the IGF axis in malignant transformation and me-
tastases [141]. BC cell proliferation is stimulated via insulin and IGF-I [142] and block-
ing the IGF-IR inhibits growth of breast tumour cells [143]. IGF-I also inhibits p53 in-
duced apoptosis and stimulates angiogenesis through the induction of hypoxia-
inducible factor 1α (HIF1α) and, vascular endothelial growth factor (VEGF) expression 
[144]. Major et al. (2010) highlighted that high serum IGF-I levels are linked to a high-
er risk of certain cancers although this is a controversial area with some conflicting 
reports [145]. Importantly in the context of BC, IGF-I increases the transcriptional ac-
tivity of ERα, in addition to enhancing expression of oestrogen-inducible genes like 
the progesterone receptor [146]. Recent evidence also suggests that IGF-I up-
regulates G protein-coupled ER (GPER) expression in BC cells [147]. This novel 
membrane-bound ER mediates rapid non-genomic effects of E2 [148] independently of 
ERα and ERβ and may play an important role in the proliferative action of ovarian, 
endometrial  and BC cells [149]. Interestingly, in BC cells, GPR30 may act via cross-
talk with the epidermal growth factor receptor (EGFR) [150] and consequently provide 
a route of escape from anti-oestrogen adjuvant therapies [151]. 
The IGF axis has also been implicated in the maintenance of cancer stem cells 
(CSCs), and Kim et al (2002) indicated that IGF-I promoted epithelial- mesenchymal 
transition (EMT) via transforming growth factor (TGF)-β [152]. This occurs via up 
regulation of matrix metalloproteinase (MMP), which converts inactive TGF-β into its 
active form [153]. By degrading the extracellular matrix (ECM), MMPs also enhance 
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cell differentiation, motility, and invasion. Furthermore, the IGF axis plays a vital role in 
the activation of the transcription factors (TFs) involved in EMT including Snail [154] 
and zinc-finger enhancer binding (ZEB) 1 [155]. Finally activation of the IGF axis can 
save tumour cells from immune response-mediated attack and improve the survival of 
malignant cells [156]. Fig 1.12 highlights some of the mechanisms by which IGFs may 
act to promote tumourigenesis. 
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Figure  1-12  Aspects of IGF axis involvement in malignancy 
The diagram shows the different routes through which the IGF axis may act to pro-
mote tumourigenesis. (A) Represents the activation of the expression VEGF by IGF-I, 
which thereby initiates angiogenesis. Also, IGF-2 serves as a chemo-attractant to 
draw the endothelial progenitor cells to ischemic sites. (B) Illustrates the induction of 
EMT (C) Demonstrates the activation of the expression of MMPs to promote cell motil-
ity and invasion by the degradation of ECM. (D) Shows the IGF axis can protect tumor 
cells from immune response-mediated attack and increase the survival of tumor cells 
by providing protection from apoptosis. (E) Indicates the IGF axis contribution to the 
maintenance of cancer stem cells (CSCs). Adapted from [156]. 
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Following on from the signalling studies reported in 1.2.5, Ahmad et al (1999) reported 
high expression of  AKT in various human breast carcinoma cell lines and confirmed 
that in the ER+ MCF-7 BC cell line AKT is modulated both by IGF-I and E2[157]. 
Independent activation of AKT leads to E2 and IGF-I independent proliferation of BC 
cells and activates several anti-apoptotic pathways. Baron et al highlighted that focal 
adhesion kinase (FAK) - a downstream signalling protein associated with integrin 
activation, is also a substrate for the IGF1R and IR [158].  IGFs also act as chemo 
attractants for BC cells possibly acting through this integrin – FAK mediated pathway 
[159] although others have shown that activation of the integrin signalling pathway 
inhibits the mitogenic action of IGF-I in BC cell lines [160]. In addition to FAK 
activation, IGF1R activation also regulates the transient tyrosine phosphorylation of 
other components of the focal adhesion complex including p130 Crk and paxillin in 
MCF-7 cells [161] which may be important for BC cell migration. In confirmation of this 
expression dominant-negative IGF1R inhibits metastasis and invasion of MDA-435 
breast cancer cells in vitro and in vivo [162]. Clearly therefore the IGF axis may plays 
an important role in some aspects of BC metastasis. 
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1.2.6 IGFBPs 
An extensive literature suggests that IGFBPs display many effects in different cancer-
ous cells. On occasion these reports have been contradictory and this is an area of 
intense ongoing research. In the first instance the effects of IGFBPs are related to the 
influence they exert on the function of the highly mitogenic growth factors IGF-I and -2 
which they bind with high affinity. These may be summarised as follows  i) They serve 
as  transporters in plasma and other biological fluids  to control the efflux of IGF-I and 
IGF-2 into the tissues, ii) they extend the half-life of IGF-I and IGF-2 and thereby influ-
ence their metabolic clearance; iii) provide a means of tissue and cell-type specific 
localization; iv) they directly modulate interaction between IGF-I and the IGF-IR, 
thereby indirectly controlling its biological activities [82]. In addition to these IGF-
dependent effects, IGFBPs in many instances display IGF-independent effects. In ad-
dition IGFBPs may show both IGF-dependent and IGF-independent effects within the 
same tissue. A further layer of complexity is added by the fact that IGFBPs can exert 
enhancing or inhibiting effects on IGF action and that such effects may show a tissue 
dependent specificity [163-167]. IGFBPs are also substrates for IGFBP proteases 
which cause the release of bound IGFs in the vicinity of cell surface receptors. BC cell 
lines and primary cultures  secrete such proteases [168, 169] and it is suggested that 
the activity of these enzymes may regulate access of growth factors to malignant 
breast epithelial cells [82]. IGFBPs also have differential effects on initiation of apop-
tosis which appear to be regulated by the nature of extracellular matrix and other con-
stituents in the vicinity of cells. The IGF-dependent and independent effects of 
IGFBPs are regulated via a complex sequence of post-translational modifications 
(PTM), including glycosylation [170], phosphorylation [171] and proteolysis [172]. All 
of these aspects of the molecular physiology of IGFBP activity make interpretation of 
data obtained from experiments with cancer cells in culture (including BC) difficult. 
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However, with these caveats in mind there follows a short discussion on the activity of 
IGFBPs in cancer cells with special reference to BC. 
IGFBP-1 inhibits IGF-I action in breast cancer cells and causes and decreases IGF-1 
stimulated cell motility [173, 174]. IGFBP-2 is over expressed in a wide variety of hu-
man malignancies, including BC [175], prostate cancer [176], ovarian cancer [177], 
and lung cancer [178]. Over expression of IGFBP-2 has also been reported in BC cell 
lines [26]. IGFBP-2 binds to integrins  on the BC cell surface in a RGD dependent 
manner and up-regulates genes involved in apoptosis (e.g. TGF-β1 and NFκB) which 
in turn inhibits cancer cell migration [102]. Interestingly, single nucleotide polymor-
phisms (SNPs) in the 3’ region of the IGFBP-2 gene have been associated with ER+ 
breast tumours carrying BRCA2 mutations [179]. Conversely, IGFBP-2 inhibited the 
tumour suppressor gene on chromosome 10 (PTEN) expression in MCF-7 BC cells 
[26].  PTEN inhibits protein synthesis and cell cycle progression and regulates phos-
phatidylinositol-3-kinase (PI3K) signalling and thus modulates IGF signalling pathways 
[23]. Therefore, IGFBP-2 over expression in this instance promoted tumour growth by 
inhibiting PTEN activity and enhancing IGF signalling. Other studies have reported the 
inhibition of cancer cell proliferation, migration, and invasion by IGFBP-2. Pereira and 
co-workers reported that, IGFBP-2 inhibited IGF-mediated tumour growth in vivo and 
cell migration in vitro via an αvβ3 integrin mediated mechanism [102]. Again in contra-
distinction, other studies show that, IGFBP-2 acts as a growth promoter in cancer. 
High levels of IGFBP-2 in serum were reported in several metastatic tumours includ-
ing ovarian, adrenocortical, prostate cancer, colorectal cancer and some leukaemias 
[180, 181].  IGFBP-2 was also reported to be over expressed in invasive breast carci-
noma and in situ breast carcinoma relative to the normal mammary gland [175]. In 
addition IGFBP-2 expression is regulated by epigenetic events such as DNA methyla-
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tion and histone acetylation within the promoter region of the gene adding a further 
level of complication to the activity of this protein [182].  
IGFBP-3 binds to IGF-I and –II to prevent interaction with the IGF-IR, thereby de-
creasing their signalling capacity [112] and inhibits the growth of Hs578T human BC 
cell line. IGFBP-3 initiates apoptosis in prostate cancer cells [183] and enhances radi-
ation induced apoptosis [184], and paclitaxel induced apoptosis in  breast cancer epi-
thelial cells [185]. In mechanistic studies, IGFBP-3 was shown to interact with the nu-
clear retinoid X receptor (RXR)-α and modify its binding to the transcription factor 
Nur77; this in turn activates the apoptosis cascade [179]. Moreover, p53 dependent 
up regulation of IGFBP-3 interrupts cell cycle progression and up regulates apoptotic 
signals interacts in a p53 independent manner with the apoptotic Bcl-2 family [113]. 
Study showed that IGFBP-3 interacts with the 78-kDa glucose regulated protein 
(GRP78), causing tamoxifen resistance in BC [186]. IGFBP-3 initiates the 
dephosphorylation of FAK, in spite of lacking an RGD sequence [187]. Recently, a cell 
surface IGFBP-3 receptor has been reported to mediate the apoptotic effects of 
IGFBP-3 through caspase-8 activation [188]. In a clinical setting, Deal et al. (2001) 
highlighted some evidence that the circulating level of IGFBP3 is inversely associated 
with the risk of many tumours, in addition some anti-proliferative agents such as anti-
oestrogens may act by up-regulating  IGFBP-3 expression [189]. 
Little data is available on the expression and activity of IGFBP-4 in BC although over-
expression of IGFBP-4 reduces proliferation in the malignant M12 prostate epithelial 
cell line in response to IGFs [190].  
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IGFBP-5 is expressed and secreted  by multiple ER+ BC cell lines  including MCF7, 
T47D, ZR751 and BT474 [191]. This positive correlation between ER expression and  
IGFBP-5 was confirmed following  mRNA and protein analysis of IGFBP-5 in 47 hu-
man breast tumours [192]. This study also concluded that normal breast tissue pro-
duced significantly less IGFBP-5 compared to adjacent primary tumour cells, suggest-
ing that IGFBP-5 expression is associated with the proliferative state. In a functional 
context Perks and colleagues reported that IGFBP-5 reduced ceramide-induced cell 
death in the Hs578T cell line [193]. IGF-I was reported to increase IGFBP-5 secretion 
in T47D cells although this was not accompanied by increased IGFBP-5 mRNA ex-
pression, suggesting that IGF-I influences IGFBP-5  synthesis in a post-translational 
manner perhaps by binding and inhibiting proteolysis of IGFBP-5 [194]. Another study 
in T47D cells revealed that progestins, anti-oestrogens and other growth inhibitory 
hormones reduced IGFBP-5 mRNA expression and protein secretion in T47D cells, 
also suggesting a role for IGFBP-5 in tumour cell proliferation [195]. IGFBP-5 has 
been used as a potential prognostic factor in BC diagnosis. [196] and Hao et al re-
ported that, IGFBP-5 is among the genes that were up regulated in metastatic lymph 
node spread of  primary breast tumours [197]. A separate study from Li et al., also 
showed that increased IGFBP-5 mRNA expression is positively associated with axil-
lary lymph node invasion in  ER+ BC [198]. Similarly in a study of ER+/PR+ patients 
BC patients low serum IGFBP-5 levels correlated with increased disease-free survival 
(DFS) [199]. Despite conflicting reports regarding the role of IGFBP-5 in normal 
mammary gland development and involution, there is a clear relationship between 
IGFBP-5 expression and breast tumour development and progression. Understanding 
this relationship may reveal IGFBP-5 as a predictive factor in patient survival. 
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Very little data has been published on the role of IGFBP-6 in BC physiology or even in 
normal mammary gland function. IGFBP-6 has been reported at low levels in breast 
cancer tissues [200] and levels are reported to be elevated in Her-2+ tumours which 
are resistant to trastuzumab although a causal role for IGFBP-6 in resistance has not 
been established [201]. IGFBP-6 has been reported to stimulate the migration of 
rhabdomyosarcoma cells in an IGF-independent manner [202]. 
1.2.7 IGF axis and tamoxifen resistance 
The acquisition of resistance to SERMs in ER+ BC presents a major therapeutic chal-
lenge in the treatment and management of this type of cancer.  The molecular pheno-
types associated with such escape from SERM control are the subject of intense 
study through such techniques as gene array and proteomic analyses. The design of 
such studies has been predicated on the recruitment of alternative mitogenic signal-
ling pathways by cancer cells resulting in continued tumour cell growth and metasta-
sis. In vitro, BC cell lines can acquire tamoxifen resistance through growth in the 
presence of drug. The MCF-7 cell line is most commonly used in this research and 
there is a small literature which describes perturbations in IGF axis expression and 
function in such cells following the acquisition of tamoxifen resistance. Increased IGF-
IR expression in tamoxifen resistant cells may enhance E2 independent growth of the 
cells and an early study in wild type (wt) and TamR cells suggested that this may in-
deed occur [203] . However subsequent literature in this area is contradictory with re-
ports describing both the up regulation [204-206] and down regulation [207-209] of 
IGF-IR expression in TamR cells and the significance of altered IGF-IR activity in the 
development of TamR remains under investigation. However there is evidence that in 
TamR cells which have also developed resistance to the EGF-R inhibitor AG 1478 
subsequent cell growth is largely dependent on activation of the IGF-IR [210]. This 
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may provide a mechanism of escape of BC cells from both anti-oestrogen and anti-
EGF-R (Herceptin) based therapy.  
Some early studies reported altered IGFBP profiles on the acquisition of tamoxifen 
resistance by the MCF-7 and ZR-75-1 cell lines. However the species of IGBP report-
ed in these studies were not identified immunologically but only by molecular weight 
on ligand blot [211]. Subsequently the same group identified IGFBP-2 as down regu-
lated in TamR MCF-7 cell lines [212] although dexamethasone – a known regulator of 
IGFBP expression in mammary epithelial cell lines [213] - was present in these cul-
tures. Recently, IGFBP-5 has been reported to be down regulated at both mRNA and 
protein levels in TamR MCF-7 cells. This may have biological significance as this 
binding protein has been shown to inhibit growth of BC cells [163] and IGFBP-5 
treatment of BC tumour cells in a xenograft mouse model has been shown to restore 
tamoxifen sensitivity [132]. The mechanism of action of the SERD fulvestrant may be 
associated with increased expression of IGFBP-5 in BC cells [55]. However fulves-
trant treatment of MCF-7 cells also enhances ERα association with IGF-IR in a Src 
dependent fashion and is associated with ERα translocation to the plasma membrane, 
phosphorylation of IGF-IR and MAPK activation [75]. These findings are unexpected 
for a drug whose principle use is in the inhibition of BC cell mitogenesis by enhancing 
ERα degradation. The findings of this particular study are important enough to require 
independent confirmation. Figure 1.12 summarises the main role of the IGF involve-
ment in cancer. 
Currently many approaches aimed at inhibition of inappropriate signalling activity 
through the IGF-IR are under investigation. Tyrosine kinase inhibitors and monoclonal 
antibodies (Mab) are the two most common types of targeted therapies used in clinical 
trials in this area [29], principally small molecule inhibitors of IGF-IR tyrosine kinase 
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activity [31] and humanised blocking monoclonal antibodies to the IGF-IR [214] see 
Fig 1.13. However other strategies have also been adopted including the expression 
of IGF1R-inhibitory proteins [215] along with antisense oligonucleotides [216] and 
RNA interference strategies aimed at reducing expression of IGF-IR [217].  
 
Figure  1-13  Schematic representation of anti-IGF directed therapies used in BC. 
Shown are monoclonal antibodies (Mabs) directed to IGF-1 or IGF-1R and small mol-
ecule intracellular inhibitors of IGF-1R tyrosine kinase (TK) activity.  
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To date the most successful use of Mab in breast cancer has been the development 
of trastuzumab – a humanised Mab which blocks signalling through the HER2 recep-
tor. Only about 25% of patients respond to trastuzumab reflecting essentially that co-
hort in whom the protein is present and active. In combination with more traditional 
chemotherapeutic strategies trastuzumab has been used to treat metastatic breast 
cancer patients. In a modified strategy the agent pertuzumab – an inhibitor of HER 
family dimerisation – is also used in combination with trastuzumab and with chemo-
therapy in some instances [218]. However it remains the case that anti-Her directed 
therapy is not appropriate in many ER+ BCs. Because of this anti-oestrogen directed 
treatment remains a cornerstone of therapeutic approach. Accordingly anti-IGF di-
rected strategies have been applied either as mono-therapy or in combination with 
anti-oestrogen directed therapy (SERM, SERD or AI). Despite some initially encourag-
ing data it is fair to say that the outcome of most clinical trials is not encouraging. The 
most recent of these is the reported lack of efficacy of the humanised anti-IGF-IR Mab 
in association with exemestane (AI) or fulvestrant (SERD) in increasing progression 
free survival compared to placebo with anti-oestrogen therapy [66]. Nevertheless, 
more effort along with some thoughts of potential explanations for the failure of such 
strategies could result in development of improved approaches [219]. For example In 
terms of the targeting the IGF-IR by Mabs, concern has been expressed that blockade 
of the IGF-1R may result in activation of the IR. This effect may occur secondarily to 
rises in pituitary growth hormone (GH) secretion because of only partial feedback by 
IGF-I at the pituitary level. Elevated GH levels will trigger an increase in serum insulin 
and subsequent activation of IR. Because blockade of the IGF-1R leads to a general-
ised hyperinsulinemia prophylactic treatment with metformin has been examined in an 
attempt to deal with this problem [220].  
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Furthermore BC cells typically present with a heterogeneous array of insulin/IGF re-
ceptors. As well as IGF-1R, IR-A and IR-B (the A and B isoforms of the insulin recep-
tor) BC cells also express hybrid receptors containing the αβ subunits of IR-A or IR-B 
in association with the αβ subunits of IGF-IR. This variation in receptor presentation 
calls for a more sophisticated approach to the development of Mabs with appropriate 
blocking activities at individual receptors. If, as indicated by some studies above, the 
acquisition of tamoxifen resistance in MCF-7 cells is associated with decreased IGF-
IR expression then the, lack of effect of anti-IGF1R antibodies may be explained by 
this phenomenon [221]. Such considerations are typically not so pressing in the de-
velopment of small molecule inhibitors of receptor tyrosine kinase activity (TKIs) [222], 
and many such molecules are currently under study in clinical trials along with trials 
using a combination of Mab/TKI directed therapy. More recently development of spe-
cific inhibitors of the mTOR serine/threonine kinase in combination with anti-IGF di-
rected therapies have shown encouraging preliminary data [223, 224]. 
Owing to some of the difficulties associated with the manipulation of IGF receptor and 
ligand activity discussed above, interest in the third main component of the IGF axis - 
the IGFBPs and their potential role in the progression of BC has received increased 
attention with a view to the investigation of this family of proteins as potential thera-
peutic targets in BC. It is this research area which is the subject of the current study. 
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1.3 Aim and Objectives of the Study 
The overall aim of this report is to test this hypothesis – “Acquisition of tamoxifen 
resistance by BC cells is associated with perturbations in the IGF axis and such 
perturbations play a causal role in the establishment of tamoxifen resistance”  
1.3.1  Objectives: 
 examination of IGF axis gene expression  in Tam-R vs. wt. MCF-7 cells using 
rt-PCR, protein blotting and ELISA methodologies  
  use of gene knockout strategies to regulate the expression of candidate IGF 
axis genes in wt and TamR cells and subsequent examination of tamoxifen 
sensitivity in stably transfected cells 
 To investigate whether  candidate IGF axis genes regulate the phenotype of 
cell migration in wt and TamR cells 
  to investigate the expression of candidate IGF axis genes in tamoxifen 
sensitive and tamoxifen resistant BC tissue microarrays 
 to evaluate the prognostic and predictive value of candidate IGFBPs and their 
association with survival advantage in tamoxifen-resistant patients. 
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Chapter 2 Materials and Methods 
2.1 Materials 
Wild type (wt) MCF-7 and tamoxifen resistant MCF-7 (Tam-R) cells were generously 
provided by Prof Valerie Speirs (Leeds Institute of Cancer and Pathology) [225, 226]. 
RPMI-1640 media, RPMI-1640 phenol red free media (PRF), penicillin/streptomycin 
(Pen/Strep), 0.25% Trypsin-EDTA solution, foetal bovine serum (FBS) and dextran 
charcoal stripped (DCS)-FBS were from Invitrogen™, UK. Corning® 15 mL Centrifuge 
Tubes, T-75cm2 TC Flasks, 6 and 96 well tissue culture plates were from Corning Life 
Sciences, UK. Other tissue culture plastic ware was from Scientific Laboratory Sup-
plies Ltd, UK. Phosphate buffered saline (PBS) was from VWR-Lonza BioWhittaker®, 
UK. Trypan blue solution (0.4%) and dimethyl sulphoxide (DMSO) HYBRI-MAX® and 
β-mercaptoethanol were from Sigma, UK. The RNeasy® Mini Kit (cat no 74104) was 
from (Qiagen, UK). Ultrapure DNAse/RNase-free distilled water (cat no 10977035), 
DNase I (amplification Grade - cat 18068015) and RNase-Free Tubes (cat no AM 
12400) were from InVitrogen UK. Optical Adhesive Seal (No.P3-0300) was purchased 
from Geneflow Ltd, UK. High Capacity RNA to cDNA kit (cat no 4387406), Taq-
Man®Gene and expression Master Mix (cat no 4369016) were purchased from Ap-
plied Biosystems (ABI). IGF axis and TaqMan probes were also obtained from ABI 
(the details of the TaqMan probes are summarised in table 8.1 in the Appendix 2). For 
enzyme linked immunosorbent assay (ELISA) IGFBP-2 DuoSet (cat no DY674) and 
IGFBP-5 DuoSet (cat no. DY875) were purchased from (R&D Systems, UK). The 96 
well ELISA plates were purchased from Starlab, UK.  Accessory reagents for ELISA 
2N H2SO4 (cat no. DY994), Wash Buffer (cat no. WA126), Reagent Diluent (cat no. 
DY004), Streptavidin-HRP (cat no 890803), Substrate Solution Colour Reagent A 
(H2O2), Colour Reagent B (Tetramethylbenzidine) and normal goat serum (cat no 
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DY005) were also from (R&D Systems, UK). Absorbances were determined with a 
Thermo-Scientific Varioskan Flash type 300 spectrophotometer. Recombinant Human 
(rh) IGFBP2 cat no 674-B2-025,) rh IGFBP-5 (cat no 875-B5-025) and rh IGF-I (cat no 
291-G1) were from (R&D Systems, UK). Absolute ethanol (200 Proof), Molecular Bi-
ology Grade, (cat no BP2818-500) was obtained from Scientific Laboratory Supplies 
Ltd, UK.  Cell proliferation reagent WST-1 (cat no 11644807001) was from Roche, 
UK. The Cell-Lytic™ buffer (cat no. C2978), NP40 Cell lysis Buffer (cat no FNN0021), 
protease inhibitor tablets (cat no S8820), and phosphatase inhibitor cocktail 2 (cat no 
P5726) were from Sigma, (UK). BCA Protein Assay Kit (cat no PN23225) was from 
Pierce Biotechnology, UK).  The Trans-Blot®Turbo Transfer System (Serial no 69 
BR007547), Transfer pack mini format, 0.2 µm PVDF membranes (cat no 17-4156), 
10x Tris-Buffered Saline (10x TBS) and Mini-protean®TGX Stain-Free™ Gels (cat 
no456-8083), Laemmli Sample Buffer (cat no 161-0737) and Precision Plus protein ™ 
Dual Colour Standards (cat no 161-0374) marker were from Bio-Rad, UK. Gel-
Loading tips were from Sigma-Aldrich UK. Enhanced chemiluminescence (ECL) Dual-
vue Western Blot markers (cat no FRPN810) were from Scientific Laboratory Supplies 
Ltd, UK. Restore™ Plus Western Blot stripping buffer (cat no 46430) was from Ther-
mo-Scientific, UK. Bovine albumin Faction V (cat no 160069) was purchased from MP 
Biomedicals, UK. Tween® 20 (cat no C58H114O26) and Super-Signal® West Femto 
Maximum Sensitivity Substrates (cat no PN34095) were from Fisher Scientific Ltd, 
UK.  Mouse monoclonal to IGFBP-2 (cat no MAB6741) and mouse monoclonal to 
IGFBP-5 (cat no MAB8751) were from R&D System, UK. Anti-mouse HRP secondary 
(ab97046) was from Abcam, UK. Polyvinylpyrroldone (cat no 9003-39-8) and 
Tergitol® Solution (cat no NP40S) were purchased from SGMA, UK. IGFBP-5 shRNA 
plasmid (cat no sc-39591-sh), IGFBP-5 shRNA plasmid control (cat no sc-108060), 
IGFBP-2 shRNA plasmid (cat no sc-37195-sh), IGFBP-2 shRNA plasmid control (cat 
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no sc-108060) puromycin (cat no CAY13884-25), shRNA plasmid transfection medi-
um (cat no sc-108062) and transfection reagent (cat no sc-108061) were from Santa 
Cruz Biotechnology Inc., UK. Rabbit polyclonal anti-hIGFBP5 antibody (cat no ab 
4255) and rabbit monoclonal anti-hIGFBP-2 antibody (cat no ab109284) were from 
Abcam, UK. Antibody diluent Reagent Solution (cat no 00321) and was from InVitro-
gen, UK. Antigen retrieval solution (cat no, MP-607-x500) was from A.MENARINI Di-
agnostics, UK.  Novolink™ Max Polymer Detection System (Ref no RE7280-K), pe-
roxidase enzyme (cat no RE7157), protein block (cat no RE7158), Novolink™polymer 
(cat noRE7161), Novolink™DAB Substrate Buffer (cat no RE7163), DAB Chromogen 
(cat no RE7162) and haematoxylin (cat no RE7164) were from Feica Biosystem, UK.  
Xylene and alcohol were from Scientific Laboratory Supplies Ltd, UK. Cover slip (cat 
no SAJ-2240-03A) was from Cell Path Ltd, UK. A Leica incubator Microscope was 
used for cell imaging. For the immunohistochemistry TMAs, the whole slides were 
scanned using the Scan scope T3 Scanner (Aperio Technologies, Leica, UK). For cell 
migration studies Image-Lock 96-well Plate (cat no 4379) were from Essen Bio Sci-
ence, Ltd.UK and Incucyte instrumentation and software analysis packages were 
used (Essen Bio Science). Matrigel (Phenol Red Free cat no 734-0272 was from 
(VWR International, UK).  
. 
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2.2 Methods 
2.2.1 Tissue culture 
For routine culture MCF-7 (Passage range between  23-36) and TamR cells Passage 
range between  2-8) were seeded in growth medium (GM) composed of RPMI-1640 
media with phenol red supplemented with 5% (v/v) (FBS) 100U/ml penicillin, 100μg/ml 
streptomycin (PenStrep). Under experimental conditions Phenol Red free DCS medi-
um was used to remove any oestrogenic stimulus provided by these additives. Tam-R 
cells were obtained through the continuous culture of MCF-7 cells (for 21 months) in 
phenol red free RPMI containing 5% DCS-FB and 100 nM 4-hydroxytamoxifen (4-HT) 
(SIGMA, UK). After 21 months, 4-HT was withdrawn from culture medium, and cells 
passaged in phenol red free RPMI (+5% DCS-FBS) as described previously [225, 
226]. During routine tissue culture maintenance growth medium was changed every 3-
5 days.  At approximate by 70- 80% confluence, cells were washed with PBS and 
passaged (1:4) using 0.25 trypsin-EDTA. Cells were mixed with Trypan blue solution 
0.4% (SIGMA, UK) in 1:1 v/v and counted using a haemocytometer. Cell numbers 
were recorded and cells were seeded at the appropriate densities as described in the 
relevant figure legends. In 1ml of freezing medium (10% DMSO, 40% DCS- and 50% 
RPMI1640)  containing  1x106 cells/ml.  
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2.2.2 Real Time - Polymerase chain reaction 
The RNeasy® Mini Kit (Qiagen, UK) was used to extract and purify mRNA exactly ac-
cording to the manufacturer's protocol. Briefly, the buffer contains a high concentra-
tion of guanidine isothiocycanate, which supports the binding of RNA to the silica 
membrane (RLT) or RLT Lysis buffer was prepared by adding (1:100 v/v) 10µl of β-
mercaptoethanol into 990 µl of RLT.  350 µl of the RLT buffer were added to cell pel-
lets in 1.5 Eppendorf tubes. After vortexing for 1 min 350 µl of absolute ethanol were 
added. The mixture was transferred into the spin column and centrifuged at 10000g 
for 15 seconds. The flow-through was discarded and 700 µl of buffer RW1 contains a 
guanidine salt, as well as ethanol were added into the spin column and centrifuged at 
10000g for 15s. The flow-through was again discarded and 500 µl of RPE wash buffer 
was added into the spin column and centrifuged at 10000g for 15s. This step was re-
peated with centrifugation for 2min. The spin columns were placed in new 1.5 eppen-
dorf tubes and 30 µl of dH2O were added and centrifuged at 10000g for one minute. 
The mRNA was collected and quantified using a NanoDrop™ 2000 Spectrophotome-
ter. The A260/280 ratios along with mRNA concentration as ng/µl were recorded. This 
is to measure the purity of the RNA, however, there is a possibility of presence of 
DNA in RNA extracted which might have an impact on significance of the results. High 
Capacity RNA to cDNA kit (Applied Biosystems, UK) was used exactly according to 
the manufacturer’s protocol to synthesise single stranded cDNA from mRNA. Briefly, 
9μl of the RNA preparation (1μg RNA) was added to 10μl of 2x RT buffer followed by 
1μl of 20x enzyme mix to formulate a 20μl reaction. The mixture was centrifuged and 
incubated in the PTC-100 Peltier thermal cycler at 37˚C for one hour, followed by 
95˚C for 5 minutes and finally cooled to 4˚C, then stored at -20˚C until required for use. 
RT-PCR reactions were prepared under a highly sterile environment. Ultrapure 
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DNAse/RNase-free distilled RT-PCR master mix was prepared with cDNA and Taq-
Man probes ABI (see Appendix 2 Table 8.1) in 20μl total reaction volume as follows: 
Table  2-1 Summary of the RT-PCR reaction 
 
 
 
 
 
 
 
 
Expression of each gene was analysed in triplicate in 96 well PCR plates. After adding 
the appropriate volume of PCR Master Mix, cDNA Sample, Probes and dH2O in each 
well, the plate was sealed, centrifuged for 20 seconds.  Each plate contained a non-
template control and a reverse transcriptase negative control. The Taqman® probes 
were amplified using the Roche 480 LightCycler®. The amplification protocol includ-
ed;2 min at 50˚C, 10 min at 95˚C, and then 40 cycles of 2 step cycling; 15 sec at 95˚C 
and 1 minute at 60˚C. Quantification of the PCR results was estimated based on the 
threshold cycle (Ct). Ribosomal protein, large, P0 (RPLP0) was used as the house-
keeping gene (HKGs) after validation. The data were analysed by using the compara-
tive ΔCT method (ΔCt (target) – ΔCt HKG). For calculating relative changes in gene 
expression (wt MCF7 v TamR) the ΔΔCt method is used where the fold change in 
 Reagent volume (μl)  
1 PCR Master Mix 10.0μl 
2 cDNA Sample 1.0μl 
3 Probes      1.0μl 
4 dH2O 8.0μl 
5 Total volume  20.0μl 
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gene expression is defined as 2-ΔΔCt and is plotted as log10 on the ordinate axis in rel-
evant figures.  
2.2.3 Western and Ligand blot analysis 
Cell conditioned media samples (1ml) containing secreted IGFBPs were freeze dried 
and stored at -20°C prior to analysis. For Western blot freeze dried media was dis-
solved in x1 SDS-PAGE sample buffer containing (1:20 v/v) β-mercaptoethanol and 
loaded onto the 15% SDS-polyacrylamide gel (45 µl /well) along with appropriate mo-
lecular weight markers. Gels were run at 120 V for 1 hr, and proteins were transferred 
to Immobilon-P semi dry membranes using the Trans-Blot Turbo device (BioRad) for 
10 minutes. Subsequently, the membranes were blocked with 5% bovine serum al-
bumin (BSA) in 0.1% TBST for at least 1hour on a shaker at room temperature. Then, 
the membranes were incubated overnight room temperature (RT) with either anti ER-
α (1:1000 v/v) (Dako, Cambridge, MA – M704728-2), anti-ER-β (1:500 v/v) (Abcam, 
Cambridge, MA – ab288),  (1:1000 v/v) anti-IGFBP‑2 (1:1000 v/v)  (R&D System, 
Clone 92326-  MAB6741), anti IGFBP‑5 (1:1000 v/v)  (R&D System, Clone 145619-
MAB8751), antibody or anti-actin (Santa Cruz Biotechnology) with 5% BSA containing 
tween 0.1% TBST. Membranes were washed x5 with TBST and incubated with the 
appropriate horseradish peroxidase (HRP) conjugated secondary antibody cat no 
ab97046 (1:100000) for 2 hours at room temperature in TBS. The membranes were 
washed x4 with TBST and x1 with TBS, membranes were developed with ECL sub-
strate (1:1 v/v) (Pierce Rockford, IL) and images obtained on the Gel-Doc imager (Bio-
Rad). 
 For ligand blotting freeze dried medium was re-suspended in non-reducing SDS 
sample buffer (minus β-mercaptoethanol) and electrophoresis and blotting were per-
formed as describe for Western blotting. Membranes were then blocked in 3% NP40 
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in TBS for 30 min, 3% BSA in TBS for 2hr and finally in 0.1% Tween 20 in TBS for 10 
min on a shaker at RT. Filters were incubated overnight at 4°C with 20 ng mono-
biotinylated IGF-2 (GroPep) in 1 ml 1%BSA/0.1% Tween in TBS. After washing 3 x 15 
min in 1%BSA/0.1% Tween in TBS membranes were incubated in streptavidin-HRP 
conjugate (cat no ab97046) in 1%BSA/0.1% Tween (1:2000), washed 3 x 15 min in 
TBS and developed with ECL reagent. 
2.2.4 Enzyme-Linked Immunosorbent Assay  
IGFBP-5 and IGFBP-2 concentrations in conditioned media were determined by en-
zyme-linked immunosorbent assay (ELISA) (R & D Systems, UK) according to the 
manufacturer’s protocol. Briefly, diluted capture antibody at 4.0 µg/ml was plated in a 
96-well microplate (100µl/well) and incubated overnight at room temperature. On the 
following day, the plate was washed with 400µl of diluted washing buffer (1:25 v/v) 
(0.05% Tween 20 in PBS). Plates were blocked with 300µl of blocking buffer (0.5% 
Tween 20 v/v in PBS with 0.05% NaN3 w/v) and incubated for 1 hour. After washing 
100 µl of appropriately diluted standard along with samples were added and incubat-
ed for 2 hours. Plates were washed and 100µl of detection antibody (1:200 v/v) were 
added and the plates were incubated for 2 hours. After washing 100µl of working dilu-
tion (1:200 v/v) of streptavidin-HRP were added and the plates were incubated for 20 
minutes. After washing 100µl of substrate solution (1:1 v/v) (colour reagent A H2O2 
and colour reagent B Tetramethylbenzidine) were added and the plates were incubat-
ed for 20 minutes. Finally, 50µl of stop solution (2N H2SO4) were added and absorb-
ance was determined at 570nm. 
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2.2.5 Cell proliferation assay 
Cell proliferation reagent WST-1 is a formazan dye used for spectrophotometric quan-
tification of cell proliferation and viability. Cells were grown in Phenol Red (PR) free 5% 
DCS serum (PR-DCS) and then seeded in 96 well cell culture plates (TC) at 5 x 103 
cells per well (100µl suspension). Control wells where no cells were seeded were in-
cluded. Cells were left to attach overnight and then washed with PBS and treated with 
0, 0.1, 1, 10 or 100 nM IGF-1 in a background of serum free PR free medium in tripli-
cate for 48 hr. Following incubation 10µl of WST-1 reagent were added to each well 
and placed in an incubator for 0.5 – 4hr. The plate was placed on flat bed shaker for 1 
min and then absorbance was determined at 450 nm.  IGFBP-2 and IGFBP-5 were 
used at 0,1,10 or 100 nM or at a fixed concentration of 10 nM when co-incubated with 
varying concentrations of IGF-1. Details are given in the appropriate Figure legends. 
For experiments with 4-HT, cells were grown and seeded as above. To examine ta-
moxifen sensitivity of wt (MCF-7 cell passage no 35), TamR (TamR cell passage no 7), 
and IGFBP knock down (KO) cell lines stock tamoxifen was dissolved in absolute eth-
anol at 1mM and used at a final concentration of 0-1000 nM. At 0 – 5 day time points 
10 µl of WST-1 were added to the wells and plates were read at 450 nm as described 
above.  
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2.2.6 IGFBP knockdown  
IGFBP-2 and IGFBP-5 were knocked down in wt (passage no 35) and TamR cells 
(passage no 5) respectively using a short hairpin (sh) RNA based strategy. shRNA 
based knock down of gene expression occurs through stable integration of an shRNA 
containing plasmid. The subsequently transcribed shRNA product is processed to an 
si (short inhibitory) RNA product by the endoribonuclease Dicer. Further processing of 
the short inhibitory RNA (siRNA) species occurs ultimately leading to the association 
of siRNA–RISC (RNA induced silencing complex) with target mRNA and the hydroly-
sis of the latter mRNA species. A diagram outlining the mechanism of action of 
shRNA based gene silencing is shown in Fig 2.1.  Wt and TamR cells were seeded in 
Phenol Red (PR) free 5 %DCS serum (PRF-5% DCS) in two six well tissue culture 
plates at 5 x 105 cells per well. Cells were transfected according to the manufacturer’s 
protocol. Briefly, cells were incubated at 37°C until 50-70% confluency. Cells were 
washed with 1 ml transfection media and incubated with 1ug IGFBP or control shRNA 
plasmids and 0.5-3% (v/v) transfection reagent in a final volume of 1ml for 6hr. After a 
further 6 hr, 1ml of 2x DCS-FBS were added to each well and incubation continued 
overnight. Then media were replaced with PR free 5% DCS serum containing 6 μg/µl 
puromycin (the appropriate selection agent) and changed every 3-5 days. Dead cells 
were removed with media changes and around 3-4 weeks, puromycin resistant cells 
began to grow. At 70% confluence the cells were expanded prior to performing an as-
say for IGFBP-2 and IGFBP-5.  Levels of IGFBP-2 and -5 in media conditioned by 
control and knock down cells together with untransfected wt and TamR cells were de-
termined by ELISA as described above (2.2.4). Heterogeneous populations of shRNA 
IGFBP-5 and IGFBP-2 knockdown cells were cloned in 96-well plates by limiting dilu-
tion. After 2 weeks individual colonies were identifiable in a significant proportion of 
microtitre wells. Typically 6 such clones were allowed to grow to confluence and me-
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dium collected for IGFBP-2 or IGFBP-5 assay by ELISA. IGFBP concentrations in 
conditioned medium were compared to those obtained in contemporaneously grown 
wt or TamR cells. Clones which showed the highest level of knock down were subse-
quently expanded and stored in liquid N2. 
 
 
Figure  2-1 Mechanism of shRNA based gene silencing.  
Adapted from 
http://www.bing.com/images/search?q=shrna+&FORM=HDRSC2#view=detail&id=E7
A805D8BB419386DDEB59A54F35667973B7AE05&selectedIndex=0  
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2.2.7 Cell migration 
Matrigel (phenol red Free - PRF) was prepared by thawing overnight at 4 ˚C and dilut-
ed in pre-cooled RPMI-1640 PRF media to provide a final protein concentration of 
100µg/ml.  96-well Essen Image Lock plates were placed on ice and pre-cooled 200 
µl yellow tips were used to load 50µl of the diluted matrigel into each well. Plates were 
then incubated at 37 °C CO2 for 1h to allow solidification of matrix. RPMI-1640 PRF 
media with 5% DCS media was used to seed cells at concentrations of 5x105 per well. 
The plates were incubated for 18hs to allow cells to attach to the matrix following 
which sterilised 96-well Wound-Maker pins were used to simultaneously generate 
precise and reproducible cell-free zones 700-800µm wide in cell monolayers. Plates 
were placed in the IncuCyte incubator at 37°C and equilibrated for a minimum of 15 
minutes before the first scan. The software was set to scan the experiment every 1 
hour for migration assays. The IncuCyte automatically acquires images for the entire 
duration of the assay (94h). IncuCyte integrated software quantifies cell migration us-
ing the metric relative wound density (RWD). In addition to experiments on Matrigel 
we also conducted experiments which monitored cell migration on plastic. Preparation 
of seeded 96-well Essen Lock plates was exactly as described above for Matrigel 
coated plates. Migration of six different cell lines was analysed using this technique – 
parental wt (passage no 36) and TamR MCF-7 cells (passage no 7); IGFBP-2 KO 
(clone F8) and scrambled shRNA control; IGFBP-5 KO (clone B4) and scrambled 
shRNA control.  Images of wound healing were also captured at various time points 
and are presented along with plots of RWD v time. For each cell line 12 replicates 
were performed and data were generated as mean ± SD of RWD by the IncuCyte 
software. Data were subsequently imported to GraphPad Prism and  analysed for sig-
nificant differences in migratory activity using repeated measures ANOVA followed by 
Bonferroni’s post-hoc test.   
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2.2.8 Immunohistochemistry  
2.2.8.1 Breast cancer patients and ethical approval   
Breast cancer samples used for tissue microarrays (TMAs) were collected from pa-
tients who had undergone initial surgery at Leeds Teaching Hospitals (LTH) NHS 
Trust, Leeds, UK, between 03 Jul 1975 to18 Nov 1997 (22 years). Before starting, 
ethical approval was gained from the Local Research Ethics Committee of the Leeds 
Teaching Hospitals (LTH) NHS Trust, Leeds, UK with REC reference number: 
06/Q1206/180. A total of 424 patient samples divided into two subgroups, tamoxifen-
resistant (TamR) and tamoxifen-sensitive (TamS). 289 patients had no evidence of 
acquired tamoxifen resistance. Therefore, this cohort was used as the control group in 
our investigation. On the other hand, 135 patients were confirmed to have acquired 
resistance to tamoxifen.  
2.2.8.2 Samples collection and Tissue Microarray Preparation   
Consented breast tissue samples were fixed in formalin, paraffin-embedded (FFPE) 
blocks. A 5µM section was taken and an H&E stain was conducted to identify tumour 
regions. A 0.6mm core was taken from the tumour area and transferred to a recipient 
paraffin TMA block in triplicate (Fig 2.2). During TMA construction a border and orien-
tation cross of easily identifiable tissue is used to aid the analysis and scoring the 
stained TMA slide. 5µm sections were cut from the complete TMA and stained by 
Immunohistochemistry staining procedure (see section 2.2.8.4).   
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Figure ‎2-2 Diagram illustrates the TMAs constructions. 
The arrays are collected by selecting core needle biopsies from a specific area of 
breast tumour in pre-existing paraffin-embedded tissue blocks and then re-embedding 
them into another arrayed “master” block, using an apparatus developed by Konenen 
et al. Each core is about 0.6mm and therefore, more than 600 specimens can be rep-
resented in a single paraffin block.  5µm sections are cut from the complete TMA and 
stained by Immunohistochemistry. 
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2.2.8.3 Antibody Optimisation 
An online system called The Human Protein Atlas was used as a pilot to choose the 
appropriate tissues and specific IGFBP-2 antibody http://www.proteinatlas.org/. The 
anti-IGFBP-2 antibody was then initially optimised in kidney at 1:50, 1:100, 1:200 and 
1:400 dilutions, and  the 1:100 IGFBP-2 antibody concentration was chosen on the 
basis of its having superior cytoplasmic staining (see Appendix 3). 
Multi-tissue slides containing tonsil, mucinous ovarian tumour, colon, muscle, colorec-
tal tumour, oesophagus, placenta, desmoids type smooth muscle tumour and spleen 
were used for antibody optimisation. A staining was performed using polyclonal anti-
body against IGFBP-2 (Abcam) and IGFBP-5 (Santa Cruz) and was optimized by se-
rial dilution. Figure 2.3 is representative of IGFBP-2 multi-tissue staining and the opti-
mised images included in Appendix 3. 
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Figure ‎2-3 FFPE multi- tissue sections.   
Multi-tissue slides containing tonsil, mucinous tumour, colon, muscle, colorectal tu-
mour, oesophagus placenta, desmoids type smooth muscle tumour and spleen. Tis-
sues were stained with IGFBP-2 at a dilution of 1:100.  
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2.2.8.4 Immunohistochemistry  
To enhance detection, antigen retrieval was achieved after de-waxing using Mena 
Path Revelation buffer solution (cat no MP-607-X500) in the Mena Path pressure 
cooker containing 500 ml distilled water for 40 minutes. Immediately following this 
slides were immersed in PBST (1x TBS containing 0.2% Tween 20) buffer then dis-
tilled water. A liquid wax border was applied to the glass microscope slides around the 
tissue and TMAs to prevent reagent dispersion. Then the slides were washed in PBST 
and blocked with 100 µl Novacastra peroxidase (cat no RE7101) for 10 minutes at RT. 
Slides were then washed with PBST and 100 µl of protein blocking solution (cat no 
RE7102) was added and slides were incubated at RT for 2 minutes. Rabbit monoclo-
nal antibodies against hIGFBP-2 (1:50 v/v) and rabbit polyclonal antibody against 
IGFBP-5 (1:800 v/v) were added and incubated at RT for 1 hour. These specific anti-
bodies do not cross react with the other IGFBPs.  Slides were washed 3 times for 5 
minutes with PBST and 100µl of secondary antibody (Novolink polymer cat no 
RE7112) was added and incubated for 30 minutes. After washing 3 times in PBST for 
5 minutes 100 µl of the diluted DAB chromogen (1:20 v/v) (cat no RE7105) was added 
to each slide and incubated at room temperature (RT) for exactly 5 minutes. Rehydra-
tion of slides was conducted in a series of alcohols, 100%, 75%, 50%, and 25% for 3 
minutes in each concentration, and washed in running tap water. Endogenous peroxi-
dase activity was blocked using 0.75% H2O2 for 20 minutes and then rinsed in running 
tap water.  Slides were counter stained by immersing in Mayer’s haematoxylin for 1 
minute and washed in running tap water, then immersed in Scott’s tap water for 2 
minutes followed by a further wash in running tap water. The slides were then dehy-
drated in a series of ethanol (25% for 15 seconds, 50% for 2 minutes, 70% for 5 
minutes, and 100% for 5 minutes) and were immersed in xylene 3 times for 3 minutes. 
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Finally, the sections were mounted in DPX and cover-slips applied. For negative con-
trols, primary antibody was omitted. 
2.2.8.5  Definition for cut-off point 
After staining, slides were scanned (see Scope Scan® system, Aperio). Subsequent-
ly, the pixel intensity Aperio algorithm was used (Developed by A.Wright, Leeds Virtu-
al Pathology Department) and the scanned slides were uploaded into a locally devel-
oped computational system by Alexander Wright called Tissue Microarray Informatics, 
to calculate the algorithmic score. Pixel intensity data were then exported to excel. To 
our knowledge this method had not been used for the antibodies studied in this thesis, 
therefore a cut-off point was required to enable dichotomisation of the data for down-
stream analysis. As specimens were triplicates, an average of scoring was taken. A 
Receiver Operating Characteristic Curve (ROC) was used to determine a point of di-
chotomisation. All these data were entered into an excel file, then saved as text file 
and uploaded into the cut-off finder online program (see 
http://molpath.charite.de/cutoff/) [227].  
As an outcome, the cut off point was determined to be 0.1 for both cohorts with sensi-
tivity of 66.7 % and specificity of 41.5%. Accordingly, TMA specimens were catego-
rised into two categories; a positive group that represents strong staining (> 0.1) and 
the negative group with very weak or absent of staining (< 0.1). With help from clini-
cians at St James Teaching Hospital (Prof Christopher Twelves, Dr Maria Jove), clini-
cal history and tumour characteristics were retrieved from the patients’ clinical system. 
Survival durations in months and the event of ‘death’ was retrieved from the patients’ 
clinical system and reported as 1 for ‘alive’ and 0 for ‘dead’. Statistical Package for 
Social Sciences (SPSS) version 22 software and Log-rank test (Mantel–Cox test) hy-
pothesis test was used to plot Kaplan-Meier graphs. 
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Chapter 3 Results 
The IGF axis in wt and TamR MCF-7 cells  
3.1 Introduction  
We assessed expression of the IGF axis (IGF-1, IGF-2, IGF-1R, IGF-2R, IGFBP-1, 
IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6) in TamR vs Wt MCF-7 cells. 
mRNA from both cell lines was extracted and used for first strand cDNA synthesis. 
TaqMan probes were used for qRT-PCR and eight biological repeats were performed 
for each cell line with triplicate technical replicates within each PCR microtitre reaction. 
RPLP0 was validated and used as a housekeeping gene (HKG). 
3.2 RNA Quantification 
Purity of RNA was determined using the ratio of A260/A280.  RNA quality is generally 
considered adequate when the A260/A280 ratio value is > 1.85.  A260/A280 ratios 
were typically 1.9-2.1 which is indicative that our RNA was mostly free of protein con-
tamination. However, there is a possibility of presence of DNA in RNA extracted which 
might have an impact on significance of the results. Figure 3.1-A demonstrates the 
A260/A280 ratios in several RNA preparations from eight different batches of wt and 
TamR cells.  RNA concentrations were between 200-640 ng/µl (Figure 3.1-B) and no 
reproducible differences were apparent between MCF-7 and TamR cells. 
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Figure  3-1 (A) A260/280 ratios and mRNA concentrations for eight different 
preparations of mRNA from wt MCF-7 and TamR cells. 
Triplicate technical repeats were performed for each mRNA preparation. (B) Corre-
sponding mRNA concentrations in preparations described in (A).  
 A 
 B 
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3.3 Validation of housekeeping gene. 
The 36B4 gene encodes the acidic ribosomal phosphoprotein P0 (RPLP0) and pro-
vides a very reliable and consistent standard for use in gene expression analysis in 
several tissues including, breast, brain and heart. Accordingly Ct values were deter-
mined for RPLP0 in wt and TamR MCF-7 cells. No statistical significance (Student’s t-
test) was seen in Ct values for cDNA preparations from the two different cell lines wt 
=20.01±1.21; TamR 19.29±0.82 (mean ± SD n=6; p=0.47) – Fig 3.2 and RPLP0 was 
therefore used as a HKG for qRT-PCR experiments. 
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Figure  3-2 Validation of housekeeping gene (RPLP0). 
Ct values for RPLP0 expression in wt and TamR cells. Data are presented as 
mean+/-SD of Ct (n=6). 
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3.4 Raw Ct values for qRT-PCR 
Four separate analyses of IGF axis gene expression in wt and TamR cells were 
performed. Ct values for a representative experiment are presented in Table 3.1. 
Based on these Ct values we were able to make some qualitative remarks about 
expression of the IGF axis genes in these cells. Consistently in our experiments IGF-I, 
IGF-2, IGFBP-1, IGFBP-3 and IGFBP-6 showed low abundance (mean Ct > 33). The 
other five IGF axis genes IGF-1R, IGF-2R, IGFBP-2, IGFBP-4 and IGFBP-5 were 
expressed at moderate to high levels (mean Ct < 26). An outlying value for a Ct 
obtained for IGF-2R expression in TamR cells (Ct3) is indicated in red although this 
value was included in the calculation of mean +/- SD for this gene.  
 Qualitative guide to Ct values in RT-PCR; – 
 Ct > 40 almost certainly not expressed 
 Ct 35-39 very low abundance           
 Ct 30-34 low abundance 
 Ct 25-29 moderate expression                                
 Ct 20-24 moderately high expression 
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Table ‎3-1 Individual Ct values for IGF axis expression in wt and TamR  
 
 
Table 3.1 Individual Ct triplicate values (Ct1 – Ct3) for IGF axis expression in wt and 
TamR are indicated along with mean +/- SD. N/A no value obtained. This experiment 
was repeated four times and a representative data table is shown. Moderate to highly 
expressed genes are highlighted in bold red.  
Wt  TamR 
Ct1 Ct2 Ct3 Mean STD IGF axis Ct1 Ct2 Ct3 Mean STD 
20.83 20.8 20.28 20.64 0.31 RPLP0 19.23 18.91 19.06 19.07 0.16 
41.92 41.87 41.21 41.67 0.40 IGF-I 41.36 N/A 40.93 41.15 0.30 
36.47 36.78 36.61 36.62 0.16 IGF-2 N/A 40.27 N/A 40.27 N/A 
23.86 23.87 23.66 23.80 0.12 IGF-IR 23.61 23.59 23.39 23.53 0.12 
25.99 25.31 26.52 25.94 0.61 IGF-2R 25.21 25.17 17.62 22.67 4.37 
35.45 35.58 35.19 35.41 0.20 IGFBP-1 42.28 N/A 39.86 41.07 1.71 
25.66 25.51 25.19 25.45 0.24 IGFBP-2 22.69 22.7 22.64 22.68 0.03 
33.79 32.74 33.97 33.50 0.66 IGFBP-3 34.2 34.39 34.4 34.33 0.11 
23.7 23.33 23.36 23.46 0.21 IGFBP-4 24.20 23.23 25.52 24.32 1.15 
24.04 23.7 23.48 23.74 0.28 IGFBP-5 28.2 26.45 26.52 27.06 0.99 
35.25 34.91 34.77 34.98 0.25 IGFBP-6 32.71 32.85 32.49 32.68 0.18 
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3.5 Expression of the IGF Axis in wt v TamR cells 
A profile of IGF axis gene expression in wt v TamR cells indicated some differences in 
expression of these genes (Fig 3.3).  Repeated analysis of expression of these 5 
genes in wt v TamR cells indicated that IGFBP-5 was consistently down regulated 
whereas IGFBP-2 was consistently up regulated in TamR cells. In contrast no con-
sistent changes in expression of IGF-1R, IGF-2R or IGFBP-4 between wt and TamR 
cells were evident (Fig 3.3). For IGFBP-2 consistent 2-4 fold increases in expression 
were seen in TamR cells v wt cells whereas IGFBP-5 expression was down regulated 
5-7 fold in TamR v wt cells.  
[72] 
 
 
 
Figure  3-3 Fold changes in selected IGF axis genes in TamR v wt cells.  
The expression of IGF-1R, IGF-2R, IGFBP-2, -4 and -5 is compared between wt and 
TamR cells. Data is plotted as 2 –ΔΔCt and represents the fold change in expression in 
TamR v wt MCF-7 cells. This experiment was repeated at least six times and similar 
results were obtained in each case. The mean of the experiments is shown with data 
presented as mean ± SD. 
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3.6 Western blot 
In order to confirm the changes evident in IGFBP-2 and -5 mRNA expression in wt v 
TamR cells at the protein level we used the techniques of Western and Ligand blotting. 
IGFBPs are essentially secreted proteins and accumulate in medium which is condi-
tioned by cells in culture. Freeze dried conditioned medium of three wells of wt and 
TamR cells were reconstituted in sample buffer and analysed by Western blot for 
IGFBP-5 and IGFBP-2 expression (Fig 3.4 and 3.5). For IGFBP-5 it is clear that the 
protein shows increased abundance in medium conditioned by wt compared to TamR 
cells (Fig 3.4A). This agrees with the results obtained by qRT-PCR (Fig 3.3). Densi-
tometric analysis of band intensity (Fig 3.4B) suggested a 6-fold decrease in protein 
expression in TamR compared to wt cells which also agrees closely with qRT-PCR 
data. Freeze dried conditioned medium was also reconstituted and analysed for 
IGFBP-2 protein by Western blot (Fig 3.5A). IGFBP-2 was expressed at a higher level 
in TamR cells compared to wt cells. Densitometric analysis of the data (Fig 3.5B) sug-
gested that IGFBP-2 concentrations were approximately 3-fold higher in TamR cells 
than in wt cells. This data also agrees well with qRT-PCR results.  
[74] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-4A Western blot for IGFBP-5.  
Expression of IGFBP-5 in wt and TamR cell conditioned medium. IGFBP-5 was clear-
ly identified following enhanced chemiluminescence (ECL) detection. Images were 
typically captured after 1-15s of exposure.  This experiment was repeated 3 times with 
similar results in each instance.  
Figure3.4B Densitometric analysis of IGFBP-5 band intensity.  
Triplicate lanes per blot were analysed for band intensity for both wt and TamR condi-
tioned media using Image Lab software. Data are presented as mean +/- SD (n=3) of 
Arbitrary Unit (AU) intensity. This experiment was repeated 3 times with similar results 
in each instance. * P< 0.005 Students t-test; GraphPad Prism. 
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Figure  3-5A Western blot for IGFBP-2 
Expression of IGFBP-2 in wt and TamR cell conditioned medium. IGFBP-2 was clear-
ly identified following enhanced chemiluminescence (ECL) detection. Images were 
typically captured after 1-15s of exposure. This experiment was repeated 3 times with 
similar results in each instance.  
Figure 3.5B Densitometric analysis of IGFBP-2 band intensity.  
Triplicate lanes per blot were analysed for band intensity for both wt and TamR condi-
tioned media using Image Lab software. Data are presented as mean +/- SD (n=3) of 
Arbitrary Unit (AU) intensity. This experiment was repeated 3 times with similar results 
in each instance. P< 0.005 Students t-test; GraphPad Prism 5.0.  
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3.7 Ligand blot   
Ligand blotting using biotinylated IGF derivatives can be used to profile all of the IGF 
binding species in a particular biological sample (see methods Section 2.2.3). The re-
sults of such an experiment are shown in Fig 3.6. Two bands with Mr ~34kDa (IGFBP-
2) and ~31 kDa (IGFBP-5) were detected. As identified by Western blotting the inten-
sity of the IGFBP-2 band was higher in TamR than in wt cell conditioned media. Con-
versely the IGFBP-5 band was higher in the wt cell conditioned media than in TamR 
cells. In the latter cell conditioned media the level of IGFBP-5 was close to the lower 
detection limit of this technique. Although we did not expect to find IGFBP-1 or 
IGFBP-6 in either cell conditioned media, IGFBP-4 on PCR showed a similar Ct value 
for BP-2 and BP-5 in TamR and wt cells respectively (Table 3.1). However we did not 
detect IGFBP-4 at a typical Mr of 24 kDa in either wt or TamR conditioned cell media. 
There may be several reasons for this including proteolysis of IGFBP-4 or protein lev-
els below the detection sensitivity of ligand blotting. However as we have no evidence 
that IGFBP-4 expression is altered in wt compared to TamR cells we did not investi-
gate this matter further (see Discussion section 3.9).  
[77] 
 
 
 
 
Figure  3-6 Ligand blot analysis of medium conditioned by wt and TamR MCF-7 
cells.  
Global IGFBP species secreted by wt and TamR MCF-7 cells were identified by blot-
ting with biotinylated IGF-1 as described in the Methods section. IGFBP-2 and -5 are 
clearly identified in wt conditioned medium and IGFBP-2 in TamR medium. In these 
experiments exposure times of up to 30s were used. This experiment was repeated 3 
times with similar results and a representative blot is shown. Expected migration posi-
tions of IGFBPs are indicated (inset). 
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3.8 Elisa 
As a final confirmation of the alteration of IGFBP-2 and -5 expression in wt and TamR 
cells we undertook ELISA experiments using media conditioned by both cell types. 
For IGFBP-5 the standard curve for the ELISA was linear between 0.75 – 40 ng/ml 
and dilutions of conditioned media were appropriately adjusted to fall in this linear 
range. The results of such an experiment are shown below for IGFBP-5 Fig 3.7- upper 
panel and show that levels in wt cell conditioned media (~7 ng/ml) are around 5-fold 
higher than those in TamR cells (~1.4 ng/ml). This data agrees very closely to that 
obtained with qRT-PCR, Western and Ligand blot (Fig 3.3, 3.4 and 3.6). For IGFBP-2 
ELISA the linear portion of the standard curve extended over the range 0.0625- 4 
ng/ml and again samples of conditioned medium were appropriately diluted to fall in 
this region of the standard curve. Fig 3.7 (lower panel) indicates that IGFBP-2 concen-
tration in TamR cell conditioned medium (~10 ng/ml) is around 7-fold higher than that 
in medium conditioned by wt cells (~1.4 ng/ml). Once again this data for IGFBP-2 ex-
pression is consistent with results obtained by qRT-PCR, Western and Ligand blotting 
(Fig 3.3, 3.5 and 3.6). It is also interesting that there is a correlation between absolute 
levels of IGFBP-2 and -5 as determined by ELISA and the raw Ct values obtained by 
qRT-PCR for both of these genes see Discussion section 3.9.  
[79] 
 
 
Figure  3-7 ELISA determination of IGFBP-5 (upper panel) and IGFBP-2 (lower 
panel) concentration in wt and TamR conditioned medium 
IGFBP-5 and IGFBP-2 concentrations in medium conditioned by wt or TamR cells 
were determined by ELISA. Triplicate technical repeats were performed on media ob-
tained from three separate wells for both wt and TamR cells. The data are expressed 
as mean ± SD (n=3) *p<0.01 TamR v wt (Student’s t-test). This experiment was re-
peated 3 times with similar results in each case. A representative experiment is 
shown.  
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3.9 Discussion 
Our initial screening studies of IGF axis expression in wt and TamR MCF-7 cells indi-
cated that of the 10 genes examined 5 were expressed at moderate to high abun-
dance (IGF-1R, IGF-2R, IGFBP-2, IGFBP-4 and IGFBP-5) and 5 were either not ex-
pressed or expressed at very low levels (IGF-1, IGF-2, IGFBP-1, IGFBP-3 and 
IGFBP-6). Essentially this expression profile agrees with that previously reported for 
MCF-7 cells [173, 191, 228] and indeed for other ER+ BC cell lines [229-231]. Early 
MCF-7 passage was used (passage no 25). There is some controversy with respect 
to IGFBP-3 expression with some studies reporting expression in MCF-7 cells [232-
234]. This may be associated with the degree of confluence in cell cultures or cell se-
nescence [235-237] and one study reported IGFBP-3 expression using confluent cul-
tures of MCF-7 cells [233]. Our qRT-PCR studies were generally done in cells which 
had achieved 70-80 % confluence and this may provide an explanation for discrepant 
results. Another possibility is that IGFBP-3 expression may vary with passage num-
ber. We did not rigorously examine this possibility. 
It is well known that breast epithelial cells do not secrete IGF growth factors. Early re-
ports of IGF activity in BC epithelial cell conditioned medium were subsequently found 
to be the result of incomplete extraction of IGFBPs leading to cross reactivity in radio-
immunoassay used at that time [238-241] and the well-established paradigm is that 
mammary stromal cells express IGF-1 and IGF-2 which then act as a mitogens [235-
237] by binding to cognate receptors on the mammary epithelial cell surface. Our data 
confirm that IGF-1R and IGF-2R are expressed in both wt and TamR MCF-7 cells with 
IGF-1R more abundant at the mRNA level. We did not confirm if this is also the case 
at the level of protein expression in the cell membrane. In addition we did not examine 
insulin receptor (IR) expression in either wt or TamR cells although they have been 
reported to express this protein. Although IGF-2 is believed to exert mitogenic effects 
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via the IGF-1R this growth factor can also bind and signal through IR and future stud-
ies should include a report of IR expression in wt and TamR cells. This is increasingly 
important due to reports of hybrid IGF-R/IR species in BC cells [242] and thus infor-
mation on the levels of both A and B isoforms of the IR would be informative. An im-
portant observation from our studies is that in repeat experiments neither IGF-1R nor 
IGF-2R expression was altered in TamR v wt cells (Table 3.1 and Fig 3.3). This is sig-
nificant because increased IGF-1R expression has been mooted as possible mitogen-
ic driver in tamoxifen resistant BC cells [203]. However the literature is contradictory in 
this area with reports that IGF-1R is either up regulated or down regulated in TamR 
cells [204-206]. Repeat analysis in our study indicated little change in IGF-1R expres-
sion at least at the mRNA level. Clearly it would be important to confirm such findings 
at the protein level. 
Perhaps the most interesting results in this section of our work were the findings in 
relation to IGFBP expression. Raw Ct values (see Table 3.1) suggest that the relative 
abundance of the IGFBPs at the mRNA level was BP4 = BP5 > BP2 (wt cells) and 
BP2 > BP4 > BP5 for TamR cells. However while the expression of IGFBP-4 did not 
change between wt and TamR cells we repeatedly observed a reciprocal relationship 
between IGFBP-2 and IGFBP-5 in the two cell lines. Therefore in TamR cells repeat 
qRT-PCR experiments suggested that IGFBP-2 was up regulated 2-5 fold and IGFBP-
5 was down regulated approximately 7-fold compared with wt cells (Fig 3.3). Because 
of the repeated robustness of our qRT-PCR findings we decided to investigate wheth-
er these changes in BP-2 and BP-5 mRNA expression were also evident at the pro-
tein level. Western blot analysis using specific anti-BP2 or anti-BP5 antibodies 
showed that the data obtained by qRT-PCR was confirmed in terms of protein abun-
dance. Densitometry of repeat Western blots indicated a significant difference be-
tween BP-2 and BP-5 levels in wt and TamR cells (Fig 3.4A and 3.4B). Although we 
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show only that portion of the blot containing intact IGFBP protein(s) inspection of 
whole blots did not indicate a significant degree of proteolysis of either IGFBP-2 or 
IGFBP-5 in medium conditioned by either cell line. Western blotting data was con-
firmed using the technique of Ligand blotting which detects only IGF binding species 
following blotting with appropriately labelled IGF-1 or IGF-2. In our experiments we 
used biotinylated IGF-1 (see Materials & Methods section) and found both IGFBP-2 
and IGFBP-5 in wt MCF-7 cell conditioned medium (Fig 3.5). As expected the signal 
for IGFBP-2 was stronger and the signal for IGFBP-5 was weaker in TamR cells. In 
fact in some experiments it was difficult to detect IGFBP-5 signal in TamR cell condi-
tioned medium suggesting that the sensitivity of the ligand blot method was less than 
that of western blotting in this particular instance. Interestingly although IGFBP-4 
showed an equivalent expression by qRT-PCR with IGFBP-5 in wt cells and was also 
robustly expressed in TamR cells we did not detect any signal for this binding protein 
which would be expected to run at around 24 kDa (Fig 3.6 – inset). Although we have 
no ready explanation for this it may be that BP-4 is proteolysed in MCF-7 cell condi-
tioned medium and thus not detectable by Western blotting. In any case because 
IGFBP-4 expression was not altered when examined by qRT-PCR between wt and 
TamR cells and because the intact protein was not detected in either wt or TamR 
conditioned medium we did not pursue this area further. However differential proteoly-
sis of IGFBP-4 in BC cells is a potentially important research area. 
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Because Western and Ligand blots are at best only semi-quantitative techniques we 
used ELISA methodology to get an accurate measurement of IGFBP-2 and IGFBP-5 
levels in conditioned medium. Fig 3.7 shows the result of a typical ELISA experiment 
and the concentrations obtained are reported in Section 3.8. It is clear from inspection 
of Figs 3.4 and 3.7 that the fold changes in mRNA and protein expression are of the 
same order and that consequently changes in mRNA expression are accurately trans-
lated in terms of protein abundance. It is also apparent that the global protein concen-
trations for both IGFBPs – approximately 2-10 ng/ml lie within an order of magnitude. 
This raises the possibility that there is co-ordinate regulation of IGFBP-2 mRNA and 
protein expression and we return to this theme in the final chapter of this thesis. 
 There is only a limited literature describing altered IGFBP expression profiles on the 
acquisition of tamoxifen resistance in BC cells. Early studies described altered IGFBP 
profiles after development of tamoxifen resistance in the MCF-7 and ZR-75-1 cell lines 
although the IGFBP species in this report were not identified immunologically but only 
assigned by molecular weight on ligand blot [211]. This group subsequently reported 
that IGFBP-2 was down regulated in tamoxifen resistant MCF-7 cells [212] which is 
contrary to our findings. However these authors included the synthetic corticosteroid 
dexamethasone in their cultures and this agent is a known regulator of IGFBP-2 
expression in mammary epithelial cell lines [213]. Of more relevance is the study by 
Juncker-Jensen et al [243] who demonstrated IGFBP-2 up regulation in Tam R MCF-7 
cells as well as cells resistant to the SERD fulvestrant and the pure anti-oestrogen 
R58,668. Although such observations are similar to those described in the current 
thesis Juncker-Jensen et al demonstrated that IGFBP-2 knock down using antisense 
oligonucleotides or siRNA did not affect the growth of resistant cells and concluded 
that IGFBP-2 may be a marker for resistance but had no causal role in this respect 
(see Chapter 4). In the context of IGFBP-5, the  most relevant study with respect to 
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our findings is that of Ahn et al who used an RNA interference based screening 
methodology to identify IGFBP-5 as a determinant of tamoxifen sensitivity [132].  They 
demonstrated that shRNA based knockdown of IGFBP-5 expression in MCF-7 cells 
conferred tamoxifen resistance in these cells perhaps related to a concomitant loss of 
ERα expression. Further to this tamoxifen resistant MCF-7 cells showed decreased 
IGFBP-5 expression and addition of exogenous IGFBP-5 partly restored sensitivity to 
tamoxifen. We also found that ERα expression was down regulated by approximately 
60% in TamR cells (see Fig 4.18). In the next chapter we examine further the 
hypothesis that IGFBP-2 and -5 play a causal role in the acquisition of tamoxifen 
resistance in MCF-7 cells. 
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Chapter 4 Results 
Role of the IGF axis in development of tamoxifen resistance 
4.1 Introduction 
Since our results clearly confirmed that the acquisition of tamoxifen resistance in 
MCF-7 cells is associated with a down regulation of IGFBP-5 and up regulation of 
IGFBP-2 we next addressed the question of whether either of these changes in 
IGFBP profile was causally associated with the development of tamoxifen resistance. 
To investigate this possibility we decided to use a gene knock out strategy. Therefore 
we designed experiments to investigate whether IGFBP-2 knock down in TamR cells 
restored sensitivity of these cells to tamoxifen. In reciprocal experiments we also in-
vestigated whether knock down of IGFBP-5 in wt MCF-7 cells conferred tamoxifen 
resistance to these cells. We employed an shRNA based knock down strategy (see 
Methods section 2.2.6) with puromycin selection of stably transfected cell colonies. 
4.2 Puromycin optimisation  
Determination of the optimum puromycin concentration for selection of stably trans-
fected clones was performed for both wt and TamR cells in 6 well plates and a range 
of puromycin concentrations of 0-10 ug/ml. We found that for both wt and TamR cells 
the minimal concentration of puromycin required for 100% cell death was 6 ug/ml and 
we therefore used this concentration in all of our subsequent experiments. 
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4.3 IGFBP-2 knockdown 
We used the shRNA interference technique in attempt to knockdown IGFBP-2 ex-
pression in TamR cells. These experiments proved to be successful in TamR early 
cell passage (passage no 7). The shRNA preparation is a pool of 3 target-specific len-
tiviral vector plasmids each encoding 19-25nt (plus hairpin) designed to knockdown 
gene expression. In a six well plate transfections of target and control plasmids were 
performed at a ratio of 1:1 to 1:6 where the concentration of plasmid is held constant 
at 1ug and the volume of transfection reagent is varied from 1-6 ul. Such protocols 
were performed essentially according to the manufacturer’s instructions (see Methods 
section 2.2.6 for further details). Under these conditions puromycin resistant colonies 
were established in 6 well clusters after approximately 3 weeks. The results of these 
IGFBP-2 knockdown experiments are shown in Fig 4.1. Scrambled shRNA was used 
as control. IGFBP-2 ELISA of conditioned medium for each of these cultures indicated 
statistically significant knockdown of IGFBP-2 expression in cell populations #1, #3, 
#5 and #6 (p<0.005). For cell populations #2 and #4 significance was almost reached 
with p=0.065 and 0.062 respectively.  Levels of knockdown varied from 21% (#3) to 
55% (#1) – see Table 4.1 To confirm knock down at mRNA level we conducted qRT-
PCR using cDNA prepared from all six heterogeneous cell populations. When data 
were compared to control cells we found that levels of knockdown varied from 48% to 
72% (see Fig 4.2.). In addition the level of IGFBP-2 knockdown in different cell popu-
lations as determined by qRT-PCR followed closely the data obtained by ELISA 
(compare Figs 4.1 and 4.2). In experiments which knock down components of the IGF 
axis it is important to establish that knock down of individual genes does not lead to 
compensatory effects in the expression of other components of the axis. This is par-
ticularly important for IGFBPs where in vivo genetic knock out studies indicate there 
may be some redundancy of function in this gene family. Therefore we used qRT-
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PCR analysis to profile changes in the five IGF axis genes expressed in TamR cells 
following knock down of IGFBP-2. Profiling of gene expression confirmed that IGFBP-
2 was knocked down in these cells (Fig 4.3). There was no change in IGF-1R or IGF-
2R expression in knock down cells. In addition there was no compensatory increase in 
expression of IGFBP-4 or -5 in IGFBP-2 knockdown cells. Indeed data suggested a 
small fold decrease in expression of these IGFBPs in IGFBP-2 knockdown cells com-
pared to parental TamR cells.  
As the lowest absolute level of protein in knockdown cells was seen in cell population 
#6 – 3.45±0.34 ng/ml - (see Fig 4.1 and Table 4.1) we chose this cell population for 
cloning by limited dilution. The results of such an experiment are shown in Fig 4.4 
where we established 6 different clones for IGFBP-2 shRNA transfected cells and as-
sayed conditioned medium for IGFBP-2. For one of these clones (F8) the levels of 
IGFBP-2 in conditioned medium at 2.33 ng/ml were 66% decreased compared to pa-
rental TamR cells and approached the values seen for wt cells (see Fig 3.7). In all 
subsequent experiments clone F8 was used as a knockdown IGFBP-2 model and 
puromycin was included in all subsequent studies with the cell line. 
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Figure ‎4-1 Knockdown of IGFBP-2.  
Cells were treated with IGFBP-2 shRNA (KO – red bars) or control scrambled shRNA 
(C – green bars) at transfection reagent: plasmid ratios of 1-6. IGFBP-2 in conditioned 
medium was assayed by ELISA as described in Fig 3.7 IGFBP-2 was also assessed 
in medium conditioned by untransfected wt and TamR cells. Data are expressed as 
mean ± SD n=3 of triplicate technical repeats. * p<0.005 KO v control Student’s test 
GraphPad Prism 5.0.  
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Table ‎4-1 Knockdown of IGFBP-2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-1 IGFBP-2 knockdown in transfected cell populations. Mean ng/ml 
IGFBP-2 for medium conditioned by cell populations #1-6 (KO and control) are report-
ed. % IGFBP-2 knockdown in each transfection is reported relative to controls. Values 
for TamR and wt cells are 5.9 and 2.15 ng/ml respectively. 
 
 
 
  
 
 
Cells 
 
 
 IGFBP-2 (ng/ml)  
  
 
% KO 
KO-1         3.7  55 
Control-1         8.3   
KO-2         5.4  25 
Control-2         7.3   
KO-3         6.2  21 
Control-3         8.0   
KO-4         5.3  35 
Control-4         8.2   
KO-5         3.4  42 
Control-5         5.9   
KO-6 
 
TamR      
                      
        3.4 
 
        5.9                                   
 48 
 
N/A 
Wt                      2.1                                   N/A 
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Figure  4-2 IGFBP-2 KO evaluation by qRT-PCR.  
Confirmation by qRT-PCR of IGFBP-2 mRNA knockdown in transfected cell popula-
tions #1-6.  Knockdown in IGFBP-2 shRNA transfected cells is expressed as 2-ΔΔCt 
relative to scrambled shRNA transfected control – (C1 Fig 4.1) Data represent mean 
levels of KO from duplicate technical repeats.  
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Figure  4-3 Profiling of IGF axis after Knockdown of IGFBP-2.  
The levels of the five IGF axis genes expressed in TamR cells (IGF-1R, IGF-2R, 
IGFBP-2, -4 and -5) were examined by qRT-PCR following IGFBP-2 knockdown (KO6 
Fig 4.1). IGFBP-2 levels were significantly altered in IGFBP-2 KO cells in comparison 
to control transfected cells (C6 Fig 4.1). Data are expressed as 2-ΔΔCt KO v control 
transfected TamR cells and represent mean ± SD (n=3).  
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Figure  4-4  Limited dilution cloning of IGFBP-2 knockdown cells.  
Heterogeneous cell population (KO6 Fig 4.1) was cloned by limiting dilution. Six dif-
ferent clones were selected and expanded. Conditioned medium from each was as-
sayed by ELISA for IGFBP-2. The red column represents a scrambled shRNA control 
(C6 – Fig 4.1). Data are expressed as mean ± SD n=3; Columns with different super-
scripts are statistically different at p<0.05 (One way Anova with Tukey’s Multiple 
Comparison post-hoc test - GraphPad Prism 5.0).  
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4.4 IGFBP-5 knockdown 
IGFBP-5 proved more difficult to knockdown in wt MCF-7 cells. However at the third 
attempt we were able to achieve some knockdown of IGFBP-5 in this cell population 
(see Fig 4.5). As for IGFBP-2 knockdown transfections of target and control plasmids 
were performed in 6 well plates at a ratio of 1:1 to 1:6 where the concentration of 
plasmid is held constant at 1ug and the volume of transfection reagent is varied from 
1-6 ul. In contrast to IGFBP-2 transfections, cells transfected at a ratio of 1:1 and 1:2 
did not grow through puromycin selection and therefore only data for cell populations 
#3-6 are shown. Figure 4.5 shows the results of ELISA analysis of IGFBP-5 protein in 
medium conditioned by each of the test and control transfected wt cells along with un-
transfected wt and TamR cells. For cell population #3 IGFBP-5 concentration in 
knockdown cells was actually greater than that in putative knockdown cells. However 
cell populations #4, #5 and #6 all demonstrated significant knockdown of BP-5 in test 
v scrambled control transfected cells p< 0.005 Student’s t-test.  The concentration of 
IGFBP-5 in medium conditioned by KO #4 cells was not significantly different from 
that seen for wt cells and we did not work further with these cultures. Of the two re-
maining cultures the greatest degree of knockdown was seen in cell population #6 
although to some extent this was due to the higher scrambled control IGFBP-5 levels 
for cell population #6. Nonetheless in #6 KO cells IGFBP-5 levels were 4.9 ± 0.13 
ng/ml v 10.8 ± 0.27 ng/ml (mean ± SD n=3; KO v scrambled control p< 0.0001) repre-
senting a 55% level of knockdown in this cell population. This represents a similar de-
gree of maximal knockdown as that achieved for IGFBP-2 knockdown (cell population 
#6) (see Fig 4.1 and Table 4.1). However of some concern was the evidence that 
IGFBP-5 knockdown in wt cells was also associated with down regulation of the other 
4 IGF axis genes which are expressed in MCF-7 cells (Fig 4.6). Therefore expression 
of IGF-1R, IGF-2R, IGFBP-2 and IGFBP-4 was 76, 60, 34 and 23 % of that seen in 
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control transfected cells. In fact the level of knock down of BP-4 expression ap-
proached that seen for BP-5 itself (20%). We discuss this at more length in Section 
4.7 and despite potential difficulties with interpretation of results we proceeded to 
clone out IGFBP-5 knockdown cells from population #6 using limiting dilution. The re-
sults of these experiments are shown in Fig 4.7 where we selected 11 clones which 
grew through puromycin selection in 96-well plates. Of these, 6 clones showed 
IGFBP-5 levels in conditioned medium which were significantly lower than those of a 
scrambled control transfected cells. Clone B4 had the lowest concentration of IGFBP-
5 in conditioned medium 3.1 ± 1.5 ng/ml v 8.3 ± 0.81ng/ml n=3 ± SD; KO v control, 
p=0.003 representing a 63% knockdown of IGFBP-5 at the protein level. In all subse-
quent experiments clone B4 was used as a knockdown IGFBP-5 model and puromy-
cin was included in all subsequent studies with the cell line. 
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Figure ‎4-5 Knockdown of IGFBP-5 in wt MCF-7 cells. 
Cells were treated with IGFBP-5 shRNA (KO) or control scrambled shRNA (C) at 
transfection reagent: plasmid ratios of 1-6. Cells transfected at ratios of 1 and 2 did 
not grow under puromycin selection and only the data from transfections 3-6 are 
shown. IGFBP-5 was assayed by ELISA as described in Fig3.7. Red bars IGFBP-5 
shRNA transfected; green bars scrambled control transfected. IGFBP-5 was also as-
sessed in untransfected wt and TamR cells as indicated. Data are expressed as mean 
± SD n=3; * p<0.005 KO v control (Student’s t-test; GraphPad Prism 5.0.). 
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Figure ‎4-6 Profile of IGF axis after knockdown of IGFBP-5. 
The levels of the five IGF axis genes expressed in TamR cells (IGF-1R, IGF-2R, 
IGFBP-2, -4 and -5) were examined by qRT-PCR following IGFBP-5 KO (KO6 Fig 
4.5). Expression of all 5 IGF axis genes levels were altered in IGFBP-5 KO cells in 
comparison to control transfected cells (C6 Fig 4.1). Data are expressed as 2-ΔΔCt 
KO v control transfected wt cells. This experiment was performed once and means 
values of triplicate technical repeats are shown. 
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Figure ‎4-7 Limited dilution cloning of BP-5 KO cells. 
Heterogeneous cell population KO6 – (Fig 4.5) was cloned by limiting dilution. Eleven 
different clones were selected and expanded. Conditioned medium from each was 
assayed by ELISA for IGFBP-5. The red column is scrambled shRNA control (C6 – 
Fig 4.5). Data are expressed as mean ± SD n=3; statistically significant v control a 
(p<0.05); b (p<0.01); c (p<0.005); d (p<0.001) ns not significant (Student’s t-test; 
GraphPad Prism 5.0). 
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4.5 Cell proliferation and tamoxifen sensitivity 
The purpose in establishing IGFBP-2 and IGFBP-5 knockdown cells was to test the 
hypothesis that either and/or both of these genes played a role in the development of 
tamoxifen resistance in MCF-7 cells. As a read out of tamoxifen resistance we adopt-
ed a well-established cell viability and proliferation assay which uses the formazan 
dye WST-1 (see Methods section 2.2.5). Such reagents assay both cell number and 
viability and are a convenient monitor of both cytostatic and cytotoxic activities dis-
played by test compounds. The shift in absorbance produced by cleavage of the te-
trazolium salt WST-1 to its formazan product through the NADH- generating dehydro-
genase(s) is considered to be directly proportional to the number of metabolically ac-
tive cells. Such an assay format lends itself to reasonably high throughput with appro-
priate replication with respect to time points. Preliminary experiments identified an op-
timal seeding density of 5000 cells/well for these experiments which were conducted 
in 96 well plates. MCF-7 passage no 35 and TamR passage no 7 were used. In Fig 
4.8 A and B we show the results of two replicated representative experiments which 
report the effect of 4HT (1uM) on the growth of wt and TamR cells over the time peri-
od 0-96hr. For Expt 1 described in Fig 4.8A in the absence of 4HT (upper panel) alt-
hough the curves show a significant difference using a repeated measures ANOVA 
(p=0.0176) this is solely due to the 96 hr time point. No significant difference is appar-
ent at any of the other time points (Bonferroni’s post-hoc test). In contrast there is a 
highly significant difference be in the growth curves in the presence of 4HT Fig 4.8A 
(lower panel) (repeated measures ANOVA p<0.0001). In addition Bonferroni’s post-
hoc analysis indicates a significant difference between cell responses at the 48 
(p<0.01), 72 and 96 hr time points (both p<0.001). Collectively these data suggest that 
the growth of wt MCF-7 cells is inhibited in 1uM 4HT whereas the growth of TamR 
cells, as expected, is largely unaffected. Therefore this WST-1 based assay combined 
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with the IGFBP knockdown cells represents an appropriate experimental design to 
examine whether IGFBPs play a causal role in the development of TamR. 
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Figure  4-8A Growth of wt or TamR cells in 1uM 4HT  
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates in the absence (top panel) or presence (bottom panel) of 1uM 4HT. Cell 
growth was monitored over the period 0-96 hr. by WST-1 assay as described in Mate-
rials &Methods and was normalised to t=0 (100%). Each data point represents the 
mean +/-SD of triplicate technical repeats. Curves were analysed by repeated 
measures ANOVA followed by Bonferroni’s post-hoc test *p< 0.05 ** p<0.01; 
***p<0.001; GraphPad Prism 5.0. Raw OD450 values are reported in Appendix – Fig 
4.8A (S).  
-4HT 
+4HT 
-4HT 
+4HT 
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Accordingly we used the cloned knockdown cell lines F8 (for IGFBP-2) and B4 (for 
IGFBP-5) prepared as described in Figs 4.4 and 4.7 and examined their sensitivity to 
growth in 4HT. Initially we used the TamR IGFBP-2 knockdown cells (clone F8) and 
reasoned that if increased IGFBP-2 expression in TamR cells (see Figs 3.3 – 3.7) was 
associated with development of TamR then knockdown of IGFBP-2 in these cells 
should restore sensitivity to 4HT. The result of such an experiment is shown in Fig 4.9. 
In the absence of 4HT (Fig 4.9 - upper panel)  repeated measures ANOVA analysis 
followed by Bonferroni’s post-hoc test indicates that only the 96hr time point shows 
significant difference between control and IGFBP-2 knockdown cells (p<0.05). No 
significant difference is apparent at any other time points. In contrast in the presence 
of 4HT (Fig 4.9 bottom panel) repeated measures ANOVA analysis indicates a highly 
significant difference between the growth curves for IGFBP-2 knockdown and control 
cells (p<0.001). In addition at 24, 48 and 72 hr time points there is a significant 
difference between the two cell lines (p<0.001). At the 96 hr time point these 
differences in cell growth are not seen. Therefore our data suggest that at least earlier 
time points knockdown of IGFBP-2 restores tamoxifen sensitivity to TamR cells as 
evidenced by compromised growth of the IGFBP-2 knockdown clone F8 compared 
with scrambled control transfected TamR cells. This data therefore partly supports the 
hypothesis that over expression of IGFBP-2 by TamR cells has a causal role in the 
acquisition of tamoxifen resistance. We also conducted parallel experiments with the 
wt IGFBP-5 knockdown clone B4 (see Fig 4.7). In this instance we reasoned that if 
increased expression of IGFBP-5 in wt cells in comparison to TamR cells was 
associated causally with tamoxifen sensitivity then knockdown of IGFBP-5 in wt cells 
may result in the acquisition of tamoxifen resistance. The results of such an 
experiment are shown in Fig 4.10.  In line with previous experiments, in the absence 
of 4HT there was little difference in growth curves for IGFBP-5 knockdown and control 
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cells. Therefore repeated measures ANOVA  followed by Bonferroni’s post-hoc test 
showed no significant difference between the time points for control and knockdown 
cells (p>0.05). For IGFBP-5 knockdown only the 24hr time point showed a significant 
difference between control and knockdown cells (p<0.001) with no difference at any of 
the other time points. Therefore our data indicate that knockdown of IGFBP-2 in 
TamR cells restores sensitivity to 4HT in these cells perhaps indicating a causal role 
for IGFBP-2 in the development of tamoxifen resistance. In contrast, knockdown of 
IGFBP-5 in wt cells does not confer resistance to 4HT in these cells arguing that 
IGFBP-5 does not play a role in the development of tamoxifen resistance. 
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Figure  4-9 Growth of TamR BP-2 KO clone F8 or scrambled control transfected 
cells in 1uM 4HT. 
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates in the absence (top panel) or presence (bottom panel) of 1uM 4HT. Cell 
growth was monitored over the period 0-96 hr. by WST-1 assay as described in Mate-
rials &Methods and was normalised to t=0 (100%). This experiment was repeated 
three times with three technical repeats in each experiment and data is presented as 
mean ±SD (n=3). Curves were analysed by repeated measures ANOVA followed by 
Bonferroni’s post-hoc test *p< 0.05 ** p<0.001; Raw OD450 values are reported in 
Appendix – Fig 4.9S. 
-4HT 
+4HT 
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Figure ‎4-10 Growth of wt BP-5 KO clone B4 or scrambled control trans-
fected cells in 1um 4HT. 
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates in the absence (top panel) or presence (bottom panel) of 1uM 4HT. Cell 
growth was monitored over the period 0-96 hr. by WST-1 assay as described in Mate-
rials &Methods and was normalised to t=0 (100%). This experiment was repeated 
three times with three technical repeats in each experiment results in each instance 
and data is presented as mean ±SD (n=3). Curves were analysed by repeated 
measures ANOVA followed by Bonferroni’s post-hoc test *p <0.001; Raw OD450 val-
ues are reported in Appendix – Fig 4.10S.  
-4HT 
+4HT 
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4.6 Effects of exogenous IGFBP-2 and IGFBP-5 on wt and 
TamR cells. 
Because the data obtained in the previous section using knockdown studies suggest-
ed that IGFBP-2 and IGFBP-5 could influence tamoxifen sensitivity in MCF-7 cells it 
was important to examine whether these effects could be replicated by the presence 
of exogenous IGFBPs. This hypothesis postulates that in the presence of increased 
exogenous IGFBP-2 wt cells would acquire tamoxifen resistance and that conversely 
in the presence of excess IGFBP-5 TamR cells would regain sensitivity to 4HT. These 
experiments also test the hypothesis that IGFBPs are able to exert these effects ex-
tracellularly. As a preliminary to this work we performed experiments to examine the 
effects of IGFBP-2 or IGFBP-5 alone or complexed with IGF-1 on wt and TamR cell 
growth and viability as determined by WST-1 assay. Such preliminary experiments 
are necessary for accurate interpretation of subsequent experiments which investigate 
the effects of extracellular IGFBPs in the presence of 4HT. We also included experi-
ments which examined the effects of IGF-1 on MCF-7 cell growth. IGF-1 is a well 
characterised mitogen for MCF-7 cells and these experiments were designed to con-
firm that in our hands the mitogenic signalling pathways stimulated by IGF-1 were in-
tact in our cell cultures. It should be noted that in order to maximise signal-to-noise 
ratio, these experiments were performed in a serum-free background. Figures 4.11, 
4.12 and 4.13 show dose response curves for IGF-1, IGFBP-2 and IGFBP-5 in both 
wt and TamR cells.  Wt and TamR MCF-7 cells responded in a dose-dependent fash-
ion to IGF-1 (Fig 4.11) over the concentration range 0-100 nM. A maximum response 
was already evident at 10nM and cells responded to IGF-1 concentrations as low as 
0.1 nM. There was some evidence that wt cells were more sensitive to IGF-1 stimula-
tion than TamR cells.  However the level of response of both cell types was limited 
and the standard deviations associated with technical replicates within this series of 
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experiments were large and this tended to compromise the quality of the data. This 
was particularly evident in experiments with TamR cells and Bonferroni post-hoc anal-
ysis indicated no significant difference between the response of wt and TamR cells at 
any IGF concentration. We discuss these findings in more detail elsewhere. For 
IGFBP-2 there was no consistent dose-dependent effect of binding protein in either wt 
or TamR cells. There was a trend for stimulation by IGFBP-2 at lower concentrations 
but there was a return to control values at higher concentrations of binding protein 
(Fig 4.12). Interestingly for IGFBP-5 there appeared to be a stimulatory effect on both 
cell lines as monitored by the WST-1 assay (p<0.001 repeated measures ANOVA). 
For wt MCF-7 cells effects were already evident at 0.1 nM and had plateaued at 1nM 
binding protein. For TamR cells maximum stimulation was apparent at 1 nM and the 
stimulation peaked at this concentration. However there was no statistically significant 
difference in the response of wt compared to TamR cells p>0.05 Bonferroni post-hoc 
test (Fig 4.13). 
We then investigated the effect of co-incubation of IGF-1 ± IGFBP-2 or IGFBP-5 on 
the proliferation of wt and TamR MCF-7 cells. The result of such an experiment with 
wt cells is shown below in Fig 4.14. Again IGF-1 caused a dose dependent increase in 
wt MCF-7 cell proliferation with a 75% increase in cell proliferation at 10 nM IGF-1 
where the effect of growth factor plateaued. In the presence of 10 nM IGFBP-2 the 
response to IGF-1 was significantly affected (p< 0.0 01; repeated measures ANOVA). 
Post-hoc Bonferroni analysis indicated a significant inhibition of IGF-1 activity at each 
concentration of growth factor in the presence of 10nM IGFBP-2 (p<0.001). For 
IGFBP-5 the data were somewhat less clear cut. Therefore while repeated measures 
ANOVA suggested a significant difference in response in the presence of IGF-1 + 
IGFBP-5 compared to IGFBP-5 alone post-hoc analysis indicated a significant differ-
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ence (p< 0.05) only at the lowest (0.1 nM) and the highest (100nM) concentrations of 
IGF-1. 
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Figure ‎4-11 Effect of IGF-1 on growth of wt and TamR MCF-7 cells. 
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates. After overnight attachment cells were treated with the indicated con-
centrations of IGF-1 in 100 ul of serum free PR free medium. After 48 hr WST-1 rea-
gent (10ul) was added and A450 was determined after 30 min incubation at 37˚C. 
This experiment was repeated three times with triplicate technical repeats in each ex-
periment. Data are presented as mean±SD (n=3) and are expressed as % control 
(0nM IGF-1). Curves were analysed by repeated measures ANOVA followed by Bon-
ferroni’s post-hoc test. Raw OD450 values are reported in Appendix – Fig 4.11S.  
  
[107] 
 
0.1 1 10 100
90
100
110
120
130
wt
TamR
0
*
IGFBP-2 (nM)
%
 c
h
a
n
g
e
 i
n
 c
e
ll 
p
ro
lif
e
ra
ti
o
n
re
la
ti
v
e
 t
o
 c
o
n
tr
o
ls
 
Figure ‎4-12 Effect of IGFBP-2 on growth of wt and TamR MCF-7 cells. 
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates. After overnight attachment cells were treated with the indicated con-
centrations of IGFBP-2 in 100 ul of serum free PR free medium. After 48 hr WST-1 
reagent (10ul) was added and A450 was determined after 30 min incubation at 37˚C. 
This experiment was repeated three times with triplicate technical repeats in each ex-
periment. Data are presented as mean±SD (n=3) and are expressed as % control 
(0nM IGFBP-2). Curves were analysed by repeated measures ANOVA followed by 
Bonferroni’s post-hoc test. * p < 0.05 (wt v TamR) Raw OD450 values are reported in 
Appendix – Fig 4.12S. 
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Figure ‎4-13 Effect of IGFBP-5 on growth of wt and TamR MCF-7 cells. 
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates. After overnight attachment cells were treated with the indicated con-
centrations of IGFBP-5 in 100 ul of serum free PR free medium. After 48 hr WST-
1reagent (10ul) was added and A450 was determined after 30 min incubation at 37˚C. 
This experiment was repeated three times with triplicate technical repeats in each ex-
periment. Data are presented as mean±SD (n=3) and are expressed as % control 
(0nM IGFBP-5). Curves were analysed by repeated measures ANOVA followed by 
Bonferroni’s post-hoc test Raw OD450 values are reported in Appendix – Fig 4.13S. 
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Figure ‎4-14 Effect of IGF-1 ± IGFBP-2 or IGFBP-5 on growth of wt cells. 
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates. After overnight attachment cells were treated with the indicated con-
centrations of IGF-1 (0-100nM) in the presence or absence of fixed concentrations (10 
nM) of IGFBP-2 or IGFBP-5 in 100 ul of serum free PR free medium. After 48 hr WST-
1 was added and A450 was determined after 30 min incubation at 37˚C. This experi-
ment was repeated three times with triplicate technical repeats in each experiment. 
Data are presented as mean±SD (n=3) and are expressed as raw data (A 450)  (0nM 
IGF-1) Curves were analysed by repeated measures ANOVA followed by Bonferroni’s 
post-hoc test. * p < 0.05 (IGF-1 v IGF-1 + BP-5); ** p < 0.001 (IGF-1 v IGF-1 + BP-2). 
Raw OD450 values are reported in Appendix – Fig 4.14S. 
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Figure ‎4-15 Effect of IGF-1 ± IGFBP-2 or IGFBP-5 on growth of TamR 
cells. 
Cells were seeded in 100 ul of 5% DCS, PR free medium at 5000/well in 96-well mi-
crotitre plates. After overnight attachment cells were treated with the indicated con-
centrations of IGF-1 (0-100nM) in the presence or absence of fixed concentrations (10 
nM) of IGFBP-2 or IGFBP-5 in 100 ul of serum free PR free medium. After 48 hr WST-
1 was added and A450 was determined after 30 min incubation at 37˚C. This experi-
ment was repeated three times with triplicate technical repeats in each experiment. 
Data are presented as mean±SD (n=3) and are expressed as raw data (A450) (0nM 
IGF-1). Curves were analysed by repeated measures ANOVA followed by Bonferro-
ni’s post-hoc test. ** p< 0.01, *** p<0.001 (IGF-1 v IGF-1 + BP-5) * p<0.01, **p<0.001 
(IGF-1 v IGF-1 +BP-2). Raw OD450 values are reported in Appendix – Fig 4.15S. 
  
[111] 
 
When these experiments were repeated in TamR cells (Fig 4.15) IGF-1 stimulated cell 
proliferation although again the response to added growth factor in these cells was 
less robust than that seen for wt MCF-7 cells (compare redlines Fig 4.14 and 4.15). 
As for wt cells there was a trend for inhibition of IGF-1 action when IGF-1 was co-
incubated with 10 nM IGFBP-2 (p < 0.0001 repeated measures ANOVA) and this 
reached statistical significance at IGF-1 concentrations of 0.1 and 1nM. This inhibitory 
effect of IGFBP-2 was overcome at higher IGF-1 concentrations. Co-incubation of 
IGFBP-5 increased the cell response to IGF-1 (p< 0.0001 repeated measures ANOVA) 
with a statistically significant difference seen at the two highest concentrations of IGF-
1 (p< 0.01) an effect which replicated to some extent the results seen in wt cells (Fig 
4.14). In fact the response to IGF-1 + IGFBP-5 (60 % increase compared to control at 
100 nM IGF-1 + 10 nM IGFBP-5) is greater than that seen for either IGF-1 or IGFBP-5 
alone in TamR cells (see Figs 4.11 and 4.13) suggesting a synergistic effect of IGF-1 
+ IGFBP-5 in these cells. 
These preliminary experiments were conducted to establish the growth parameters of 
wt and TamR MCF-7 cells in response to IGF-1, IGFBP-2, IGFBP-5 and binary 
combinations of growth factor and binding proteins. However because our earlier 
observations clearly demonstrated that IGFBP-2 and IGFBP-5 were reciprocally 
regulated in wt and TamR cells it was important to examine how the presence of 
extracellular IGFBPs affected tamoxifen sensitivity. Accordingly we examined the 
tamoxifen sensitivity of wt cells in the presence of elevated extracellular 
concentrations of IGFBP-2 and also the tamoxifen sensitivity of TamR cells in 
elevated concentrations of extracellular IGFBP-5. The results of these experiments 
are shown in Figs 4.16 and 4.17. For wt cells 4HT again inhibited cell growth (Fig 
4.16). Although in the presence of 50 nM IGFBP-2 there appeared to be a statistically 
significant increase in cell growth in comparison to wt cells grown in the absence of 
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extracellular IGFBP-2 this effect was not dramatic and the growth curves did not 
resemble those seen for parental TamR cells (see Fig 4.8 A and B).  
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Figure ‎4-16 Effect of extracellular IGFBP-2 on Tamoxifen sensitivity of wt 
MCF-7 cells.  
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates in the absence or presence (+BP-2) of 50nM BP-2. Cell growth was 
monitored over the period 0-96 hr in the Absence (upper panel) or presence (lower 
panel) of 1uM 4HT using WST-1 assay as described in Materials &Methods and was 
normalised to t=0 (100%). Each data point represents the mean +/-SD of triplicate 
technical repeats. This experiment performed twice with similar results in each in-
stance and a representative experiment is shown. Curves were analysed by repeated 
measures ANOVA followed by Bonferroni’s post-hoc test. Raw OD450 values are re-
ported in Appendix – Fig 4.16S. 
-4HT 
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Figure ‎4-17 Effect of extracellular IGFBP-5. 
Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well mi-
crotitre plates in the absence (TamR) or presence (+BP-5) of 50nM BP-5. Cell growth 
was monitored over the period 0-96 hr in the presence of 1uM 4HT using WST-1 as-
say as described in Materials &Methods and was normalised to t=0 (100%). Each da-
ta point represents the mean +/-SD of triplicate technical repeats. This experiment 
performed twice with similar results in each instance and a representative experiment 
is shown. Curves were analysed by repeated measures ANOVA followed by Bonfer-
roni’s post-hoc test. Raw OD450 values are reported in Appendix – Fig 4.17S. 
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4.7 Oestrogen Receptor (ER) expression 
Because some reports associate lack of effect of tamoxifen with the absence or down 
regulation of ER expression in TamR cells we first of all analysed the expression of 
ER isoforms in wt and TamR MCF-7 cells. We investigated the expression of ERα, 
ERβ isoforms 1 and 2(ERβ1, ERβ2) as well as the recently described plasma 
membrane G protein linked GPR30. Ct values for expression of these genes as 
determined by qRT-PCR are shown in Table 4.2 ERα is expressed at a moderate to 
high abundance whereas all other receptor isoforms are only expressed at very low 
levels Ct >33. In four separate experiments with wt and TamR cells which examined 
the expression of ERα in triplicate technical repeats we found a 50% reduction in ERα 
expression in TamR cells compared to wt cells. Thus although ERα is down regulated 
in TamR cells it is still clearly expressed. These results are consistent with other 
reports in the literature. However of more interest for the current study is the recent 
report by Foulstone et al which shows that silencing of IGFBP-2 in MCF-7 cell leads to 
a loss of expression of ERα with consequent effects on cell growth. For this reason 
we also examined ERα expression in IGFBP-2 knockdown TamR cells and this data 
is presented in Fig 4.18. As indicated the expression of ERα in untransfected and 
control transfected TamR cells is similar at 62 ± 8.2% and 71 ± 16.6% of the levels 
seen in untransfected wt MCF-7 cells (mean ± SD n=3; p= 0.47). For IGFBP-2 
knockdown cells the expression of ERα is further reduced to 45 ± 11.9% of 
untransfected wt MCF-7 cells. This level marginally fails to reach significance against 
both un transfected (p= 0.113) and control transfected (p=0.092) TamR cells. 
Nonetheless mRNA for ERα is clearly present in IGFBP-2 knockdown TamR cells.   
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Table ‎4-2 Raw Ct values after qRT-PCR of ER isoforms in wt and TamR 
MCF-7 cells.  
 
 
Table 4.2 Raw Ct values after qRT-PCR of ER isoforms in wt and TamR MCF-7 
cells. ERα, Rβ1, ERβ2 and GPR 30 expression was analysed in wt and TamR MCF-7 
cells Individual triplicate are reported. ΔCt represents Ct target – Ct HKG (RPLP0). 
  
Wild Type  Tamoxifen Resistant cells 
 
Ct1 Ct2 Ct3 Mean STD ΔCt ER Ct1 Ct2 Ct3 Mean STD ΔCt 
20.19 20.16 19.88 20.09 0.17 N/A RPLP0 18.49 18.44 18.21 18.38 0.15 N/A 
22.9 23.58 22.87 23.12 0.40 3.04 ESR1-α 22.62 22.38 22.51 22.50 0.12 4.12 
34.56 33.87 N/A 34.22 0.49 14.14 ESR2-β 33.92 34.49 32.66 33.69 0.94 15.31 
34.57 32.47 34.18 33.74 1.12 13.66 ESR2-β1 36.52 33.99 34.30 34.94 1.38 16.56 
38.66 36.54 32.80 36.00 2.97 15.92 ESR2-β2 36.31 36.23 35.98 36.17 0.17 17.79 
32.59 32.47 32.35 32.47 0.12 12.39 GPR30 33.56 33.39 33.34 33.43 0.12 15.05 
             
[116] 
 
 
1
0.0
0.2
0.4
0.6
0.8
1.0
1.2
TamR
SC
BP-2 KO
2
- 

C
t
 
 
Figure ‎4-18 Expression‎of‎ERα‎in‎untransfected‎TamR‎cells‎control‎trans-
fected TamR cells (sc) and IGFBP-2 KO TamR cells.  
Three experiments were performed with each cell line with triplicate technical repli-
cates within each experiment. Data are presented relative to ERα expression in wt 
untransfected cells in the form 2-ΔΔCt and indicate the decrease in ERα expression in 
each cell line relative to untransfected wt cells. Mean ± SD (n=3). 
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4.8 Discussion 
In order to examine whether alterations in IGFBP-2 or -5 expression had any causal 
role in the acquisition of TamR in MCF-7 cells we used an shRNA knockdown strate-
gy. We reasoned that if over expression of IGFBP-2 by TamR cells were associated 
with TamR then knockdown of IGFBP-2 should result in restoration of tamoxifen sen-
sitivity. Conversely if decreased IGFBP-5 expression by TamR cells is associated with 
TamR then knockdown of IGFBP-5 in wt cells should impart tamoxifen resistance. The 
use of stably expressed shRNA from an appropriately designed and integrated vector 
is a well-established route for gene knockout studies (Fig 2.1) and 
http://link.springer.com/protocol/10.1007%2F978-1-4939-1538-5_1. We found it rela-
tively straightforward to reduce IGFBP-2 expression in TamR cells using this strategy 
with success achieved at all transfection reagent: plasmid ratios examined (Fig 4.1and 
Table 4.1). In addition we were able to fairly quickly establish clonal cell lines form ini-
tial heterogeneous cell populations with the former growing through puromycin selec-
tion in about 3 weeks after cloning by limiting dilution.  
 One difficult issue relates to the degree of target knock down and whether it is suffi-
cient to allow observable biological effects. This can only be addressed experimentally 
and may only be relevant to carefully defined biological end points. In our case we 
provide clear cut evidence that attenuation of IGFBP-2 expression in TamR cells is 
associated with the partial reversal of 4HT resistance supporting a role for IGFBP-2 in 
the development of tamoxifen resistance (Fig 4.9). We can find no exact parallel stud-
ies reported in the literature using TamR MCF-7 cells although there are some studies 
which report IGFBP-2 KO in wt MCF-7 cells. Foulstone et al used an siRNA based 
strategy to transiently transfect MCF-7 cells [71]. They reported that loss of IGFBP-2 
expression induces cell death. However they also reported that attenuation of IGFBP-
2 using this strategy resulted in increased sensitivity of MCF-7 cells to paclitaxel and 
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doxorubicin induced cell death. Perhaps of more relevance to our studies, in supple-
mentary material published with this report they indicate that IGFBP-2 expression is 
greater in TamR cells than in wt MCF-7 cells. Although the degree of fold increase in 
their study approximately 2.2 v 3.5 ng/105  cells/24 hr is somewhat less than we re-
port,  their observations agree qualitatively with data in this current thesis ( see Fig 
3.9) and indeed basal values of IGFBP-2 protein as determined by ELISA are very 
similar in both reports. Although these studies are not exactly comparable with ours 
the increased sensitivity to chemotherapeutic agents and increased cell death in 
IGFBP-2 KO and wt MCF-7 cells are not inconsistent with an increased sensitivity to 
4HT in IGFBP-2 knockdown cells reported in our study. The design and aim of our 
work meant that we did not undertake knockdown of IGFBP-2 in wt MCF-7. Nonethe-
less we believe that our data and that reported by Foulstone et al support a tumour 
promoter function for IGFBP-2 in BC. 
IGFBP-5 knockdown proved more problematical and we did not achieve successful 
and stable attenuation of IGFBP-5 expression until our third attempt. We have no 
ready explanation for this although it should be noted that BP-5 knockdown studies 
were performed in wt cells passage no 35 whereas IGFBP-2 knockdown studies were 
conducted in TamR cells passage no 7 and perhaps cells may show differential effi-
ciency of plasmid uptake. The late passage no of MCF-7 may have a significance ef-
fect on the results. This is perhaps confirmed by the observation that in our successful 
IGFBP-5 knockdown experiment the lower transfection reagents: plasmid ratios (1 
and 2) did not allow the establishment of puromycin resistant colonies (Fig 4.5). 
Against this in our early failures we did achieve selection in puromycin but no attenua-
tion of IGFBP-5 expression. Although successful knockdown is sequence dependent 
and specific with respect to the shRNA vector we used the same reagent (s) through-
out our IGFBP-5 transfection studies and have no evidence that the manufacturer 
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changed the targeted sequences for successive batches of the product. It is possible 
that the appropriate cellular machinery required to process the IGFBP-5 shRNA tran-
script (see Mats & Methods Fig 2.1) is dependent on cell passage number but we did 
not rigorously investigate this possibility. Of equal concern was our observation that 
the expression of the other 4 IGF axis genes examined were also inhibited in IGFBP-5 
knockdown cells v transfected controls (Fig 4.6). This was not seen for our IGFBP-2 
knockdown studies and it argues that there may be “off target” effects following trans-
fection with the IGFBP-5 shRNA construct or even widespread non-specific effects. 
Whatever the case we were eventually able to create both heterogeneous and clonal 
cell populations with attenuated IGFBP-5 expression (Fig 4.5 and 4.7). We found that 
knock down of IGFBP-5 in wt MCF-7 cells did not influence tamoxifen sensitivity. 
These generally negative effects meant that we did not pursue qRT-PCR experiments 
with the IGFBP-5 knockdown clone further – for example to establish whether IGF ax-
is was generally down regulated in this clone as was described in the heterogeneous 
population of cells from which it was derived (#6 – Fig 4.5).  As for IGFBP-2 studies it 
is difficult to find similar studies of IGFBP-5 KO in the literature especially with respect 
to tamoxifen resistance as a biological end point. An early study using antisense oli-
gonucleotide directed attenuation of BP-5 expression in wt MCF-7 cells reported an 
ablation of sensitivity to the SERD fulvestrant [244]. Our hypothesis was that inhibition 
of IGFBP-5 expression through a stably transfected shRNA strategy would induce ta-
moxifen resistance in wt MCF-7 cells which is somewhat at odds with the findings of 
Huynh et al [55]. However these findings may be explained by differences in transfec-
tion strategy and anti-oestrogen challenge. 
As well as examining the effects of IGFBP-2 and IGFBP-5 knockdown we also con-
sidered it important to investigate the consequences of over expression of IGFBP-2 
and IGFBP-5 in wt and TamR cells respectively. As a prelude to this we undertook 
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some preliminary experiments to examine the effects of IGFBPs in both TamR and wt 
cells in the absence of 4HT. These are required in order to interpret accurately the 
results of experiments subsequently conducted in 4HT. In general terms we found that 
wt and TamR cells responded mitogenically to IGF-1 and that this effect was inhibited 
by co-incubation with IGFBP-2 but was enhanced on co-incubation with IGFBP-5. On 
its own IGFBP-5 also appeared to have a stimulatory effect in both cell types. The ef-
fects of IGF-1 in our cultures were not large and this may reflect the insensitivity of the 
WST-1 assay relative to other mitogenic read outs such as 3 H-thymidine incorpora-
tion. In addition these experiments were done under serum free conditions to avoid 
any potential interference from endogenous IGFs or IGFBPs and under these condi-
tions cell responses may be blunted. However there is evidence in the literature to 
support both the inhibitory effects of exogenous IGFBP-2 on IGF-1 activity in MCF-7 
cells [245] and also to confirm   the enhancing activity of IGFBP-5 on IGF-1 action in 
this cell line [165]. 
However the main thrust of this experimental work was not to confirm or refute 
previous studies on IGF and IGFBP effects on the growth of MCF-7 cells but to 
examine the role of extracellular IGFBP-2 and IGFBP-5 on tamoxifen resistance in 
these cells and in the absence of expression vectors for IGFBP-2 or IGFBP-5 we used 
addition of exogenous IGFBPs in our cell cultures to examine the effects of these 
binding proteins with respect to tamoxifen resistance.  When we conducted these 
experiments we found that neither extracellular IGFBP-2 nor IGFBP-5 affected 
tamoxifen sensitivity in either wt or TamR cells (Fig 4.16 and 4.17). There may be 
many explanations for this but possibly the two most important are as follows.  Firstly, 
in these experiments it is assumed that it is extracellular effects of IGFBPs which are 
being examined. The establishment of stably transfected MCF-7 cell lines over 
expressing IGFBPs would theoretically allow for both intracellular and extracellular 
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effects of IGFBPs to be examined (although a strategy to differentiate between these 
effects would have to be adopted). It may be that the effects of IGFBPs on tamoxifen 
sensitivity are cell compartment specific and there is evidence that for both IGFBP-2 
and -5 this is the case in many cell types including BC cells [163, 246-248]. The 
second caveat is that the development of tamoxifen resistance typically takes place 
over a period of several months during which cells are exposed to the drug with 
resistant cells eventually growing through. This suggests that such a process involves 
perhaps long term reprogramming of gene expression and it may therefore be 
unrealistic to expect that the acute treatment of tamoxifen sensitive wt MCF-7 cells 
would result in the rapid development of TamR.  Whatever the case experiments with 
stably transfected over expressing wt and TamR cells may help at least partly address 
this issue.  
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Chapter 5 Results  
Cell migration  
5.1 Introduction 
One way in which tamoxifen resistant cells can display a more aggressive phenotype 
is by acquiring increased migratory activity [249]. For this reason we decided to under-
take experiments to investigate whether in our hands TamR cells displayed increased 
migratory capacity and whether this property could be manipulated by the knock down 
of IGFBP-2 or IGFBP-5 using the stably transfected cell lines described and charac-
terised elsewhere in this thesis (see Figs 4.4 and 4.7). We had access to the In-
cucyteTM automated 96-well wound creation and real time monitoring instrumentation 
and used this for the experiments described in this Chapter (see also materials and 
Methods for further details section 2.2.7 on page 60 ). MCF-7 cells are relatively non-
invasive [250] therefore only cell migration and not invasion experiments were per-
formed. In our laboratory MCF-7 cells did not achieve the required density when 
seeded onto Matrigel to perform robust migration experiments and therefore all migra-
tion experiments were performed on plastic. 
5.2 Migration of parental wt and TamR cells 
The cell migration assay was designed to examine the effect of IGFBP-2 and IGFBP-5 
KO on cell migration. However in preliminary experiments we first of all examined the 
migration of parental wt MCF-7 cells. Cells were seeded and allowed to attach over-
night. Subsequently 700-800µm wounds were made using the Incucyte instrumenta-
tion as described in Methods section 2.2.7. Cell migration was measured by following 
wound closure in real time.  Images were captured every hour for 94 h and we present 
images for three different time points, (0, 48, and 72h after wounding) quantitative da-
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ta was collected each hour over the 94hr time course.  Fig 5.1 shows representative 
images of wound closure for parental wt and TamR MCF-7 cells and the metric of rel-
ative wound density (RWD) is used to analyse and quantify the cell migration data 
over the 94 h time course of the experiment. Analysis of such data in Fig 5.2 shows 
that TamR cells show more rapid wound closure (migration) than wt MCF-7 cells (P< 
0.0001; 2-way ANOVA) thus confirming data published by other laboratories [26] and 
providing a base from which to study the effects of IGFBP-2 KO in TamR cells and 
IGFBP-5 KO in wt cells.  
5.3 Migration of IGFBP-2 KO cells 
Figure 5.3 shows images of wound closure in IGFBP-2 KO and scrambled (sc) control 
KO cells. In Fig 5.4 this data is analysed quantitatively and indicates that although 
IGFBP-2 KO is associated with a significant inhibition of migration of TamR cells (re-
peated measures ANOVA followed by Bonferroni’s post-hoc test) the migration profile 
of the sc control cells  is not statistically different from the IGFBP-2 KO TamR cells 
(p> 0.05). It is not possible therefore to draw any conclusions with respect to the effect 
of IGFBP-2 knock down on TamR cell migration. 
5.4 Migration of IGFBP-5 KO cells 
More encouraging data was obtained following analysis of IGFBP-5 KO in wt MCF-7 
cells (Figs 5.5 and 5.6). Therefore analysis showed that knock down of IGFBP-5 in wt 
MCF-7 cells resulted in a statistically significant increase in cell migration compared to 
either parental untransfected MCF-7 cells or scrambled (sc) control transfected cells 
(p < 0.0001) repeated measures ANOVA. Importantly in this instance no statistically 
significant differences were evident between parental untransfected MCF-7 cells and 
sc control transfected cells (Bonferroni’s post hoc test p>0.05 at all time points). Clos-
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er inspection of the data indicated that statistically differences in wound closure rates 
between IGFBP-5 KO and parental/control transfected cells were apparent at 9 and 
27 hr within the time course and remained significant until the end of the experiment 
(94 hr). 
                         
wt                   0h                                  48h                                           72h 
 
            
TamR            0h                                  48h                                           72h 
Figure ‎5-1 Migration of wt and TamR MCF-7 cells 
Images represent cell migration (wound closure) at three different time points. Cells 
were plated at 5 x 104 cells per well directly on plastic. After overnight incubation In-
cucyte was used to create uniform width scratches and wound closure images were 
subsequently captured after 0, 48, and 72 h after wounding at 10 x magnifications by 
the IncuCyte™ software. Top panels wt MCF-7 cells; bottom panels TamR cells.  
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Figure  5-2 Migration of wt and TamR cells plotted RWD vs time. 
Real time analysis of relative wound density (RWD) for MCF-7 and TamR. Cell migra-
tion was monitored over the period 0-94 hr. The black curve represents wt and the red 
curve represents the TamR MCF-7 cells. Data are presented as mean ± SD; n=12 for 
each time point. This experiment was performed twice with similar results in each in-
stance and a representative experiment is shown. Curves were analysed by repeated 
measures ANOVA followed by Bonferroni’s post-hoc test.  p< 0.0001 wt v TamR 
GraphPad Prism 5.0. 
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Figure ‎5-3 Migration of IGFBP-2 KO clone F8 and scrambled control (sc) cells.   
The images represent cell migration (wound closure) at three different time points. 
Cells were plated at 5 x 104 cells per well directly on plastic. After overnight incubation 
Incucyte was used to create uniform width scratches and wound closure images were 
subsequently captured after 0, 48, and 72 h after wounding at 10 x magnifications by 
the IncuCyte™ software. KO - IGFBP-2 KO TamR cells; sc scrambled control TamR 
cells. 
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Figure ‎5-4 Migration of IGFBP-2 KO clone F8 and scrambled control (sc) cells 
plotted as relative wound density v time. 
Cells were seeded at a concentration of 5 X 104 cell per well on plastic. The graph 
demonstrates the relative wound density for IGFBP-2 Ko and scrambled control over 
time. Cell migration was monitored over the period 0-94 hr. The black curve repre-
sents the scrambled control (sc) and the red curve represents the IGFBP-2 KO clone 
F8. Data are presented as mean ± SD; n=12 for each time point. This experiment was 
performed twice with similar results in each instance and a representative experiment 
is shown. Curves were analysed by two way ANOVA followed by Bonferroni’s post-
hoc test.  p< 0.0001 wt v TamR GraphPad Prism 5.0.  
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Figure  5-5 Migration of IGFBP-5 KO clone B4 and scrambled control (sc) cells.  
The images represent cell migration (wound closure) at three different time points. 
Cells were plated at 5 x 104 cells per well directly on plastic. After overnight incubation 
Incucyte was used to create uniform width scratches and wound closure images were 
subsequently captured after 0, 48, and 72 h after wounding at 10 x magnifications by 
the IncuCyte™ software. 
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Figure  5-6 Migration of IGFBP-5 KO clone B4 and scrambled control (sc) cells 
plotted as relative wound density v time. 
Cells were seeded at a concentration of 5 X 104 cell per well on plastic. The graph 
demonstrates the relative wound density for IGFBP-5 KO and scrambled control over 
time. Cell migration was monitored over the period 0-94 hr. The black curve repre-
sents the scrambled control (sc) and the red curve represents the IGFBP-5 KO clone 
B4. Data are presented as mean ± SD; n=12 for each time point. This experiment was 
performed twice with similar results in each instance and a representative experiment 
is shown. Curves were analysed by two way ANOVA followed by Bonferroni’s post-
hoc test.  p< 0.0001 wt v TamR GraphPad Prism 5.0. 
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Figure ‎5-7 Composite data from Figs 5.2, 5.4 and 5.6 representing migration of 
all six cell lines studied. 
Note that for clarity standard deviations have been omitted. 
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5.5 Discussion  
In this chapter we aimed to investigate the effect of knock down of IGFBP-2 and 
IGFBP-5 on cell migration. We initially demonstrated that TamR cells had a greater 
migratory activity than wt cells and that therefore this IncuCyte based protocol could 
be used to monitor the effects of IGFBP-2 knock down in TamR cells and IGFBP-5 
knockdown in wt cells on cell migration. Earlier work in this thesis showed that knock 
down of IGFBP-2 restored tamoxifen sensitivity to TamR MCF-7 cells (Fig 4.9). As 
such we tested the hypothesis that this restoration of tamoxifen sensitivity may be as-
sociated with a diminished cell migratory activity i.e. a restoration of wt MCF-7 pheno-
type. Although the stably transfected IGBP-2 knock down clone F8 did indeed show 
reduced migratory activity with respect to untransfected TamR cells (Fig 5.4) we noted 
that migratory potential was also diminished in the scrambled shRNA stably transfect-
ed clone. Although it is unclear why this should be the case it may be that there are 
some off target effects of the control shRNA which effect the expression or activity of 
genes closely associated with cell migration. Whatever the case we cannot conclude 
based on our current evidence that knock down of IGFBP-2 restores a phenotype of 
reduced migration in clonal cell line F8. 
There is a literature which supports a role for IGFBP-2 in the regulation of MCF-7 cell 
migration and associated phenotypes although it is in part conflicted. For example 
IGFBP-2 has been shown to down-regulate PTEN expression by an integrin-mediated 
mechanism in MCF-7 cells culminating in a marked increase in cell proliferation [26]. 
However there are also reports which suggest that IGFBP-2 may inhibit tumourigene-
sis in vitro and in vivo and in MCF-7 cells over expressing integrin β3, IGFBP-2 asso-
ciated with the αvβ3 complex and inhibited IGF-1 or -2 mediated cell migration. Re-
duced tumour growth in these transfected cells was associated with integrin mediated 
localisation of IGFBP-2 to the cell surface [102]. Similarly an engineered protease re-
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sistant IGFBP-2 inhibits MCF-7 tumour cell growth as a xenograft in a female nude 
Balb/c mouse model illustrating the importance of post-translational modification on 
the activity of IGFBPs. [245]. On occasion pleiotropic effects of IGFBP-2 are evident. 
Therefore in the ER -ve Hs578T cell line, although IGFBP-2 promoted de-adhesion of 
cells it also inhibited proliferation through an α5β1 integrin binding mechanism [251]. 
As this cell line lacks a functional IGF1R such effects were postulated to occur in an 
IGF-1 independent fashion and indeed subsequent studies using microarray analysis 
in Hs578T cells demonstrated that exogenous IGFBP-2 regulated the expression of 
several genes associated with cell proliferation, adhesion and apoptosis [252].  
In contrast to the results for IGFBP-2 knock down we found clear evidence that knock 
down of IGFBP-5 in wt MCF-7 cells was associated with increased cell migration and 
therefore resembled the phenotype of TamR cells where IGFBP-5 expression is re-
duced. In these experiments sc control transfected cells showed a migratory activity 
which was not significantly different from untransfected wt cells. In fact an analysis of 
the composite data for cell migration (Fig 5.7) indicates that IGFBP-5 knock down 
cells show the highest migratory activity of all lines examined including the TamR 
cells. As IGFBP-5 protein expression levels in B4 knockdown cells approached the 
low levels seen in TamR cells but were not less than TamR cells (see Figs 4.5 and 
4.7) this suggests that IGFBP-5 is not the sole determinant of cell migration in this ex-
perimental system. It is also interesting that IGFBP-5 knock down Clone B4 did not 
shown any indication of a tamoxifen resistant phenotype arguing that tamoxifen re-
sistance and cell migration in our experimental may be dissociated with respect to 
IGFBP-5 action. 
In analogy with IGFBP-2 there is also a somewhat conflicted literature with respect to 
the activity of IGFBP-5 in the regulation of BC cell migration and related phenotypes. 
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Our data are consistent with previous findings from our group which report that 
IGFBP-5 inhibits cell migration in MCF-7 cells [130] and therefore any decrease in 
IGFBP-5 expression may be associated with increased migratory potential. In fact 
IGFBP-5 also enhances adhesion of MCF-7 cells to mesenchymal cell derived matrix 
and may play a role in the inhibition of epithelial-mesenchymal transition (EMT) a pro-
cess closely associated with tumour cell development and metastasis [131]. In con-
trast to an inhibitory effect of IGFBP-5 on cell migration, Kricker et al reported that 
IGFBP-5 enhanced IGF-1 stimulation of MCF-7 cell migration when cultures were 
grown on vitronectin [253]. However, as always, a distinction must be made between 
IGF-dependent and independent effects of IGFBPs.  
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Chapter 6 Clinical significance of IGFBP2 & IGFBP-5 expres-
sion in tamoxifen-resistant breast cancer  
6.1 Introduction 
It has been reported that insulin-like growth factor-binding protein (IGFBP)-2 is asso-
ciated with breast tumour progression [254] and antiestrogen resistant breast tumour 
[255]. This association indicates that the up-regulation of IGFBP-2 in breast cancer 
(BC) can potentially be an important event in breast neoplasia. Moreover, as present-
ed in previous chapters, our results showed some evidence that knocking out IGFBP-
2 restores tamoxifen sensitivity. Therefore, an evaluation of the prognostic value of 
IGFBP-2 and IGFBP-5 is necessary in order to identify their association with survival 
advantage in tamoxifen-resistant patients as these may have potential to be use as 
predictive markers in these individuals. 
This chapter details an investigation into the potential prognostic value of IGFBP-2 
and IGFBP-5 expression in BC. Prognostic value relates to the measurement, at the 
time of diagnosis, of a biomarker that indicates the predictability of disease-free sur-
vival (DFS) or overall survival (OS) of a patient prior to administration of a treatment. 
Therefore, the aim of the investigation described in this chapter was to assess the 
prognostic values of IGFBP-2 and IGFBP-5 in a cohort of 424 tumours obtained from 
women with oestrogen receptor (ER) + BC.  
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Follow-up data covering a 22-year period were available, and a pathology database 
was used to identify pathological parameters. In missing cases, individual patient case 
notes were reviewed. Immunohistochemistry (IHC) was performed using tissue micro-
arrays (TMAs) to evaluate whether IGFBP-2 or IGFBP-5 expression observed in clini-
cal samples was predictive of tamoxifen resistance in BC patients, as described in the 
Methods section 2.2.8. In order to conduct such an evaluation, it is essential to 
choose an appropriate IGFBP-2 or IGFBP-5 antibody (Ab). According to the Human 
Protein Atlas, IGFBP-5 has been detected with weak cytoplasmic positivity in 14 of 80 
tissues http://www.proteinatlas.org/ENSG00000115461-IGFBP5/tissue. Our initial at-
tempt to optimise IGFBP-5 showed inconsistent IGFBP-5 IHC staining (see Appendix 
3). As a result of several difficulties with IGFBP-5 Ab optimisation, including identifica-
tion of the correct primary IGFBP-5 Ab and suitable tissue for optimisation, as well as 
time limitations, we focused on IGFBP-2, and therefore optimised the IGFBP-2 Ab. 
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6.2 Antibody optimisation 
An online system called The Human Protein Atlas was used as a pilot to choose the 
appropriate tissues and specific IGFBP-2 antibody http://www.proteinatlas.org/. The 
anti-IGFBP-2 antibody was then initially optimised in kidney at 1:50, 1:100, 1:200 and 
1:400 dilutions, and  the 1:100 IGFBP-2 antibody concentration was chosen on the 
basis of its having superior cytoplasmic staining (see Appendix 3). Following optimisa-
tion of the IGFBP-2 antibody, the BC TMAs were stained with IGFBP-2 antibody at a 
1:100 dilution. The slides were scanned at x20 magnification using the ScanScope™ 
system, and were visualised for scoring using the ImageScope™ pixel (Px) intensity 
Aperio algorithm. There are currently no established criteria for determining IGFBP-2 
positivity, so definition of the cut-off point was essential. 
6.3 Definition of cut-off point for scoring  
Our initial cohort consisted of 493 people with BC. However, 69 patients were exclud-
ed from the final analysis due to missing clinical data (n = 12) or a core missing TMA 
(n = 57). Therefore, algorithm scoring was carried out in the remaining 424 patients 
(289 tamoxifen-sensitive and 135 tamoxifen-resistant), as shown in Figure 6.1. 
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Figure  6-1 Consort diagram representing the patient samples used in the 
study. 
A total of 289 samples from TamS patients and 135 samples from TamR patients 
were used, giving a total of 424 samples. 
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After application of the algorithm, the results ranged between 0.00297±Px and 
0.96279±Px, with an average of 0.214718± Px for the tamoxifen-sensitive (TamS) co-
hort and 0.21797± Px for the tamoxifen-resistant (TamR) cohort. This data range ne-
cessitated a dichotomisation point that categorised positive and negative staining 
groups. Scores provided by the Aperio algorithm were then exported to Excel. The 
data were saved as a text file and uploaded into the cut-off finding system (see 
http://molpath.charite.de/cutoff/). Receiver Operating Characteristic (ROC) curve was 
generated [227], and the  cut-off point was determined to be 0.1, with 66.7% sensitivi-
ty and 41.5% specificity (see Appendix 4). Therefore, any data above 0.1 were con-
sidered positive, and any data below 0.1 were considered negative, accordingly. Fig-
ure 6.2 illustrates the ROC curve.  
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Figure  6-2 ROC curve to determine optimum cut-off point.  
Using an online cut-off finding system (see http://molpath.charite.de/cutoff/), the cut-
off point shown is 0.1 (red cross), with 66.7% sensitivity and 41.5% specificity. A total 
of 424 samples were included, and the algorithm results ranged between 0.00297± Px 
and 0.96279± Px.  
  
[140] 
 
6.4 Scoring algorithm  
Scoring was conducted on the basis of the cut-off point, using the ImageScope™ pixel 
intensity Aperio algorithm. On IHC staining before application of the algorithm, the 
blue stain represented the negative, while the brown stain represented the positive. 
After application of the algorithm, the blue still represented the negative, while the 
brown stain turned to red to represent positive staining. An example of IGFBP-2 stain-
ing before and after application of the algorithm is shown in Figure 6.3.   
Following the scoring, the event of ‘death’ was retrieved from the patients’ clinical sys-
tem and reported as 1 for ‘alive’ and 0 for ‘dead’. The data were analysed using Sta-
tistical Package for Social Sciences (SPSS) version 22 software, and a log-rank test 
(Mantel–Cox test) hypothesis test was used. All statistical tests were two-sided, with a 
p value of less than 0.05 considered statistically significant.   
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Figure  6-3 IGFBP-2 immunohistochemistry in breast TMA cores 
Representative tissue cores showing cytoplasmic staining that represents expression 
of IGFBP-2 in breast cancer before (left) and after (right) image analysis. The slides 
were scanned at x20 magnification using the ScanScope™ system, and visualised for 
scoring using the ImageScope™ pixel intensity Aperio algorithm. Before application of 
the algorithm, the blue indicates the negative and the brown represents the positive. 
After application of the algorithm, the blue indicates the negative and the red repre-
sents the positive. 
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Over two thirds of the samples (71.5%) showed positive IGFBP-2 expression, while 
only approximately a third (29.5%) of the samples were negative for IGFBP-2. The 
data were dichotomised on the basis of the cut-off point; positive data were repre-
sented as 1 and negative data were represented as 0. Survival duration data were 
retrieved from the clinical data system, and entered into SPSS version 22 software, 
and survival was calculated for the TamS cohort. Intriguingly, the Kaplan-Meier graph 
showed that a non-significant trend for higher expression of IGFBP-2 was associated 
with worse OS in the TamS cohort (Fig. 6.4). 
 
Figure ‎6-4 Kaplan-Meier survival curve showing the relative association be-
tween IGFBP-2 and survival in TamS patients. 
The relationship between positive and negative expression of IGFBP-2 was investi-
gated in TamS patient cohorts. Data from 289 TamS patients were entered into the 
SPSS and a graph was generated. The green indicates positive expression of IGFBP-
2, while the blue represents negative expression. The statistical log-rank test (Mantel–
Cox test) test used was two-sided, with a p value of 0.127 considered non-significant.   
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In addition, IGFBP-2 expression was also examined in the TamR cohort, of which 
51% showed positive expression of IGFBP-2, while 49% showed negative expression. 
To study the relationship between positive and negative IGFBP-2 expression and OS 
in the TamR cohort, the data were entered into the SPSS and the survival curve was 
plotted.  It was found that IGFBP-2 expression was non-significantly (p=0.771) corre-
lated with OS (Figure 6.5). 
 
Figure ‎6-5 Kaplan-Meier survival curve showing the relative association be-
tween IGFBP-2 and survival in the TamR cohort. 
The relationship between the positive and negative IGFBP-2 expression was investi-
gated in the TamR patient cohort using data from 135 patients. Data were entered into 
the SPSS and a graph generated. The green indicates positive expression of IGFBP-
2, while the blue represents negative expression.  The statistical log-rank test (Man-
tel–Cox test) test used was two-sided, with a p value of 0.771 considered non-
significant. 
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6.5 Positive expression of IGFBP-2 is significantly associated 
with a survival advantage in TamR patients. 
The group expressing positive IGFBP-2 levels represented 71% of the TamS cohort 
(178 patients) and 51% of the TamR cohort (62 patients). To study the relationship 
between IGFBP-2 expression and survival rates between these two cohorts, a Kaplan 
Meier survival analysis was performed. The TamS cohort had significantly (p<0.001) 
worse survival compared to the TamR cohort.  Approximately two thirds of the pa-
tients who expressed IGFBP-2 in the TamS patient cohort were dead at 10 years of 
follow-up, compared to one third of the TamR patient cohort at the same time point, 
suggesting that IGFBP-2  expression was significantly (p<0.001) associated with im-
proved survival in TamR patients. Therefore, IGFBP-2 expression might be useful as 
a predictive biomarker for TamR in BC. Figure 6-6 illustrates the relationship between 
high IGFBP-2 expression and OS in both cohorts.   
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Figure  6-6 Kaplan-Meier survival curve showing the analysis of positive IGFBP-
2 expression in non-TamR vs TamR patients. 
The curve represents the relative association between IGFBP-2 expression and sur-
vival in TamS and TamR cohorts. Green indicates TamR, while blue represents 
TamS. The statistical log-rank test (Mantel–Cox test) test was used. The difference is 
significant (p< 0.001).  
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6.6 Negative expression of IGFBP-2 is significantly associated 
with poor survival in TamR patients 
Negative IGFBP-2 expression was shown in 29% of the TamS cohort (87 patients) 
and 49% of the TamR cohort (57 patients). Therefore, we compared the patients with 
negative IGFBP-2 expression in both cohorts; a total of 144 patients. The TamR co-
hort had a significantly (p<0.001) higher correlation with poor survival than the TamS 
group. Figure 6-7 demonstrates the comparison of negative expression of IGFBP-2 in 
both cohorts.   
  
Figure  6-7 Kaplan-Meier survival curve showing negative IGFBP-2 expression in 
non-TamR vs. TamR cohorts. 
The curve represents the relative association between negative IGFBP-2 expression 
and survival in the TamS and TamR cohorts. Data from 87 non-TamR patients and 57 
TamR patients were entered into SPSS version 22 software and used to plot the 
graph. Green indicates TamR, while blue represents TamS. The statistical log-rank 
test (Mantel–Cox test) test was used, and the difference is significant (p<0.001). 
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As previously mentioned, we were unable to evaluate the relationship between 
IGFBP-5 expression and OS because of difficulties in optimising the IGFBP-5 Ab. 
Therefore we used an alternative online KM-plotter system to study the prognostic 
value of IGFBP-5.  
6.7 Mining a public data set for IGFBP-2 and IGFBP-5 
6.7.1 IGFBP-2 assessment in ER+ BC patients treated with tamoxi-
fen  
The Kaplan-Meier (KM)-plotter was developed to assess the survival and  prognostic 
value of biomarkers online [256]. This system is capable of evaluating the effect of 
22,277 genes on the survival of 4,142 people with BC, 1,648 with ovarian cancer, 
2,437 with lung cancer and 765 with gastric cancer, and the aim is to conduct a meta-
analysis for in silico biomarker assessment [256]. We used this online tool to compare 
our results with microarray data from 4,142 ER+ BC patients (Fig 6.8). A log-rank test 
(Mantel–Cox test) hypothesis test was used to plot the OS and recurrence-free sur-
vival (RFS) curves.  
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Figure  6-8 Consort diagram representing the patient samples used 
in the study. 
Data from 754 patients were used for RFS and data from 65 patients 
were used for OS 
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The ER+ patient samples were split into two groups by median and compared using 
a Kaplan-Meier survival plot to analyse the potential prognostic value of IGFBP-2. 
The RFS and OS rates indicated no association between IGFBP-2 expression and 
TamR in BC. Data from 700 patients were used for RSF, and data from 65 patients 
were used for OS. Figure 6-9 shows the relative association between IGFBP-2 and 
survival 
  
 Recurrence free survival (RFS)              overall survival (OS)    
Figure  6-9 Meta-analysis of IGFBP-2 expression in ER+ patients treated with ta-
moxifen.  
The RFS (left, p = 0.74) and OS (right, p = 0.95) rates are non-significant. The values 
shown in red represent IGFBP-2 expression, and those shown in black denote no 
IGFBP-2 expression.   
[150] 
 
6.7.2 IGFBP-5 assessment in ER+ BC patients treated with tamoxi-
fen  
Data from 700 patients for RFS and data from 65 patients for OS were used to evalu-
ate the prognostic value of IGFBP-5. We applied the KM-plotter system, which 
showed that IGFBP-5 expression was unrelated to RFS and OS (Fig. 6-10). The log-
rank test (Mantel–Cox test) hypothesis test was used. The RFS (p=0.3663) and OS 
(p=0.3595) were non-significant. 
    
Recurrence free survival (RFS)              overall survival (OS)    
Figure  6-10  Meta-analysis of IGFBP-5 expression in ER+ patients treated with 
tamoxifen.  
The RFS (p=0.3663) and OS (p=0.3595) are non-significant. The values shown in red 
and black denote high and low IGFBP-5 expression, respectively.   
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6.8 Discussion 
To date, clinical data have provided ambiguous evidence as to whether IGFBP-2 and 
IGFBP-5 serve as valuable prognostic biomarkers for BC [257]. A well-documented 
finding is that IGFBP-2 serum levels in ER+ BC patients significantly increases. More-
over, IGFBP-2 is associated with tumour progression in several different cancers, in-
cluding prostate cancer [258], ovarian cancer [259], colon cancer [260], lung cancer 
[261], adrenocortical cancer [262], breast cancer [254] and leukaemia [263], as well 
as in drug-resistant tumours [255]. This association indicates that the up-regulation of 
IGFBP-2 in different tumours can potentially be an important event in breast neo-
plasia. Accordingly, we examined the prognostic value of IGFBP-2 and IGFBP-5. 
An IGFBP-2 specific Ab was used to evaluate IGFBP-2 expression. Since we used an 
automated algorithm scoring system, definition of a cut-off point was necessary in di-
chotomising the data for downstream analysis. An ROC (Fig 6-2) was used to deter-
mine the point of dichotomisation by an online cut-off finder programme (see 
http://molpath.charite.de/cutoff/) [227].  
Our results showed that high IGFBP-2 expression represented 71% and 51% of the 
TamS (178 patients) and TamR (62 patients) cohorts, respectively. These findings are 
supported by the results of Park et al. (2008), who found that 40% of BC patients ex-
hibited increased IGFBP-2 expression in their tumours [264]. Nonetheless, the posi-
tive IGFBP-2 expression in the present study was correlated with poor survival pro-
spects for the people with TamS BC. Conversely, IGFBP-2 expression exhibited no 
association (p=0.771) with the OS of the TamR cohort in the present study. 
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Taylor et al. (2010) suggested that the IGFBP-2 and IGFBP-5 genes can potentially 
provide prognostic or predictive value for BC [265]. Interestingly, the authors also re-
ported that such genes can be used to predict responses to different therapeutic reg-
imens, including selective oestrogen-receptor modulators, selective oestrogen-
receptor disruptors SERDs and aromatase inhibitors [132, 244, 266].  
An interesting IHC study conducted in Norwegian women used 120 BC resections; the 
results showed a gradual elevation in IGFBP-2 expression from atypical hyperplasia 
through to carcinoma in situ and invasive carcinoma [175]. Similarly, a TMA analysis 
of over 4,000 primary invasive breast tumours revealed IGFBP-2 over-expression, 
and also indicated that an adverse survival outcome is correlated with IGFBP-2 ex-
pression in ERα-tumours [267]. Another study revealed that, combined with the cell 
adhesion protein, β-catenin, the expression of IGFBP-2 is linked with lymph-node me-
tastasis in BCs [268]. Similarly, high levels of IGFBP-2 expression, together with loss 
of PTEN expression, are associated with triple negative BC and poor survival rates 
[269]. In research using the SKBR3 cell line, IGFBP-2 was up-regulated in an in vitro 
model [270]. Such up-regulation may be postulated as occurring via an ErbB2 signal-
ling mechanism, which provides a route of escape from the anti-EGF-based therapeu-
tic strategy. Other interesting recent reports have suggested that IGFBP-2 is hypothet-
ically a target for an immune-based route for BC treatment; multiple antigenic peptides 
comprising IGFBP-2 epitopes have been used to block tumour progression in a trans-
genic mouse model of BC [264, 271]. Therefore, we adopted a Kaplan–Meier-based 
comparison of the high and low IGFBP-2 expression in both cohorts (TamS and 
TamR) in the present study. The positive and negative IGFBP-2 expression in the 
TamS group was significantly associated (p<0.001) with poor survival (Figs. 6-6 and 
6-7, respectively). In contrast, Wang et al. (2008) reported that although IGFBP-2 ex-
pression is high in ER+ tumours, such expression is unrelated to OS [272].  
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The online KM-plotter showed no association between IGFBP-2 expression and 
TamR in BC (Figs. 6.9) [256]. However, the analysis was restricted to gene expres-
sion not protein, as assessed in BC TMAs.  In addition, the KM-plotter also showed no 
association between IGFBP-5 gene expression and TamR in BC. Therefore, no evi-
dence was obtained with regard to the potential role of IGFBP-5 in breast malignancy, 
at least in terms of gene expression. However, despite this deficiency, it has been re-
ported that IGFBP-5 mRNA is up-regulated relative to a normal mammary gland in 
breast tumour tissue, although IGFBP-5 expression and tumour grade are unrelated 
[273]. Several reports have suggested that IGFBP-5 is either elevated [274, 275] or 
decreased in lymph-node metastases [273]. In a study using samples from 116 pa-
tients, Mita et al. (2007) found that high IGFBP-5/IGFBP-4 mRNA expression ratio is 
related to decreased survival with a poor prognosis [199]. Consequently, the authors 
evaluated IGFBP-5 mRNA expression as a factor for poor prognosis in BC. This is 
consistent with our KM-plotter system result, which showed that IGFBP-5 mRNA ex-
pression was unrelated to RFS and OS. Similarly, Becker et al. (2012) identified 
IGFBP-5 as being specifically expressed in invasive BC tissue, using IHC based on 
76 BC samples. Nevertheless, the study confirmed that an elevation in IGFBP-5: 
IGFBP-4 expression ratio was adversely associated with RFS and DFS in the studied 
cohort [276]. In contrast, a study of 153 BC biopsies from tamoxifen-treated patients 
showed that high IGFBP-5 expression is related to increase OS [132]. Plant et al. 
(2014) recently carried out an IHC-based study and identified reduced IGFBP-5 pro-
tein levels in the stroma surrounding aggressive metastatic BC tissues [248]. Howev-
er, the authors did not specify the source of the association between the stroma and 
IGFBP-5 expression. Altogether, the aforementioned findings reinforce the hypothesis 
that IGFBP-5 plays a role in BC progression. Some obstacles in the optimisation of 
IGFBP-5, such as choice of the appropriate IGFBP-5 Ab, choice of the suitable tissue 
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for Ab optimisation and lack of information on the Human Protein Atlas web site, as 
well as time limitations, meant that the prognostic and predictive value for IGFBP-5 in 
BC were not assessed in the present study.  
In summary, positive expression of IGFBP-2 in TamS was associated with significant-
ly (p<0.001) worse survival than in the TamR cohort, suggesting that IGFBP-2 ex-
pression was significantly associated with improved survival in TamR patients. Con-
versely, negative expression of IGFBP-2 in TamR was associated with significantly 
(p<0.001) worse survival compared to the TamR cohort. Therefore, a high level of 
IGFBP-2 in clinical samples may be used as a predictive biomarker for tamoxifen re-
sistance in BC. Although the present research was not conducted on IGFBP-5, the 
KM-plotter system showed that its expression, in terms of mRNA,  was unrelated to 
RFS and OS.  Further investigations could confirm our results.  
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Chapter 7 General Discussion 
The most striking feature in our studies was the consistently observed reciprocal regu-
lation of IGFBP-2 and -5 expression seen between wt and TamR cells whereby 
IGFBP-2 was up regulated approximately 2-5-fold in TamR v wt cells whilst IGFBP-5 
was down regulated to approximately the same level in TamR cells. This may argue 
for a co-ordinate regulation of IGFBP-2 and -5 expression and indeed we have previ-
ously reported a reciprocal regulation of IGFBP-2 and -5 expression during differentia-
tion of both mammary epithelial cell lines and primary cultures [277]. It is interesting in 
this context to note that IGFBP-2 and -5 are located very close together in a tail-to-tail 
configuration on chromosome 2 in humans separated by approximately 30 kbs of ge-
nomic sequence [118]. Such architecture suggests that IGFBP-2 and -5 may have 
arisen via a gene duplication event and that a common cis or trans acting regulatory 
mechanism of reciprocal gene expression may exist. Clearly further experimentation 
is required to test this hypothesis but such a co-ordinate and reciprocal regulation 
would provide a novel mechanism of gene regulation in the IGFBP family. 
There are some studies which describe mechanism (s) by which IGFBP-2 and IGFBP-
5 may influence tumourigenesis in BC although the literature in this area is somewhat 
contradictory and further experimental clarification would be welcome. Nonetheless 
these reports may have some relevance to the findings presented in the current study. 
For example IGFBP-2 was reported to act via an integrin based mechanism to sup-
press PTEN activity in MCF-7 cells thus prolonging PI3K activity to provide a pro-
tumourigenic signal [26]. Further studies suggested a pro-survival action of IGFBP-2 
through an ERα dependent mechanism. Interestingly knock down of IGFBP-2 ablated 
ERα expression and this effect was reversed by addition of exogenous IGFBP-2 [71].  
A related study from this group confirmed decreased ERα expression when IGFBP-2 
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secretion was inhibited by the flavinol EGCG in MCF-7 cells. Under these conditions 
cell growth was inhibited and the expression of the p53 and p21 tumour suppressors 
was enhanced [278]. Similarly analysis of shRNA based IGFBP-2 knockdown in the 
BC cell line BT474 indicated regulation of numerous pro-tumourigenic pathways. In a 
different experimental model using the neuroblastoma cell line SK-N-SHEP over ex-
pression of IGFBP-2 stimulated the proliferation and migration of cells through ECM 
suggesting a mitogenic and metastatic action of this protein [279] . From a protein 
structure perspective, site directed mutagenesis studies suggest that these pro-
tumourigenic effects of IGFBP-2 are dependent on an intact heparin binding domain 
(HBD) in the protein. However in another model of neurological tumourigenesis 
IGFBP-2 was reported to bind  integrin α5 in an RGD-dependent manner to promote 
JNK mediated migration of glioblastoma cells [202, 280] and subsequent studies also 
suggested the involvement of integrin β1 activation of integrin linked kinase (ILK) and 
the NF-κB pathway in this process. IGFBP-2 has also been reported to have tumour-
igenic activity in the prostate and yeast two hybrid analysis using a human prostate 
cDNA library identified Pim-1 associated protein (PAPA-1) as an IGFBP-2 binder and 
suggested that this nucleolar protein may act to inhibit the growth promoting activity of 
IGFBP-2 in the prostate [281]. An alternative tumour promoting function of IGFBP-2 
may be through activation of VEGF expression and subsequent stimulation of angio-
genesis [282, 283]. In a very recent study such activity was found to be dependent on 
the nuclear translocation of IGFBP-2 through a canonical importin-α based mecha-
nism and IGFBP-2 was identified in both nuclear and cytoplasmic compartments by 
cell lysate and immunofluorescent analysis. Accordingly neuroblastoma cells express-
ing a nuclear localisation signal (NLS) mutant of IGFBP-2 fail to stimulate angiogene-
sis in vivo in comparison to wt IGFBP-2 transfectants.[247]. 
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Any strategy which aims to reduce pericellular IGFBP concentrations e.g. via sh/si/mi 
RNA methodologies may result in increased local abundance of IGF growth factors 
resulting in an increased IGF dependent mitogenic stimulation [284].These pleiotropic 
effects of IGFBPs are typical in many cell lines and primary cultures and mean that 
caution must be exercised in the interpretation of experimental findings. We have 
clearly presented evidence that the over expression of IGFBP-2 may be associated 
with the development of TamR in MCF-7 BC cells. In this context it is important to 
note that the expression of IGFBP-2 in MCF-7 cells is regulated through the 
PI3K/Akt/mTor pathway to up regulate mRNA expression through a trans acting Sp1 
activation on the IGFBP-2 promoter [285, 286]. We did not examine whether this 
pathway was up regulated in TamR cells where IGFBP-2 expression is increased alt-
hough such studies would clearly be of merit. In addition, whether any of the mecha-
nisms discussed above pertain in tamoxifen resistant tissues are clearly worthy of fur-
ther study as they may provide a route for therapy in such cases.  
 There is also a limited literature on the potential role (s) of IGFBP-5 in BC – reviewed 
recently in [100] although again much of it is contradictory in nature. In the normal 
mammary gland IGFBP-5 may regulate the involution phase of the lactation cycle and 
may also play a role in  differentiation and morphogenesis of the gland [127, 277, 287, 
288]. IGFBP-5 induces cell adhesion but inhibits migration in MCF-7 cells [130, 131] 
and Butt et al report inhibition of MDA-MB-231 and Hs578T cell line growth following 
stable or adenovirus based transfection of IGFBP-5 [163]. An interesting observation 
is that intracellular location of IGFBP-5 can differentially regulate the activity of the 
protein in BC cells. Therefore despite the fact that IGFBPs in general are viewed as 
secreted proteins, in MDA-MB-435 BC cells nuclear location of IGFBP-5 is associated 
with a growth inhibitory action whereas accumulation of IGFBP-5 in the cytoplasm is 
associated with a growth stimulatory activity and is a poor prognostic factor for BC 
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[246].In Hs578T cells IGFBP-5 inhibits ceramide or RGD induced apoptosis [289] and 
subsequent studies suggested that IGFBP-5 may regulate apoptosis and cell survival 
through sphingosine kinase and PKC mediated survival signals [166]. However effects 
of IGFBP-5 show BC cell line specificity. Thus both wt and a non-IGF binding mutant 
of IGFBP-5 inhibit ceramide induced apoptosis in Hs578T cells but only the wt IGFBP-
5 was effective in MCF-7 cells. In addition mutant IGFBP-5 ablated the pro-survival 
effects of IGF-1 in MCF-7 cells (an IGF responsive cell line) whereas the wt protein 
enhanced IGF-1 survival properties [290]. Such exquisite regulation of IGF and 
IGFBP-5 activity has obvious significance in a tissue such as the mammary gland 
where IGF-IGFBP affinity can be regulated by mechanisms such as IGFBP-ECM as-
sociation and post-translational modification of IGFBP (including proteolysis). Alt-
hough it is difficult to set our observations of reduced IGFBP-5 expression in TamR 
cells in context with the above studies it may be that  those reports of other workers 
describing growth inhibitory effects of IGFBP-5 may have relevance and some of the 
associated mechanisms may operate when IGFBP-5 levels are decreased in TamR 
cells [130, 131, 163, 246]. In a similar vein our group recently reported that IGFBP-5 is 
involved in maintenance of epithelial-mesenchymal cell barriers and thus may inhibit 
the process of epithelial-mesenchymal transition (EMT) [131] . Such processes are 
generally believed to play an important role in the local and systemic dissemination of 
tumour cells (including BC) [30]. Therefore in tamoxifen resistant BC reduced IGFBP-
5 expression may promote EMT leading to tumour metastasis. 
In a clinical context, IGFBP-2 and/or IGFBP-5 is may have predictive or prognostic 
value in BC [265] and may also be used to predict responses to different therapeutic 
regimes including SERMs, SERDs and AIs [132, 244, 266]. In general terms in-
creased expression of IGFBP-2 in BC tissues is associated with poorer survival rates. 
An IHC based study in Norwegian women using 120 breast resections reported a 
[159] 
 
gradual increase in IGFBP-2 expression from atypical hyperplasia through to carci-
noma in situ and invasive carcinoma [175]. Similarly a TMA analysis of over 4000 pri-
mary invasive breast cancers identified over expression of IGFBP-2 in tumour tissue 
and an adverse survival outcome correlated with IGFBP-2 expression in ERα negative 
cancers [267]. Interestingly over expression of IGFBP-2 in the MDA-MB-231 cell line 
was associated with increased chemotherapeutic resistance in vitro and in vivo and 
this effect could be ablated by down regulation of IGFBP-2 expression using anti-
sense directed oligonucleotides. A subsequent study reported that expression of 
IGFBP-2 in association with the cell adhesion protein β-catenin is associated with 
lymph node metastasis of BCs [268] and high levels of IGFBP-2 expression together 
with loss of PTEN expression were associated in triple negative (TN) BC along with 
poorer survival rates [269]. For IGFBP-5 in the clinical setting of BC there is less evi-
dence for a potential role in tumourigenesis and the literature is still occasionally con-
flicted. For example, IGFBP-5 mRNA was reported to be up regulated in breast can-
cer tissue relative to normal gland although there was no correlation between tumour 
grade and IGFBP-5 expression [273]. Similarly there is evidence that IGFBP-5 is ele-
vated [274, 275] or decreased in lymph node metastases [273].  An analysis of 116 
patient samples identified that a high IGFBP-5/IGFBP-4mRNA ratio was related to 
poorer prognosis and a decreased period of disease free survival [199] and therefore 
high expression of IGFBP-5 mRNA was defined as a poor prognostic factor in BC. 
However a more recent tissue microarray analysis (TMA) of 153 BC biopsies from ta-
moxifen treated patients suggested that high expression of IGFBP-5 was associated 
with increased overall survival [132]. An IHC based study of 76 BC samples indicated 
BP-5 expression in invasive BC tissue. This same study also reported that an in-
creased BP-5: BP-4 expression ratio was negatively associated with recurrence free 
survival (RFS) and disease free survival (DFS) in this cohort of patients [276]. In con-
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trast to this a very recent IHC based study reduced IGFBP-5 protein in the stroma sur-
rounding metastatic BC tissues[248]. Although it is difficult to resolve these con-
trasting observations it should be noted that in the latter study the cellular source of 
stromal associated IGFBP-5 was not clear. 
 Interestingly single nucleotide polymorphisms (SNPs) in the 3’ end of both IGFBP-2 
and IGFBP-5 were reported to be associated with an increased risk of BC in a cohort  
American-African women age< 40 and similar findings were confirmed in a population 
of Nigerian women [291]. These observations have been developed by the publication 
of an extensive SNP analysis in the 5’region of the IGFBP-5 gene (at 2q35 in humans) 
which describes an SNP close to an enhancer region of the IGFBP-5 promoter. The 
authors provide evidence that expression of this allele is associated with down regula-
tion of IGFBP-5 and increases risk of ER+ breast cancers [292]. Whether this SNP is 
associated with TamR BC is unknown but the association of TamR with decreased 
IGFBP-5 expression highlighted in this study suggests that this is worthy of further 
investigation.  
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Conclusions 
1. Both wt and TamR MCF-7 cells express 5 of the IGF axis genes – IGF-1R, 
IGF-2R, IGFBP-2, IGFBP-4 and IGFBP-5. 
2. In TamR cells IGFBP-2 and -5 are reciprocally regulated such that BP-2 is up 
regulated and BP-5 is down regulated with respect to wt cells at both the 
mRNA and protein level. 
3. Attenuation of IGFBP-2 expression in TamR cells partially restores sensitivity 
to 4HT suggesting a causal role for this binding protein in the development of 
TamR 
4. Attenuation of IGFBP-5 expression in wt cells has little effect on sensitivity to 
4HT. 
5. Extracellular IGFBP-2 or IGFBP-5 has no effect on the sensitivity of either wt 
or TamR cells suggesting an intracellular mechanism of action for IGFBP-2. 
6. IGFBP-5 knock down in wt MCF-7 cells increases cell migration whereas 
IGFBP-2 knock down in TamR cells has no effect. 
7. High IGFBP-2 expression is significantly (P< 0.001) associated with survival 
advantage in tamoxifen resistant patients cohort. 
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Further Studies 
The work currently reported used a KO strategy to investigate the role of IGFBP-2 and 
-5 in the development of TamR in MCF-7 cells. In the absence of vectors over ex-
pressing BP-2 or BP-5, we manipulated extracellular concentrations of IGFBPs as a 
surrogate for the creation of cell lines over expressing BP-2 or BP-5. However this is 
somewhat unsatisfactory on a number of counts (see Section 4.7) and ideally we 
would like to produce wt MCF-7 cells over expressing BP-2 and TamR cells over ex-
pressing BP-5. The acquisition of TamR by the former cells and the restoration of ta-
moxifen sensitivity in the latter would provide direct confirmation of a role for each of 
these IGFBPs in the phenotype of TamR. We hope to create these cell lines in the 
near future. 
Earlier work from our group has suggested that IGFBP-5 may play a role in the regu-
lation of MCF-7 cell adhesion and migration [130, 131]. In this model BP-5 acts 
through an α2β1 integrin mediated mechanism involving activation of the Rho 
GTPase family member Cdc42 with subsequent increased adhesion and decreased 
migration on a mesenchymal extracellular matrix. In the current work we report that 
knock down of IGFBP-5 increases cell migration and this is consistent with our earlier 
studies. It would be interesting to confirm whether this also involves a Rho 
GTPase/Cdc42 based mechanism. Investigations into the potential mechanisms as-
sociated with IGFBP-2 involvement in TamR are also worthy of further study. Some of 
these are already being elucidated [71] and it is an important research area.  
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Appendixes     
1- Supplementary Figures 4.7S -4.16S  
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Figure 4.8A(S) Growth of wt or TamR cells in 1uM 4HT. Cells were seeded in 
100 ul of 5% DCS PR free medium at 5000/well in 96-well microtitre plates in the 
absence (top panel) or presence (bottom panel) of 1uM 4HT. Cell growth was 
monitored over the period 0-96 hr. by WST-1 assay as described in Materials 
&Methods 
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Figure 4.8B (S) Growth of wt or TamR cells in 1uM 4HT. Cells were seeded in 
100 ul of 5% DCS PR free medium at 5000/well in 96-well microtitre plates in the 
absence (top panel) or presence (bottom panel) of 1uM 4HT. Cell growth was 
monitored over the period 0-96 hr. by WST-1 assay as described in Materials 
&Methods 
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Figure 4.9S Growth of TamR BP-2 KO clone F8 or scrambled control transfected 
cells in 1uM 4HT. Cells were seeded in 100 ul of 5% DCS PR free medium at 
5000/well in 96-well microtitre plates in the absence (top panel) or presence (bottom 
panel) of 1uM 4HT. Cell growth was monitored over the period 0-96 hr. by WST-1 as-
say as described in Materials &Methods 
 
0 24 48 72 96
0.0
0.2
0.4
0.6
0.8
F8
Sc
hr
A
4
5
0
0 24 48 72 96
0.0
0.2
0.4
0.6
0.8
F8
Sc
hr
A
 4
5
0
[182] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.10S Growth of wt BP-5 KO clone B4 or scrambled control transfected cells 
in 1um 4HT. Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 
96-well microtitre plates in the absence (top panel) or presence (bottom panel) of 1uM 
4HT. Cell growth was monitored over the period 0-96 hr. by WST-1 assay as de-
scribed in Materials &Methods 
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Fig 4.11S Effect of IGF-1 on growth of wt and TamR MCF-7 cells. Cells were 
seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well microtitre plates. 
After overnight attachment cells were treated with the indicated concentrations of IGF-
1 in 100 ul of serum free PR free medium. After 48 hr WST-1 reagent (10ul) was add-
ed and A450 was determined after 30 min incubation at 37C. 
 
 
 
 
 
 
 
Fig 4.12S Effect of IGFBP-2 on growth of wt and TamR MCF-7 cells. Cells were 
seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well microtitre plates. 
After overnight attachment cells were treated with the indicated concentrations of 
IGFBP-2 in 100 ul of serum free PR free medium. After 48 hr WST-1 reagent (10ul) 
was added and A450 was determined after 30 min incubation at 37C. 
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Fig 4.13S Effect of IGFBP-5 on growth of wt and TamR MCF-7 cells. Cells were 
seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well microtitre plates. 
After overnight attachment cells were treated with the indicated concentrations of 
IGFBP-5 in 100 ul of serum free PR free medium. After 48 hr WST-1reagent (10ul) 
was added and A450 was determined after 30 min incubation at 37C. 
 
 
 
 
 
 
 
Fig 4.14S Effect of IGF-1 ± IGFBP-2 or IGFBP-5 on growth of wt cells. Cells were 
seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well microtitre plates. 
After overnight attachment cells were treated with the indicated concentrations of IGF-
1 (0-100nM) in the presence or absence of fixed concentrations (10 nM) of IGFBP-2 
or IGFBP-5 in 100 ul of serum free PR free medium. After 48 hr WST-1 was added 
and A450 was determined after 30 min incubation at 37C. 
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Fig 4.15S Effect of IGF-1 ± IGFBP-2 or IGFBP-5 on growth of TamR cells. Cells 
were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 96-well microtitre 
plates. After overnight attachment cells were treated with the indicated concentrations 
of IGF-1 (0-100nM) in the presence or absence of fixed concentrations (10 nM) of 
IGFBP-2 or IGFBP-5 in 100 ul of serum free PR free medium. After 48 hr WST-1 was 
added and A450 was determined after 30 min incubation at 37C. 
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Fig 4.16S Fig 4.15  Effect of extracellular IGFBP-2 on Tamoxifen sensitivity of wt 
MCF-7 cells. Cells were seeded in 100 ul of 5% DCS PR free medium at 5000/well in 
96-well microtitre plates in the absence (wt) or presence (+BP-2) of 50nM BP-2. Cell 
growth was monitored over the period 0-96 hr in the presence of 1uM 4HT using 
WST-1 assay as described in Materials &Methods 
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Fig 4.17S Fig 4.16  Effect of extracellular IGFBP-5 on tamoxifen sensitivity of 
TamR MCF-7 cells. Cells were seeded in 100 ul of 5% DCS PR free medium at 
5000/well in 96-well microtitre plates in the absence (TamR) or presence (+BP-5) of 
50nM BP-5. Cell growth was monitored over the period 0-96 hr in the presence of 
1uM 4HT using WST-1 assay as described in Materials &Methods. 
[188] 
 
2- Taqman assay identifiers 
                         
No  Reverse Primer Seq Assay ID Lot 
Number 
Amplicon 
Length 
1 GAPD
H 
GGGCGCCTGGTCACCAGGGC
TGCTT 
Hs99999905_
m1 
1127396 124 
2 RPLP0 TGTTTCATTGTGGGAGCAGAC
AATG 
Hs99999902_
m1 
1159813 105 
3 IGF1 TTATTTCAACAAGCCCACAGG
GTAT 
Hs01547656_
m1 
1127281 68 
4 IGF2 GGCCATGCAGACACCAATGG
GAATC 
Hs04188276_
m1 
4351372 83 
5 IGF1R CCATCTTCGTGCCCAGACCTG
AAAG 
Hs00609566_
m1 
1128743 64 
6 IGF2R TGTCAGAGTGGAAGGGGACA
ACTGT 
Hs00974474_
m1 
1110170 59 
7 IGFBP
1 
CAGCAGACAGTGTGAGACATC
CATG 
Hs00236877_
m1 
1139777 69 
8 IGFBP
2 
ACAACCTCAAACAGTGCAAGA
TGTC 
Hs01040719_
m1 
1111303 54 
9 IGFBP
3 
AGACGCCTGCCGCAAGGTTAA
TGTG 
Hs00426289_
m1 
1109668 84 
10 IGFBP
4 
CCCCAAGCAGTGTCACCCAGC
TCTG 
Hs01057900_
m1 
4351372 81  
11 IGFBP
5 
GCAAGTCAAGATCGAGAGAGA
CTCC 
Hs00181213_
m1 
1134543 85 
12 IGFBP
6 
GCCCGCGCGCCTGCTGTTGC
AGAGG 
Hs00181853_
m1 
1115870 145 
13 ESR1 TGATGAAAGGTGGGATACGAA
AAGA 
Hs00174860_
m1 
1113405 62 
14 ESR2 ACCTGTAAACAGAGAGACACT
GAAA 
Hs01100353_
m1 
1110864 73 
      
[189] 
 
3-  Optimisation of IGFBP-2 ( kidney) 
 
    
1:50                                       1:100 
 
    
1:200                                    1:400 
  
[190] 
 
        Optimisation of IGFBP-2 in multi-tissues (1:100) 
 
     
Tonsil                                                       Colorectal tumour 
     
Mucinous tumour                                     Placenta 
 
[191] 
 
     
Colon                                                      Desmoid type smooth muscle tumour 
 
 
     
Muscle                                                     Spleen 
 
  
[192] 
 
4- Optimisation of IGFBP-5 (kidney) 
 
    
1:50                                     1:100 
    
1:200                                    1:400 
  
[193] 
 
5- Definition of cut-off point for scoring 
ROC curve to determine optimum cut-off point.  
Using an online cut-off finding system (see http://molpath.charite.de/cutoff/), 
the cut-off point shown is 0.1, with 66.7% sensitivity and 41.5% specificity. A 
total of 424 samples were included, and the algorithm results ranged be-
tween 0.00297± Px and 0.96279± Px. The red cross represents the cut-off 
point 
[1] 
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6- Awards  
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            Appendix 5: Publication 
 
Publications  
1) Hawsawi, y., El-gendy, R., Twelves, C., Speirs, V. & Beattie, J. 2013. Insulin-like 
growth factor - oestradiol crosstalk and mammary gland tumourigenesis. 
Biochim Biophys Acta, 1836, 345-53. 
2) Beattie, J., Hawsawi, y., Alkharobi, H., El-Gendy, R., 2015. IGFBP-2 and -5: 
important regulators of normal and neoplastic mammary gland physiology. J. 
Cell Commun. Signal, DOI 10.1007/s12079-015-0260-3 
 
 
Awards  
I was awarded the British Association for Cancer Research (BACR) - Hamilton-Fairley 
Young Investigator Award at the 10th National Cancer Research Institute (NCRI) Confer-
ence held in Liverpool (2-5 Nov 2014). 
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Hawsawi YM, Beattie J, El-Gendy R, Speirs V, Twelves C. UT Health Science Center 
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1- University of Leeds School of Dentistry, Leeds, UK  
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